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Preface
This book is a useful resource that every physician taking care of patients with cardiac ar‐
rhythmias should be familiar with. This book includes six chapters written by experts in
their field.
Chapter 1 is a very comprehensive article on basic mechanisms of cardiac arrhythmias.
Chapter 2 discusses the chronobiological aspects of the impact of apnoic episodes on ven‐
tricular arrhythmias.
Chapter 3 focuses on the most recent developments in navigation, detection, and tracking
during cardiac ablation interventions.
Chapter 4 discusses the epidemiology and pathophysiology of ventricular arrhythmias in
several noncardiac diseases, the main methods used to assess arrhythmia risk, and their as‐
sociation with long-term outcomes. Dyslipidemia, diabetes mellitus, obesity, and liver, hem‐
atologic, neurologic, and psychiatric disorders are discussed.
Chapter 5 discusses the prevalence and prognosis of ventricular arrhythmias in patients
with and without heart disease. Medical therapy including use of antiarrhythmic drugs and
invasive intervention for complex ventricular arrhythmias are discussed. Studies on the ef‐
fect of the automatic implantable cardioverter-defibrillator (AICD) on mortality in patients
with ventricular tachyarrhythmias are discussed. Indications for implantation of an AICD
for primary and for secondary prevention in patients with and without congestive heart fail‐
ure are discussed.
Chapter 6 discusses surgical management of atrial fibrillation.
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1. Introduction
1.1. What should the activity of the heart and the action of the heart mean?
The term “action of the heart” was discussed in detail in my recent publication [1]. The terms
“(any) cardiac activity” or “(any) activity of the heart” should be used only for designation
any aimless functioning of the heart. On the other hand, “the action of the heart” or “the cardiac
action” should be comprehended as the functioning of the heart that is directed to maintenance
of physiological homeostasis, which is the target function in this case. Obviously, the action of
the heart can be put into effect only due to a quantity of control loops and guidance loops2,
which all together organize one and indivisible cardiovascular system. Electrical phenomena,
that accompany the functioning of the heart and can be recorded by electrocardiography, are
nowise satisfying the target of the cardiovascular functioning, because they are but side effects
of the autowave function of the heart [1, 2]. In English scientific and medical literature, the
electrical phenomena to accompany the functioning of the heart are referred to as “the electrical
activity of the heart” in a good accordance with the remarks above.
Any action of the heart that differs from its normal action ought to be ranked among cardiac
arrhythmias. The normal action of the heart (the normal cardiac action) should be understood
as the averaged round the human population cardiac behavior in comfort conditions. The
cardiac arrhythmia arising in comfort conditions is undoubtedly considered to be pathologic.
However, different kinds of cardiac arrhythmia arising in conditions distant from the comfort
may be either pathologic cardiac behavior or normal adaptive response of the heart.
1This chapter is mainly based on our previous publication [2], which is revised and renewed for the aims of this book.
The chapter contains some materials that have not been available previously to English-speaking readers.
2 Notice that the control is used to maintain a desired output of the system under control, while the guidance is intended
for shifting the system from a state A to a state B.See more below.
© 2014 Moskalenko; licensee InTech. This is a paper distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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To make the proper diagnosis of arrhythmia type, one requires a deep understanding of the
basic mechanisms of the cardiac action in being normal as well as in its various disorders.
1.2. Has the time come for alteration of the cardiologic paradigm?
Despite major scientific, medical and technological advances over the last few decades, a cure
of cardiac arrhythmias remains elusive. As a very appropriate example of the problems of
traditional cardiology, which is generally based on physiological approach, is the result of the
CAST [3, 4], a multicenter, double-blind, randomized controlled trial, that has revealed a
higher rate of death from arrhythmia of the patients treated with antiarrhythmic agents in
comparison with the patients assigned to placebo. One of the well-known Russian cardiologists
having analyzed a number of multicenter trials came to the conclusion [5] that treatment with
antiarrhythmic drugs is prescribed nearly at random; he shared his impression with the
following words3: “Potentially any of the known antiarrhythmic drugs can 1) cause an antiarrhythmic
effect, 2) not cause it, 3) be arrhythmogenic. And each of these cases happens unpredictably for a patient.
Therefore, pharmacological tests are strongly required for selecting not only effective but, at least,
harmless therapy for patients with malignant ventricular arrhythmias.” Another author impressed
by the result asserted that antiarrhythmic drugs have “cost more American lives than the Vietnam
War” [6].
Another convincing example of the same is given to us by the recent discussion about the
mechanisms of cardiac fibrillation [7]. The intensity of authors’ disappointment is expressed
by their writing that the nature of fibrillation remains “still so puzzling after 160 years of
inquiry”. A generally accepted definition of cardiac fibrillation is lacking.
Hence, it remains to add that the history of science gives a lot of resembling examples
convincing us that the actual state of affairs suggests a self-evident necessity of drastic
alteration of the scientific paradigm that forms the basis of modern cardiology.
1.3. The physiological description of the heart
The discovery of “animal electricity” must undoubtedly be recognized as a very important
step in understanding the causes and mechanisms of cardiac disorders. Furthermore, this
discovery quickly led to the development of a new language, the physiological language, which
appeared to be very convenient for a generalized description of such properties of living matter
that had been believed to be absolutely different before.
Indeed, what common features between functions of the brain and of the muscles can be found
out by somebody without special knowledge? What common, it would seem, can be between
muscular power and the power of thought? However, the discovery of the “animal electricity”
allowed registering a certain process that can be observed both in nervous and in muscle
3 In the original: «потенциально любой из известных антиаритмических препаратов может: а) обеспечить
антиаритмический эффект; б) не обеспечить его; в) проявить аритмогенное действие. И все это индивидуально
непредсказуемо. Поэтому для больных со злокачественными желудочковыми аритмиями выбор не только
эффективной, но и безопасной терапии требует проведения фармакологических проб» [Голицын С.П. Грани
пользы и риска при лечении желудочковых нарушений ритма сердца. Международный журнал медицинской
практики 2000;(10) 56–64].
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tissues; the process was given the name “excitation”. Since then the nervous and muscle tissues
have been referred to as “excitable tissues”. Further development of ideas about excitable
tissues made scientists draw some extremely important generalizations of all those experi‐
mental data which were collected by the end of the 19th century. It was as long ago as 1900 [8]
that T.W. Engelmann, K.F. Wenckebach and H.P. Bowditch postulated the basic properties of
the myocardium, namely: 1) automaticity, 2) refractory period, 3) all-or-nothing response, 4)
staircase phenomenon. It is the concept of “animal electricity” that has formed the basis for all
the subsequent physiological investigations.
Here we will not dwell on the peculiarities of the physiological language used for description
of biological objects, as these are written in many textbooks of physiology quite a lot and in
detail (for example, see [8–10]). It should only be emphasized that, after replacing the old notion
of a special “living substance”, the physiological language has entirely dominated among
biologists and medical professionals for the whole 20th century.
However, the discussion between modern investigators of the heart reveals faultiness of the
cardiologic paradigm, which is constructed owing to the epoch-making discoveries made by
the greatest physiologists of the 19th and 20th centuries. The faultiness appears to be caused
by our rather simple comprehension how biological systems work, which arose from the
historic specificity of scientific knowledge evolution. During 17–19th centuries the science
development is known to be mainly grounded on the notions of determinism, with great
advantage in applied mechanics to constitute their historical basis. It resulted in permeating
the conception, which is referred to as mechanistic approach4 now, into many fields of science.
Nor has medicine escaped the common lot, since all modern physiology is per se a manifes‐
tation of the mechanistic approach in biology. In accordance with scientific tradition, the
phenomena observed in physiology are explained, in the frames of the mechanistic approach,
as a result of different simple mechanical movements. The movement of ions through mem‐
brane of a biological cell in order to explain the action potential is a good example of the
approach. Prevalent endeavors of modern cardiologists to treat cardiac disorders by adjusting
membrane channels using one or another drug is another such example.
More and more researchers [11–15] are coming to an increasingly profound understanding
that there is a need for an alternative or modified paradigm, in order to consider the multi-
systemic nature of the body's function and its environmental interface if new and more
effective therapies are to be developed. Recognizing a problem is the first step to its solution...
1.4. Cardiophysics
Over the past few decades, it have been accumulated quite a large number of experimental
observations and theoretical results which are poorly fit within the constraints set by the
physiological language. These new discoveries were called attention to, which has resulted in
both drawing new generalizations of the collected scientific knowledge and developing a new
4 To distinguish the “mechanistic approach” and “insight into mechanisms” is extremely important. In the terms of
mathematical physics, the mechanistic approach is based on linear description of nature, with the principle of superpo‐
sition being correct in the frames of this approach; however, non-linear mechanisms are shown to underlie a huge number
of natural phenomena (for example, see [16, 17]), and, hence, insight into such non-linear mechanisms is also very desired.
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language, the biophysical one. For example, while the physiological approach fails to take
chaotic dynamics into account, the biophysical way of living system description, mainly based
on the theory of dynamical system, has equipped scientists with reliable quantitative methods
of studying enorganic phenomena of deterministic chaos. Modern scientific disciplines lead
to the conclusion that often adequate comprehension of a complex system requires analyzing
not the observed values, but some of its integral characteristics, which can be mathematically
obtained as a combination of a number of the observed. Chaotic attractor is a good illustration
of how important ideas of modern physics are for cardiology [16–18]. Whether any sort of
chaotic attractors correspond to the normal cardiac activity, remains still a very good question.
Other crucial phenomena that must certainly be taken into account when treatment for a
cardiologic patient is provided are caused by so-called “bifurcation memory”, which has
attracted special attention of investigators since recently [19–21]. Recent evidence suggests that
similar phenomena can be found in the heart [1, 2]. The results of investigating the bifurcation
memory in a cardiac model are presented and discussed below.
The following three other examples are intended to illustrate how the use of new biophysical
laws has led to a substantially deeper understanding of well-known phenomena, not achiev‐
able within the frames of physiology.
Experimental results from studies in electro- and magnetocardiology gave rise to the modern
biophysical conception of “equivalent bioelectric generator” [22], which is strongly based on
classical electrodynamics. The first example is to demonstrate how the conception of “equiv‐
alent bioelectric generator” was useful for investigation of the QT dispersion problem. QT
dispersion (QTD) is simply defined as the difference between the longest (QTmax) and the
shortest (QTmin) QT intervals within a 12-lead ECG; since its description in 1990, it has been
considered as “undergoing vigorous assessment” for the purpose of early identifying subjects
at high risk of sudden cardiac death, because it was supposed that “the interlead QT interval
differences within a 12-lead ECG might reflect regional differences in myocardial refractori‐
ness, and that this might predict cardiac dysrhythmias” [23]. Common sense based on the
physiological concept seemed to point quite convincingly to the prognostic significance of the
phenomenon of QTD, because it is expected that electrophysiological instability of activation
and recovery of the myocardium must necessarily be reflected on the surface of the torso in a
form of instability of ECG-patterns of the repolarization part of the cardiac cycle. In spite of
that, the accurate, from the standpoint of biophysics, study of possible mechanisms of QTD,
after problems of the QT-interval genesis were considered in terms of biophysical models of
the cardiac electric activity, has led to the conclusion that the duration of the QT-interval (tQT)
are the same in each electrocardiographic leads, and the “QT dispersion” phenomenon stems
mainly from mistakes in detecting the T-wave end [24, 25]. Electrical activity of the ventricular
myocardium in such models is determined only by the equivalent cardiac dipole, which the
spatial vector loops QRS and T correspond to. Although the normal work of the heart can be
successfully described by a dipole, multipole components are given rise to when cardiac
disorders occur. It can be stated therefore that the phenomenon of QTD reflects the contribution
of the multipole components in a total picture of the electrical activity of the heart. Let us denote
duration of QT in different leads as tQT(l), where l belongs to a set of leads L. The theoretical
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consideration within the dipole hypothesis has showed [24] that the QT-duration in different
leads, tQT(l), must be exactly equal to each other with the exception, perhaps, of some very
special cases as well as that, at a low noise level and, consequently, the low threshold of
identification the end of the T-wave, it is difficult to expect a large spread of the values tQT(l)
measured from leads to leads in a case of vector loops with a finite radius of curvature. The
differences in tQT(l) observed in practice can be explained only by algorithms used for
detecting the T-wave end or the ECG isoline, by choice of the thresholds of identification in
relation to the accepted rules of coding the presence of the ECG-waves, or by the actual values
of the signal / noise ratio, as well as by measurement errors. Nevertheless, the authors identified
a number of factors [25] that can even within the dipole hypothesis result in increasing
dispersion of QT-duration both in a sequence of cardiocycles from the same leads and in a set
of records of the same cardiac cycle simultaneously registered in the different leads. Two most
significant factors are following:
1. There is no clear correspondence between the positions of electrical and anatomical axes
of the heart due to physiologically normal variations in topography of His-Purkinje
system.
2. QT-dispersion also depends on the random rotations of the ventricles relative to the
measuring electrodes, for example, during rotation of the heart relative to its anatomical
axes.
Hence, the investigation [24, 25] has shown that it is impossible at present to reject the
hypothesis of random nature of the QTD changes, since all of these factors that generate QTD
changes should be considered as random variables. Regardless of the biophysical result, it is
still believed, however, that “increased QT dispersion is associated with increased risk of
cardiovascular death” [26].
The second example deals with defibrillation. Cardiologists are known to have been working
on the problem of defibrillation for several decades, but desired level of success has not yet
been achieved, and the fundamental mechanisms that underlie defibrillation still remain a
mystery [27]. At present there is no generally accepted point of view on the mechanisms of
postshock arrhythmia induction resulting from unsuccessful defibrillation. A number of
factors were assumed among the possible causes of an unsuccessful defibrillation; for example:
1) residual fibrillation activity in areas of weak voltage gradient, 2) new autowave vortices
generated by a shock, 3) focal ectopic activity in areas of myocardium traumatized the action
of electric current that a defibrillator produces. Suggested in the last years, the new Theory of
Virtual Electrodes [28, 29] helps to understand failures of the defibrillation protocols presently
in use. One of the most important practical conclusions of the theory is the recommendation
to use a biphasic defibrillation stimulus, which can significantly increase the effectiveness of
defibrillation. It should be noted that the emergence of new look at defibrillation and the
subsequent development of the theory of virtual electrodes became possible only by using one
of the fresher biophysical models of such intricate active medium as the myocardium, which
is referred to “bidomain model”. In addition, several researches [30, 31], which also are carried
out in the frames of cardiophysical approach, are aimed at developing new techniques of
defibrillation based on suppression of cardiac turbulent dynamics by weak local excitations.
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language, the biophysical one. For example, while the physiological approach fails to take
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on the theory of dynamical system, has equipped scientists with reliable quantitative methods
of studying enorganic phenomena of deterministic chaos. Modern scientific disciplines lead
to the conclusion that often adequate comprehension of a complex system requires analyzing
not the observed values, but some of its integral characteristics, which can be mathematically
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Returning to the results of CAST and other similar investigation, we ought to remind that these
results were evident directly from the very early theoretical works of those scientists who can
undoubtedly be mentioned among the founders of a new branch of science, cardiophysics.
First of all, I mean here the studies by Arthur Winfree [32], who has revealed the principal
autowave regimes of the simplest active medium and their dependence on the basic integral
parameters of the medium, as well as by Valentin Krinsky and Iury Kokoz [33], who have
shown that every active medium should demonstrate the same set of principal autowave
regimes, because the corresponding systems of partial differential equation can always be
reduced to the simplest one. Taken together these results lead to the obvious conclusion that
any manipulation with the membrane ion channels of cardiomyocytes directed to the sup‐
pression of ventricular tachycardia by forcing autowave vortices to perform uniform circular
motion (which corresponds to monomorphic tachycardia) always results in to the displace‐
ment of myocardial state very far from normal, which must inevitably increase patient
mortality. Note that the hypothesis about the displacement of myocardial state was confirmed
later in an experimental work with lidocaine [34], in good accordance with Winfree’s predic‐
tion. Another biophysical study [35] demonstrated one more reason why medicines that
exhibit strongly pronounced antiarrhythmic properties when affecting single cardiomyocyte
increase in 2-3 times the frequency of sudden arrhythmic death in comparison to untreated
patients. At first glance, it does seem paradoxical that the same drug has antiarrhythmic effect
on isolated cells and pro-arrhythmic effect on the multicellular system (the whole heart). In
the computational imitating experiments, the author managed nevertheless to discover that
sodium channel blockers can greatly increase the so-called vulnerable period in myocardium,
which occurs because of a decrease of velocity of the excitation wave, and also because of
reduction of excitability gradient. The next remark deals with ECG diagnostics. Notwith‐
standing the properties of myocardium are known to affect ECG, the investigation of the
dependence of several ECG characteristics on the threshold of excitation, which was carried
out by means of mathematical modeling monomorphic arrhythmias in a homogeneous two-
dimensional excitable medium, revealed [36] that these arrhythmias appear under both
decreased and increased values of the excitation threshold. Hence, this result leads also to the
conclusion that medical treatments are prescribed nearly at random when a cardiologist make
his or her decision only on the base of ECG analysis without knowing about real changes of
the excitation threshold. Generalizing these three biophysical conclusions about medical
treatment of tachycardia, should we be surprised that the success of such treatment can hardly
be called acceptable?
In addition to remarkable progress in biophysics, another important conceptual breakthrough
of science was performed in the field that now is referred to as nonequilibrium thermodynam‐
ics, “physics of becoming” [37] or synergetics [38], which “represents a remarkable confluence of
many strands of thought, and has become a paradigm in modern culture” [39]. Biological
systems are complex and nonlinear, and, therefore, demonstrate complex and nonlinear
behavior, which may be chaotic, in many cases; the heart appears to be the same [14, 17, 18,
28, 30, 31].
All these examples should be recognized as proofs of birth of a new science. Thus, we ought
to conclude that the 21st century seems to yield a new discipline, which is referred to as
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cardiovascular physics5 or cardiophysics (since it combines cardiology with novel achievements
of physics). Cardiophysics is an interdisciplinary science that stands at the junction of cardi‐
ology and biophysics, with researchers using the methods of, and theories from, physics to
study cardiovascular system at different levels of its organization, from the molecular scale to
whole organisms. Being formed historically as part of systems biology, cardiophysics is
designed to reveal connections between the physical mechanisms, underlying the organization
of the cardiovascular system, and biological features of its functioning.
2. Basic biophysical mechanisms of maintaining the action of the heart
2.1. Historical remarks
About fifty year ago, physicists and mathematicians managed to perceive that the processes
that take place in a “purely physical” systems (e.g., lasers, or even in boiling water) are similar
in some of their properties to the processes observed in the physiology of excitable biological
tissues. The understanding came gradually that phenomena such as irritability, conductivity,
all-or-nothing response, refractory period etc. are inherent not only exclusively in biological
objects, but also typical for non-living nature. It is important to comprehend that the speech
here is not about some analogies, but exactly about a new scientific generalization of the
accumulated scientific knowledge, and that the generalization made by researchers in respect
of particular types of behavior of living and some non-living systems is based on the certain
entirely real properties of such systems. This generalization led to the development of a new
language, biophysical one, which are more universal and more powerful. The new language
has reproduced the description of all that was already described earlier in the physiology, but
it also allows in unified terms to represent a wide range of experimental data, the description
of which the physiological language performed poorly. The new expanded description of the
cardiac action is offered in this chapter further.
Undoubtedly, the term “autowave”, which refers to a large number of different biological
objects, plays one of the most important roles in the new biophysical language.
The first who studied actively the self-oscillations was Academician A.A. Andronov, and the
term “auto-oscillations” in Russian terminology was introduced by him in 1928. The term
“autowaves” was proposed in the second half of the 20th century, probably, on the analogy of
the previously used “auto-oscillations”. The classical axiomatic model of autowaves in
myocardium was published in 1946 by Norbert Wiener and Arturo Rosenblueth [40]. During
1970-80, major efforts to study autowaves were concentrated in the Institute of Biological
Physics of the USSR Academy of Sciences. A huge role in the study of autowave models of
cardiac tissue belongs to D. Noble and members of his team from the University of Oxford [12,
13]. There are a lot of other researchers over the world who contributed to development of the
5 For example, there are already the Group of Nonlinear Dynamics & Cardiovascular Physics of the 1st Faculty of
Mathematics and Natural Sciences in the Institute of Physics of Humboldt University of Berlin (German) and the
Cardiovascular Biophysics Laboratory in Washington University (USA).
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theory of the autowave processes, i.e. the processes in the active media. Since then, as the peculiar
properties of the active media has been understood, the autowave processes attract attention
of mathematicians, physicists and biologists, and it turned out, that the experience that had
been gained by physiologists before gave a very useful basis for constructing the new bio‐
physical language for describing phenomena observed in the active media of different nature.
2.2. Mathematical aspects
According to [41], the term “autowaves” is used for designation of a self-sustaining nonlinear
undulatory process in a non-equilibrium (active) medium, the process remaining unchanged
for sufficiently small changes in both the initial and boundary conditions and described by the
system of parabolic partial differential equations with a nonlinear free member, which in its
general form can be written as follows: u→ t = f
→
(u→ ) + DΔu→ , where u→  is a vector of state variables,
u→ t  is the time derivative of the u
→ , f
→
(u→ ) is a vector of free members (i.e., of nonlinear functions),
D is a diagonal matrix of the coefficients that describe diffusion of each component, and Δ is
the Laplace operator. Thus, the mathematical apparatus that are often used for describing
autowave processes are the equations of the diffusion type with an active nonlinearity (i.e.
reaction–diffusion systems).
It is impossible here to delve into the details of the mathematical description of autowave
processes, but there are an abundance of literature on this topic (for example, see [32, 33, 40–
47]). Therefore only those aspects which are the most important for understanding the nature
of cardiac arrhythmias will be touched on here. To apprehend distinctly the signification of
the term “autowaves”, several things should be noted.
Figure 1. Phase portraits (left column) and the corresponding behavior (right column) of a single element of the active
medium: row A — excitable, row B — bistable, row С — self-oscillating element types. Rose area corresponds to
f 1(u, v) > 0, and blue color highlights the area, where f 1(u, v) < 0. See description in the text.
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First of all, a general property of such systems, regardless of whether they are of animate or
of inanimate nature, is that they consist of external energy sources distributed in the space;
and such special systems were called “active media”. From the thermodynamic point of view,
these are open systems far from thermodynamic equilibrium [41]. It is the quality that compels
the behavior of the active media to differ fundamentally from that of systems which have been
familiar to physicists of the 19th and 20th centuries. Even the waves in active media propagate
according to essentially different laws than the well-known acoustic or electromagnetic waves
do. Unlike linear waves — such as sound waves, electromagnetic waves and other, which are
inherent in conservative systems and mathematically described by linear second order
hyperbolic equations (wave equations), — dynamics of an autowave in terms of differential
equations can be described by parabolic equation with nonlinear free member of a special form (the
equation is presented at a few lines above).
It was shown in 1973 [33] that every system of mathematical differential equations describing
the process of excitation of biological tissues can be simplified with use of some standard
mathematical procedures to only two equations that describe, with an acceptable accuracy, the
real object for which the “exact” original system of many equations was composed. It proved
that such systems are a very important kind of active media, which has been called “active
media with recovery” (note, that nerve impulse, which serves typical example of autowaves in
the active medium with recovery, was studied as far back as 1850 by Hermann von Helmholtz).
Thus, the following system of two equations is recognized to be the base model of the active
medium with recovery [41]:
1 1( , )e × = + Dtu f u v D u (1)
2 2( , )= + Dtv f u v D v (2)
where ε < <1.D2 =0 for excitable biological membranes, whereas both the diffusion coefficient,
D1 and D2, are different from zero for chemical systems. For biological membranes, the
meaning of the variables of state is as follows: u corresponds to the membrane potential, and
v is the conductivity of the slow component of the membrane current. Although the exact
description of a specific sort of active medium can take much more equations (for example,
the modern model of the human myocardium consists of more than twenty equations), the
most important basic properties of autowave processes are well described already within this
basic model of active media.
The next essential moment is that the active media are characterized not only by the connec‐
tions between the adjacent points of the medium (i.e. by flows of substances and / or energy,
such as heat conduction or diffusion, which is described by DΔu→  in the system of equa‐
tions).The concrete form of the free member f
→
(u→ ) is of exceptional importance, because all
wave processes are generated by the nonlinear dynamics of the point system u→ t = f
→
(u→ ), which
always must be self-oscillating or potentially self-oscillating. In the base model of the active
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medium with recovery, the complicated nonlinear behavior of a single element is described
by the free member, i.e. as the function f 1(u, v), which usually has N-shaped form (Figure 1).
Three simplest types of such elements can be distinguished [17, 42, 43]; one can also say that
a single element has three essentially different regimes of its behavior, because it is possible
to force the element change its type. These are: self-excited (or self-oscillating), excitable (or
waiting) and trigger (or bistable) regimes. Accordingly, there are three types of homogeneous
active media composed of these elements.
The excitable element (row A of Figure 1) has only one stable steady state (the point O, which
is the intersection of the two null isoclines; a quiescent state of the excitable element corre‐
sponds with this point). External impact over a threshold level (i.e., greater than the length of
the segment OA), can bring the excitable element out from its steady state and force it
accomplish a certain evolution (in the phase portrait shown by the orange line) before returning
to its quiescent state. An excited element may affect the adjacent elements moving them out
from their quiescent state. As a result, an autowave of excitation spreads through the medium.
Excitable media like the working myocardium consist of such excitable elements. Hence, it
becomes obvious the fallacy of popular opinion that “all cardiac cells have spontaneous firing
capacity, but only at a very slow heart rate”, the assertion which can be often met in books and
papers.
The bistable element (row B of Figure 1) has two steady states at the points O1 and O2, each of
which can be whether stable or unstable, while the point O in this case is always unstable.
Transitions between the two stationary states occur when an external impact exceeds a certain
threshold level (the same way as it does in the excitable element). In such media there can be
the trigger wave propagation, which switches the media from one steady state to the other. A
classic case of such a switching autowave (and, perhaps, the simplest autowave phenomena)
is falling dominoes. Another simple example of the bistable medium is burning paper: the
switching wave propagates on it in the form of a flame, switching paper from the normal state
to its ashes.
The self-oscillating element (row C of Figure 1) has no stable steady states (the point O in this
case is always unstable) and therefore it permanently performs oscillations of certain fixed
form, amplitude and frequency. An example of a self-oscillating medium is the sinus node of
the heart, in which excitation impulses arise spontaneously. External influence can disturb
these oscillations, but, after some relaxation time, all their characteristics, except for the phase,
revert to the stable values, although the phase can be changed, resulting in the phase waves
spread in the self-excited medium. Such phase waves can be observed in electro-garlands or
in certain chemical media.
So it can be clearly seen on the phase portrait of the basic system of equations describing active
medium of different types (see Figure 1) that a significant difference between these three types
of behavior of an active medium is caused by the quantity and the position of its singular
points. The shapes of autowaves observed in reality can be, however, very similar to each other,
and therefore it can be difficult to assess correctly the type of element only by the form of its
excitation impulse.
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It is reasonable that a good number of examples of combined active media, which are composed
of different types of elements, can be found everywhere. The heart is just one example of a
highly organized combined active medium.
2.3. Pacemakers
The region of a combined active medium which consists of self-oscillatory elements is called
the pacemaker. This region emits autowaves with a certain stable period. An example of a
biological pacemaker in the heart of the human is the sinus node, which is constituted of a
group of cells functioning in the self-oscillating mode.
In thin enough layers of the active medium, the pacemaker creates a picture in the form of ring
waves diverging from a center (Figure 2). Period of pacemaker oscillations is determined by
its intrinsic properties and can be arbitrary, but not less than the absolute refractory period,
because a new action potential cannot arise during the absolute refractory period (see below).
If there are a number of self-oscillating elements with different periods in the medium, every
element with low-frequency activity is suppressed by the element with the highest frequency
[41]. For a long time physiologists have known about the hierarchy of pacemakers in the heart,
and the same result was obtained mathematically in the second half of twentieth century.
Pacemakers in the heart are the sinoatrial (SA) node, the atrioventricular (AV) node and the
bundle of His and Purkinje fibers. The sinoatrial node normally initiates action potentials,
simply because it generates impulses slightly faster than the other areas with self-oscillating
activity. The remaining pacemakers normally are in a depressed state, which is reflected by
physiological language as “latent pacemaker capability.” If the SA node is suddenly “out of
order”, the fastest of the “spare” pacemakers (i.e., the AV node) enters into work, and, as a
result, the heart continues its action nearly in normal regime. This duplication of parts of the
system is aimed, evidently, to improve its reliability.
However, recent studies [49, 50] have shown that the rhythmic activity of the self-oscillating
elements in the group which form the body of the pacemaker is synchronized by more complex
laws, and the ascertained earlier variant of synchronization from the element with the highest
frequency of the oscillations is only a special case. The problem of the control of cardiac rhythm
has been considered in terms of the general theory of the synchronization of relaxation systems,
and, as result, the main pathways of the control of cardiac rhythm have been revealed: (1)
control with regard for the features of synchronization of relaxation systems during the
formation of the unified heart rhythm due to the acceleration of the slow diastole depolariza‐
tion phase; (2) control by gradual integral increase in the duration of the slow diastole
depolarization phase; (3) subsequent synchronization of the rhythm as a delay of the slow
diastole depolarization phase.
2.4. Traveling autowaves
The concept “traveling autowave” (or “autowave of excitation”, or “propagating autowave”) should
be considered as generalization made in the new biophysical language of the concept “exci‐
tation wave”, which is understood in the frames of physiology as an electrical wave that
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medium with recovery, the complicated nonlinear behavior of a single element is described
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tation wave”, which is understood in the frames of physiology as an electrical wave that
Basic Mechanisms of Cardiac Arrhythmias
http://dx.doi.org/10.5772/57557
11
propagates along a muscle fiber just before its contraction. Autowaves of excitation are perhaps
the most common in nature autowave phenomena, they occur in a variety of physical, chemical
and biological objects. According to the earliest investigations [40–42], “traveling autowave”
was a designation of the wave processes that have stable (“self-sustaining”) parameters, such
as speed, amplitude, and pulse shape, independently of initial conditions. It was believed also
that “if two autowaves propagate toward each other, they do not pass through each other, like
linear waves and solitons do it, but they annihilate in a collision” [41]. Autowaves was believed
to be not able to interfere or to reflect from obstacles. These properties were considered as a
significant difference of autowaves from the usual electromagnetic or sound waves.
Analysis of the systems of mathematical equations that describe the active medium has given
not only a quite good explanation of the phenomena known from physiology, but also has led
to the discovery of many new interesting properties of the active media, even in the earliest
works. For example, the dependence of the traveling autowave velocity on the curvature of its
front was obtained as a result of this analysis: the velocity decreases with increasing curvature,
Figure 2. Spatiotemporal organization of the normal cardiac action. Green inscriptions and arrows indicate the time
of arrival of the excitation wave in the corresponding region of the heart (using the data published in [48]). Blue incuts
show the shape of the traveling wave (“action potential”) in different areas of the heart caused by the difference in
properties of the elements of the excitable medium that forms the heart tissue. Beige incut demonstrates the normal
propagation of the traveling-wave of excitation from the pacemaker area in the center (from the sinus node) towards
the edges (through the working myocardium) in a simple simulation model.
Cardiac Arrhythmias - Mechanisms, Pathophysiology, and Treatment12
and there is a critical value of the curvature, above which the excitation wave propagation
becomes impossible. For example, see [41, 47, 51–53]. The critical curvature leads, in particular,
to the fact that the excitation autowaves can not pass through an aperture of sufficiently small
size in a non-excitable obstacle (e.g., in the postinfarction scar). Other properties of traveling
autowaves associated with critical curvature underlie different mechanisms of reentrant
tachycardias, which will be considered in more details below.
Another interesting property of active media, which was found out in the earliest works, is
that, for periodic autowaves, their velocity decreases with increasing frequency, and explicit
expressions for calculating its value were derived. In such a way, it has been shown mathe‐
matically that the stationary propagation of autowaves is possible only as long as the wave
period T  is more than a certain value Tmin, and that there is a certain mathematical dependence
of the wave velocity on the medium properties [54, 55]. When T <Tmin, the propagation occurs
in some peculiar manner: though the excitation waves propagate without attenuation, not all
of them propagate, but only, for example, every third or fourth wave, depending on T , which
is known in cardiology as Wenckebach periodicity.
The existence of Tmin is caused by the fact that the excitation autowave can not propagate until
the recovery processes, which are described with the slow variable of the base model, has
finished. This property of active media is called refractoriness, and the typical recovery time
is called the refractory period.6 Refractoriness is the fundamental property of any object of
autowave nature (especially excitable medium) not to respond on stimuli, if the object stays
in the specific refractory state. In common sense, refractory period is the characteristic recovery
time, i.e. the period of time that is associated with the motion of the image point on the left
branch of the isoclinic curve ut =0 (i.e. the segment DO; see row A of Figure 1). The relative
refractory period is understood as the immediately following interval during which initiation
of the next action potential is inhibited but not impossible. In the state of relative refractoriness,
propagation of the next autowave is possible also before the full recovery of the media, but
with slightly less velocity depending on the time elapsed since the passage of the previous
wave. For periodic pulse, this results in dispersion, which is dependence of the autowave
velocity on their frequency [44, 56]. If the time interval after the passage of the previous wave
is too short, then propagation of the subsequent wave is impossible, so that, for every excitable
medium, there is a certain minimal interval between a couple of successive waves, the absolute
refractory period. The absolute refractory period is the interval during which the next action
potential absolutely cannot be initiated, no matter how large a stimulus is applied. But, even
in a fully recovered excitable medium, velocity of the excitation autowaves can not exceed a
certain value, which is the maximum value for the medium and which is equal to the velocity
of the traveling autowave of zero curvature (i.e. with the flat front, the flat autowave). The
mathematical details can be found in the suggested literature.
6 Let us recall that the existence of the refractory period in the cardiac muscle has been ascertained as long as 1876 by EJ
Marey, who was an extremely gifted French researcher in the physiology of the heart. It was he, who also introduced this
term as well as who noted that the refractory period of the cardiac muscle lasts conspicuously longer than in skeletal
muscle or nerve. In 1906, A.J. Carlson was the first who used the terms "absolute refractory period" and "relative refractory
period"[8].
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A lot of active media are characterized by the pronounced relaxantness, i.e. the time interval of
refractoriness is noticeably longer than the time interval of excitation. In the basic model of the
active medium with recovery, relaxantness is determined by a small parameter ε [41]. For
cardiac tissue, the refractory period exceeds the excitation time approximately 300 times. This
leads to the fact that the excitation wave in the heart has a sharp front edge, but has no
pronounced trailing edge. The presence of prolonged refractoriness allows to explain, for
example, the annihilation of the excitation waves when they collide. Because of long refractory
tail, where the excitation is not possible, two waves can not pass through each other and die.
However, more recent studies [57–59] have shown that autowaves can exhibit more compli‐
cated behavior, and the properties described in the early classical works are observed only in
a number of special cases. For example, it was found out that annihilation does not always
occur in a collision of autowaves, but under certain conditions autowaves can pass through
each other like solitons. Diffraction, reflection and splitting are also possible to observe for
autowaves under certain conditions. It was shown that autowave shape and velocity may vary
during its spontaneous evolution caused by the bifurcation memory [20, 21]. It was declared
[20]:“The general theory of active media remains to be formulated, and practically each in-
depth study reveals new types of their dynamics and self-organization. There is no reason to
think that these types are unique; on the contrary, the available experience indicates that, once
described, a new dynamic regime or bifurcation is thereafter found in other systems, even
those that have been investigated for a long time”. So it can be expected that further deepening
of our knowledge of the properties of autowaves will also help us to understand the failure in
the treatment of cardiac arrhythmias.
2.5. Spatiotemporal organization of the normal cardiac action
The main goal of the normal cardiac action is the pumping function of the heart. It is the ordered
propagation of the excitation autowave in the myocardium that maintains efficient contraction
of the heart, thereby allowing blood to be pumped throughout the body. For the pumping
function of the heart to be maintained effective, appropriate spatiotemporal organization (STO)
of the excitation process is extremely important. The appropriate STO is caused by the very
structure of the heart, i.e. by the special spatial arrangement of various autowave elements
(cardiomyocytes) with significantly different behavior (which, as mentioned above, is descri‐
bed with use of the nonlinear free member f
→
(u→ ) in the base model of the active medium with
recovery). Due to the special spatial structure of the heart as a whole organ, well-known from
courses of anatomy and physiology, the only mode of traveling waves initiated from the
sinoatrial node occurs in the normal heart during the normal cardiac activity (Figure 2).
It is disorders of the spatiotemporal organization of the process of myocardial excitation and
contraction that should be understood as a generalized mechanism of cardiac arrhythmias,
which usually manifests with various electrical indications used by doctor to set the correct
diagnosis. Note that these ideas are being developed in the concept of the autowave function
of the heart [1], which has not yet received a rigorous mathematical formulation.
The simplest examples of disorders of the appropriate STO are various conduction block. The
mechanism of partial conduction block has been described above from the biophysical
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standpoint. The so called electrical conduction system of the heart should be considered only
as an illusive perception of the real complicated active media that builds the body of the heart.
The illusion is caused by sincere desire to describe the heart strictly within the frames of the
mechanistic approach, which requires that some specific electric wires were searched for.
However, there are not any electric wires in the cardiac tissue, which rather presents the
network of active elements of different types. Each of these elements can be forced change its
type by influence of humoral, nervous or metabolic factors. The target function of the inherent
circulatory regulation consists in maintaining the appropriate STO independently from
uncontrolled influence of humoral, nervous or metabolic factors. In those cases where the
regulation is untenable, pathological states develop leading to disease. For example, additional
sources of autowaves, arising from pathological changes of certain areas of the myocardium,
can result in severe cardiac arrhythmias.
It is extremely important to understand that the function f
→
(u→ ) may be changed in the same
way at various combinations of values of the individual parameters of the cardiomyocyte, but
even utterly different combinations of individual parameters may result in the same clinical
manifestations of cardiac disorders inasmuch as they are determined by the state of the
function f
→
(u→ ) rather than by any of the individual parameters of the myocardium. It is not
sodium, potassium, calcium, etc. conductivity of membrane ion channels in cardiomyocytes
(as it is usual for physiologists to think) causes the normal cardiac action, but exactly that of
their combinations which is optimal for the given conditions of functioning of the organism.
It is likely that causes of the cases of unsuccessful pharmacological treatment of cardiac
arrhythmias, which were revealed, particularly, in CAST, hide themselves somewhere here.
Hence, cardiac arrhythmia should be considered in a more general way: they occur either as
a consequence of disorders of STO, or as a consequence of disorders in inherent circulatory
regulation, but not as isolated disorders of the cardiac electrical activity.
3. Basic biophysical mechanisms of cardiac arrhythmias
Since autowave processes were pointed in the role of sources of cardiac arrhythmias, the
number of known types of sources of cardiac arrhythmias has increased significantly. This
increase is associated not only with discovery of a number of new mechanisms of arrhythmias,
but also with distinction of the mechanisms that were equated with each other before. So for
reentry, a mechanism of arrhythmias known since the 19th century, it is accepted to distinguish
now at least five types: (1) running around a ring, (2) spiral wave, (3) autowave reverberator,
(4) multiple reverberators, and (5) fibrillation as chaotic behavior of autowave reverberators.
In accordance with the classification of principal mechanisms of cardiac arrhythmias that was
suggested in [60], the running around a ring as well as the spiral wave should be reckoned
among anatomic reentry, while the others belong to functional reentry.
Altered automaticity, which is the second classical mechanism of arrhythmogenesis, can be
divided into (1) altered normal automaticity, (2) abnormal (or induced) automaticity, and (3)
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sodium, potassium, calcium, etc. conductivity of membrane ion channels in cardiomyocytes
(as it is usual for physiologists to think) causes the normal cardiac action, but exactly that of
their combinations which is optimal for the given conditions of functioning of the organism.
It is likely that causes of the cases of unsuccessful pharmacological treatment of cardiac
arrhythmias, which were revealed, particularly, in CAST, hide themselves somewhere here.
Hence, cardiac arrhythmia should be considered in a more general way: they occur either as
a consequence of disorders of STO, or as a consequence of disorders in inherent circulatory
regulation, but not as isolated disorders of the cardiac electrical activity.
3. Basic biophysical mechanisms of cardiac arrhythmias
Since autowave processes were pointed in the role of sources of cardiac arrhythmias, the
number of known types of sources of cardiac arrhythmias has increased significantly. This
increase is associated not only with discovery of a number of new mechanisms of arrhythmias,
but also with distinction of the mechanisms that were equated with each other before. So for
reentry, a mechanism of arrhythmias known since the 19th century, it is accepted to distinguish
now at least five types: (1) running around a ring, (2) spiral wave, (3) autowave reverberator,
(4) multiple reverberators, and (5) fibrillation as chaotic behavior of autowave reverberators.
In accordance with the classification of principal mechanisms of cardiac arrhythmias that was
suggested in [60], the running around a ring as well as the spiral wave should be reckoned
among anatomic reentry, while the others belong to functional reentry.
Altered automaticity, which is the second classical mechanism of arrhythmogenesis, can be
divided into (1) altered normal automaticity, (2) abnormal (or induced) automaticity, and (3)
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triggered activity. Regarding increased automaticity7, several new types of automatic nature were
also discovered, in addition to the pacemaker activity. These are: (1) induced automaticity, (2)
leading center, (3) triggered activity by the mechanism of early afterdepolarization, and (4)
triggered automaticity by the mechanism of delayed afterdepolarization.
And each of these mechanisms of arrhythmias can cause disarrangement of the cardiac action,
manifesting themselves mostly as ectopic sources of the excitation autowaves. Using new
biophysical language, we have attempted to describe below more detailed the currently known
types of mechanisms of cardiac arrhythmias.
3.1. Increased automaticity
The term “cardiac automaticity” refers to a biological event characterized by spontaneous
process of action potential generation in separate groups of myocardial cells. “Spontaneous”
should be understood as being conditioned by intrinsic dynamics, and developing or occurring
without apparent external influence, force, cause, or treatment. A spontaneous process is
capable of proceeding in a given direction without needing to be driven by an outside source
of energy. It is accepted that three different mechanisms may independently underlie cardiac
automaticity. These are: (1) the proper automaticity of specialized cells of cardiac conduction
system, (2) induced automaticity arising or growing under external influences, and (3)
triggered activity, which is the automaticity provoked by a series of electrical stimuli.
About the proper automaticity of cardiac conduction system was already told above; it
underlies normal cardiac function. It is widely thought that the proper automaticity of
specialized myocardiocytes is defined by the capability of cardiac cells to undergo spontaneous
diastolic depolarization and to initiate an electrical impulse in the absence of external electrical
stimulation. This is so indeed that the specialized conduction system of the heart has the special
property of depolarizing without any external influence with a slow, positive increase in
voltage across the cell's membrane (the membrane potential) that occurs between the end of
one action potential and the beginning of the next action potential. But let's look intently again
at Figure 1. Process of spontaneous depolarization corresponds with the motion of the image
point from the point D down the left branch of the isoclinic curve ut =0. It is easy to perceive
that a self-oscillating element differs from an excitable or from a bistable element only by the
absence of the stable steady state at the point O. This difference results in birth of a limit
cycle8, which force the element fire again and again. Hence, it is the limit cycle that should be
recognized as the cause of the proper automaticity of the specialized myocardiocytes! And
what is more, it is likely that a dynamic system described by the base model can be constructed
in such manner that the left branch of the isoclinic curve ut =0 would go in the other direction
7 Some people find it difficult to discern the difference between enhanced and increased cardiac automaticity. It seems
that to distinguish between enhanced and increased cardiac automaticity is useful for some reasons. While enhanced
cardiac automaticity is referred to reactions of normal adaptation (such as influence of autonomic nervous system because
of stress), increased cardiac automaticity is addressed rather to pathological alterations of cardiac tissue properties. Some
authors prefer using the term “abnormal induced automaticity” instead of “increased cardiac automaticity” (see for
example [60]).
8 In mathematics, in the study of dynamical systems with two-dimensional phase space, a limit cycle is a closed trajectory
in phase space.
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(i.e. line would go from the right top down to the left), and therefore we would have sponta‐
neous diastolic hyperpolarization, — however, a bistable element would fire again and again
even in such a case, because of absence of the stable steady state at the point O on the left
branch. Thus, acceptance of spontaneous diastolic depolarization as a cause of automaticity
seems to be a mistake due to misunderstanding of nature of the self-oscillating automaticity.
Figure 3. A few examples of increased automaticity caused by transformation of an excitable element in a self-oscillat‐
ing one. Designations are as in Figure 1. It is assumed that the scale is the same in all examples. See description in the
text.
Altered normal automaticity is the proper automaticity of cardiac conduction system altered by
certain influences. It should be distinguished between primary and secondary permanent
increase of frequency of the self-oscillating elements of cardiac conduction system. While the
primary increase is conditioned by the processes that have happened inside the cardiomyocyte,
and therefore may be rigid against neural and humoral influences, the secondary increase is
caused by the neural and humoral influences, and, consequently, is a reversible process. A
classic example of the secondary alteration is hyperthyroidism; myocardial infarction provides
with examples of the primary alteration.
Induced automaticity is assumed [41] to result from either transforming a waiting regime of
certain myocardial area (or even a single cardiomyocyte) in a self-oscillating regime or a
sufficient increase of self-oscillating activity of the latent pacemaker cells of the cardiac
conduction system. In either case, causes of induced automaticity are similar; among these
may be changes of characteristics and ratios of ionic currents in the cell membrane using
hormones, poisons, external sources of electric current, etc. Whether the cell spontaneously
generates action potential or not, depends on the ratio of incoming and outgoing ion currents.
However, as has been stated above, it would be a mistake to assume that it is the spontaneous
depolarization after reaching the threshold value of the transmembrane potential that leads to
generating spontaneous action potential. Let's look again at Figure 1. The distance between a
point of the stable steady state on a branch of the isoclinic curve ut =0 and the middle section
of the same curve (i.e., the segment OA in the cases of the excitable regime, as well as the
segment O1A or O2C in the cases of the triggered regime) corresponds with the threshold value;
but it is evident, however, that any saying about the threshold value sounds absurdly in the
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diastolic depolarization and to initiate an electrical impulse in the absence of external electrical
stimulation. This is so indeed that the specialized conduction system of the heart has the special
property of depolarizing without any external influence with a slow, positive increase in
voltage across the cell's membrane (the membrane potential) that occurs between the end of
one action potential and the beginning of the next action potential. But let's look intently again
at Figure 1. Process of spontaneous depolarization corresponds with the motion of the image
point from the point D down the left branch of the isoclinic curve ut =0. It is easy to perceive
that a self-oscillating element differs from an excitable or from a bistable element only by the
absence of the stable steady state at the point O. This difference results in birth of a limit
cycle8, which force the element fire again and again. Hence, it is the limit cycle that should be
recognized as the cause of the proper automaticity of the specialized myocardiocytes! And
what is more, it is likely that a dynamic system described by the base model can be constructed
in such manner that the left branch of the isoclinic curve ut =0 would go in the other direction
7 Some people find it difficult to discern the difference between enhanced and increased cardiac automaticity. It seems
that to distinguish between enhanced and increased cardiac automaticity is useful for some reasons. While enhanced
cardiac automaticity is referred to reactions of normal adaptation (such as influence of autonomic nervous system because
of stress), increased cardiac automaticity is addressed rather to pathological alterations of cardiac tissue properties. Some
authors prefer using the term “abnormal induced automaticity” instead of “increased cardiac automaticity” (see for
example [60]).
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(i.e. line would go from the right top down to the left), and therefore we would have sponta‐
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even in such a case, because of absence of the stable steady state at the point O on the left
branch. Thus, acceptance of spontaneous diastolic depolarization as a cause of automaticity
seems to be a mistake due to misunderstanding of nature of the self-oscillating automaticity.
Figure 3. A few examples of increased automaticity caused by transformation of an excitable element in a self-oscillat‐
ing one. Designations are as in Figure 1. It is assumed that the scale is the same in all examples. See description in the
text.
Altered normal automaticity is the proper automaticity of cardiac conduction system altered by
certain influences. It should be distinguished between primary and secondary permanent
increase of frequency of the self-oscillating elements of cardiac conduction system. While the
primary increase is conditioned by the processes that have happened inside the cardiomyocyte,
and therefore may be rigid against neural and humoral influences, the secondary increase is
caused by the neural and humoral influences, and, consequently, is a reversible process. A
classic example of the secondary alteration is hyperthyroidism; myocardial infarction provides
with examples of the primary alteration.
Induced automaticity is assumed [41] to result from either transforming a waiting regime of
certain myocardial area (or even a single cardiomyocyte) in a self-oscillating regime or a
sufficient increase of self-oscillating activity of the latent pacemaker cells of the cardiac
conduction system. In either case, causes of induced automaticity are similar; among these
may be changes of characteristics and ratios of ionic currents in the cell membrane using
hormones, poisons, external sources of electric current, etc. Whether the cell spontaneously
generates action potential or not, depends on the ratio of incoming and outgoing ion currents.
However, as has been stated above, it would be a mistake to assume that it is the spontaneous
depolarization after reaching the threshold value of the transmembrane potential that leads to
generating spontaneous action potential. Let's look again at Figure 1. The distance between a
point of the stable steady state on a branch of the isoclinic curve ut =0 and the middle section
of the same curve (i.e., the segment OA in the cases of the excitable regime, as well as the
segment O1A or O2C in the cases of the triggered regime) corresponds with the threshold value;
but it is evident, however, that any saying about the threshold value sounds absurdly in the
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case of the self-oscillating regime because no threshold value exists in this case. The illusion
that generating spontaneous action potential is caused by the spontaneous depolarization of
cardiac cells has spread widely among physiologists only because of their firm intention to
stay strictly within the frames of the mechanistic approach. The real cause of transition of an
active element from waiting in a self-oscillating regime is such a deformation of its phase
portrait which leads to a shift of the point O onto the middle section of the isoclinic curve.
Changes of the threshold level also occur as a result of one or another deformation of the phase
portrait. Specific causes of the phase portrait deformation are similar in either case; these are
again poisons, external electric power sources, and other unpleasant things which are almost
certain to disagree with a human being, sooner or later.
Figure 3 gives schematically several examples of the deformation of the phase portrait which
leads to induced automaticity. The example D is of special interest, because it assumes that
two different attractors exist primordially on the phase portrait.9 While external stimulus
remains near the threshold value, the active element behaves in the waiting regime (the
attractor at the left side), but the stimulus that sufficiently exceeds the threshold value will
throw it in the self-oscillating regime (the attractor at the right side).
It should only be added that latent pacemakers may become sources of arrhythmias, even
when their proper automaticity is maintained on the normal level, but, in the cardiac tissue
damaged with disease, a low frequency pacemaker is not synchronized by the waves coming
from the sinoatrial node. As a result, the distorted ventricular complexes generated by such a
source appear out of turn on the background of normal ECG. Mechanism of such arrhythmia
(which is a variant of ventricular extrasystole) could be so-called unidirectional block in a
damaged site of myocardium [52], when the autowave excitation is capable of spreading in
one direction, but is damped propagating in opposite direction. There may be different causes
of such unidirectional block; one of these may be the critical curvature, which was discussed
above.
In addition, several autowave objects were described under the general title “leading centers”
[41, 61–65]. In two-dimensional and three-dimensional excitable media, leading centers emit
concentric waves similar to the waves initiated by a pacemaker. At least three different
mechanisms of leading centers are known from theoretical studies. One of them is described
for media consisting of self-oscillatory elements with hard excitation [62]. Such a medium can
be at state of rest (i.e. in the waiting regime), but the place of the medium where an external
stimulus of suitable amplitude was applied goes into self-oscillating regime and becomes a
source of waves. The two other mechanisms of leading centers were described under the titles
of “echo” and “partition of the front.” The mechanism “echo” in the myocardium was shown
in several works [63–65] with use of microelectrode technique. However, the existence of all
these types of autowave sources should still be regarded as hypothetical.
The term “triggered activity” (TA) is used to refer to a special kind of automaticity when the
cells are in the waiting regime and go into self-oscillating regime in response to a stimulus or
series of stimuli. Although differences of opinion still exist, there appears to be good agreement
that TA is resulted from afterdepolarizations, which is understood as the membrane potential
9 Similar situation in the corresponding phase portrait (i.e. two attractors) is likely to underlie some types of the
atrioventricular nodal reentrant tachycardia, which is discussed below.
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oscillations that occur during or immediately following a preceding AP (for more details, see
[8, 60]). Based on their temporal relationship, two types of afterdepolarizations are described:
early afterdepolarizations (EADs), which occur during phase 2 or 3 of the AP, and delayed
afterdepolarizations (DADs), which occur after completion of the repolarization phase. There
has been increasing recognition of the role played by TA caused by either EADs or DADs in
the genesis of clinical arrhythmias [66, 67–69]. It is widely accepted that phenomena of either
type of afterdepolarizations are caused by a variety of conditions that raise the diastolic
intracellular Ca2+ concentration, resulting in Ca2+ mediated oscillations that can trigger a new
AP if they reach the excitation threshold. It has been found [70] that the active pumping of
calcium ions into cardiomyocytes by the Na+ / Ca2+ exchange current of abnormally increased
level is involved in the mechanism of DADs. Therefore, the depolarization is observed after
treatment of the myocardium with catecholamines [71], which accelerate the pump, as well as
with glycosides (e.g., digitalis) [72, 73], which inhibit the Na+ / K+ pump, and this leads in turn
to the accumulation of intracellular sodium ions and, hence, enhances the intensity of Na+ /
Ca2+ pump [74]. Inhibition of the Na+ / K+ pump promotes also the release of Ca2+ from the
sarcoplasmic reticulum, as well as a number of other processes of molecular level are believed
to underlie TA [60].
Although the cause of TA is believed to be the transmembrane potential oscillations exceeding
the excitation threshold, closer examination of the phase portrait of the basic model is forcing
doubt this widespread opinion. As it has already been argued logically above, the excitation
threshold can not play any role for self-oscillatory elements, as it simply does not exist in this
regime. This fact motivates to search other, more sensible, explanation. Let's assume that the
effect of catecholamines and glycosides results in a significant deformation of the phase
portrait, and it is the deformation that is the true cause for the change in behavior of the active
elements from waiting into a self-oscillating regime, manifesting it in the triggered activity.
An important factor in support of this assumption is the following. In the waiting regime, we
have a stable solution of node type at the steady point O; a local bifurcation of vector fields on
the plane occurs while transiting from the waiting regime into the self-oscillating regime, in
which the steady point O loses stability, and a new solution, a limit cycle, arises.10 Thus, in
process of the transition of the steady point O from the left branch to the middle section of the
isoclinic curve, the system passes through the state, which is referred to as bifurcation; the
bifurcation point is situated at the minimum of the N-shaped isocline. Assume that, under the
influence of various substances, the null-isocline f 2(u, v)=0 moves by parallel displacement
along the abscissa from left to right in a linear dependence on the concentration of biologically
active substances. What will be observed when the system comes to be near the bifurcation
condition? Left from the bifurcation point damped oscillations will be observed, which is in a
quite good correspondence with afterdepolarizations without TA. On the right we will observe
oscillations with increasing amplitude (the movement by escalating spiral, gradually leading
off system onto the right branch of the isocline). In other words, the assumption lead to the
conclusion that the base system near the bifurcation point behaves just exactly as it is observed
in experiments with TA.
10 The appearance or the disappearance of a periodic orbit through a local change in the stability properties of a steady
point is known as the Hopf bifurcation. For more details, see elsewhere [75].
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case of the self-oscillating regime because no threshold value exists in this case. The illusion
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source appear out of turn on the background of normal ECG. Mechanism of such arrhythmia
(which is a variant of ventricular extrasystole) could be so-called unidirectional block in a
damaged site of myocardium [52], when the autowave excitation is capable of spreading in
one direction, but is damped propagating in opposite direction. There may be different causes
of such unidirectional block; one of these may be the critical curvature, which was discussed
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In addition, several autowave objects were described under the general title “leading centers”
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concentric waves similar to the waves initiated by a pacemaker. At least three different
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source of waves. The two other mechanisms of leading centers were described under the titles
of “echo” and “partition of the front.” The mechanism “echo” in the myocardium was shown
in several works [63–65] with use of microelectrode technique. However, the existence of all
these types of autowave sources should still be regarded as hypothetical.
The term “triggered activity” (TA) is used to refer to a special kind of automaticity when the
cells are in the waiting regime and go into self-oscillating regime in response to a stimulus or
series of stimuli. Although differences of opinion still exist, there appears to be good agreement
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afterdepolarizations (DADs), which occur after completion of the repolarization phase. There
has been increasing recognition of the role played by TA caused by either EADs or DADs in
the genesis of clinical arrhythmias [66, 67–69]. It is widely accepted that phenomena of either
type of afterdepolarizations are caused by a variety of conditions that raise the diastolic
intracellular Ca2+ concentration, resulting in Ca2+ mediated oscillations that can trigger a new
AP if they reach the excitation threshold. It has been found [70] that the active pumping of
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level is involved in the mechanism of DADs. Therefore, the depolarization is observed after
treatment of the myocardium with catecholamines [71], which accelerate the pump, as well as
with glycosides (e.g., digitalis) [72, 73], which inhibit the Na+ / K+ pump, and this leads in turn
to the accumulation of intracellular sodium ions and, hence, enhances the intensity of Na+ /
Ca2+ pump [74]. Inhibition of the Na+ / K+ pump promotes also the release of Ca2+ from the
sarcoplasmic reticulum, as well as a number of other processes of molecular level are believed
to underlie TA [60].
Although the cause of TA is believed to be the transmembrane potential oscillations exceeding
the excitation threshold, closer examination of the phase portrait of the basic model is forcing
doubt this widespread opinion. As it has already been argued logically above, the excitation
threshold can not play any role for self-oscillatory elements, as it simply does not exist in this
regime. This fact motivates to search other, more sensible, explanation. Let's assume that the
effect of catecholamines and glycosides results in a significant deformation of the phase
portrait, and it is the deformation that is the true cause for the change in behavior of the active
elements from waiting into a self-oscillating regime, manifesting it in the triggered activity.
An important factor in support of this assumption is the following. In the waiting regime, we
have a stable solution of node type at the steady point O; a local bifurcation of vector fields on
the plane occurs while transiting from the waiting regime into the self-oscillating regime, in
which the steady point O loses stability, and a new solution, a limit cycle, arises.10 Thus, in
process of the transition of the steady point O from the left branch to the middle section of the
isoclinic curve, the system passes through the state, which is referred to as bifurcation; the
bifurcation point is situated at the minimum of the N-shaped isocline. Assume that, under the
influence of various substances, the null-isocline f 2(u, v)=0 moves by parallel displacement
along the abscissa from left to right in a linear dependence on the concentration of biologically
active substances. What will be observed when the system comes to be near the bifurcation
condition? Left from the bifurcation point damped oscillations will be observed, which is in a
quite good correspondence with afterdepolarizations without TA. On the right we will observe
oscillations with increasing amplitude (the movement by escalating spiral, gradually leading
off system onto the right branch of the isocline). In other words, the assumption lead to the
conclusion that the base system near the bifurcation point behaves just exactly as it is observed
in experiments with TA.
10 The appearance or the disappearance of a periodic orbit through a local change in the stability properties of a steady
point is known as the Hopf bifurcation. For more details, see elsewhere [75].
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However, the situation may be even more complicated if we consider the phenomena known
under the names of “stability loss delay for dynamical bifurcations” or “bifurcation memory” [19],
recently discovered and still little studied. The essence of the effect of bifurcation memory (BM)
lies in the appearance of a special, unusual, type of transition process. An ordinary transition
process is characterized by asymptotic approach of the dynamical system from the state
defined by its initial conditions to the state corresponding to its stable stationary regime in the
basin of attraction of which the system found itself. However, near the bifurcation boundary
can be observed two types of transition processes. Firstly, passing through the place of the
vanished stationary regime, the dynamic system slows down its asymptotic motion tempora‐
rily, “as if recollecting the defunct orbit” [19]. And only after a number of revolutions of the phase
trajectory in this area of bifurcation memory (which is referred to as “phase spot”), the phase
trajectory rushes to the state that corresponds to stable steady regime for the system. In other
words, the decedent attractor still reveals itself in a certain region near the bifurcations, as if
it were still “alive”, and this strange situation has contributed to appearance of the third name
for the phenomena, “ghost attractor” [76]. It is possible that the TA is just another example of
the bifurcation memory phenomena. It is hoped that new researches will help to clarify the
validity of this hypothesis.
Besides, another very specific new mechanism of arrhythmia is assumed [41], which is the so-
called splitting of the excitation wave. Passing through the damaged area of the heart, the
excitation wave may split into two following each other component. Investigation using special
blockers has shown that the first component is caused by activation of Na+-current, and the
second is a delayed activation of the Ca2+-current. The auxiliary component, resulting from
this splitting, can be a source of extra cardiac beat.
All these autowave phenomena is supposed to be able act as ectopic foci, resulting in ectopic
beat (or cardiac ectopy). Note that nearly all autowave sources mentioned in this section were
detected in experiments on myocardium only at very specific experimental conditions.
Nevertheless, the physician should bear in mind that the ectopic foci in the myocardium, which
gives the characteristic concentric waves of excitation, can be not only an unregulated latent
pacemaker. This remark is entirely correct also regarding so-called polytopic tachycardias, which
may be based on essentially different mechanisms of ectopia.
3.2. Circulating autowaves (reentry)
The concept of circulation of the excitation wave, which is so important for understanding the
mechanisms of a number of types of high-frequency cardiac arrhythmias (tachycardias), has
been confirmed experimentally in 1926 by D. Scherf and C. Schockhoff [8], and now it is widely
recognized that the circulation of excitation (reentry) is not confined within conducting tissues,
but can occur in any region of the heart.
3.3. A single two-dimensional autowave vortex
It is known that reentrant cardiac arrhythmias are often initiated by forming a discontinuous
propagating wave of excitation. In sufficiently thin layers (i.e., in two-dimensional media, in
mathematical language), it is refractoriness that makes possible the existence of special
circulating autowaves (Figure 4), which evolve from wave fronts with the free tip originating
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from rupture of the wave front. In a thin layer of active medium of sufficiently large extent
(“infinite” from the point of view of mathematics, i.e. a layer of such extent when a further
increase in the size does not affect the behavior of the object under study), the rotating
autowaves take shape of rotating spirals. It was shown already in the axiomatic models of
Wiener-Rosenbluth [40] that the discontinuity of a plane wave of excitation, which results from
its collision with a sufficiently large non-excitable obstacle, makes the excitation wave revolve
around this obstacle. Further studies have shown that the availability of obstacles is not
required without fail and that the rotating autowaves also arises when creating the appropriate
initial conditions. For example, the inhomogeneity of tissue refractoriness may lead to the fact
that at high repetition frequency of the excitation waves the wave front may break on rough‐
ness of the tail of the preceding wave, and the evolution of these ruptures leads to the formation
of rotating autowaves.
Figure 4. Some classic types of reverberator evolution. The inset demonstrates examples of ECG forms for different
types of evolution of reverberator: uniform circular rotation (top), meander (middle), and hyper-meander (bottom).
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However, the situation may be even more complicated if we consider the phenomena known
under the names of “stability loss delay for dynamical bifurcations” or “bifurcation memory” [19],
recently discovered and still little studied. The essence of the effect of bifurcation memory (BM)
lies in the appearance of a special, unusual, type of transition process. An ordinary transition
process is characterized by asymptotic approach of the dynamical system from the state
defined by its initial conditions to the state corresponding to its stable stationary regime in the
basin of attraction of which the system found itself. However, near the bifurcation boundary
can be observed two types of transition processes. Firstly, passing through the place of the
vanished stationary regime, the dynamic system slows down its asymptotic motion tempora‐
rily, “as if recollecting the defunct orbit” [19]. And only after a number of revolutions of the phase
trajectory in this area of bifurcation memory (which is referred to as “phase spot”), the phase
trajectory rushes to the state that corresponds to stable steady regime for the system. In other
words, the decedent attractor still reveals itself in a certain region near the bifurcations, as if
it were still “alive”, and this strange situation has contributed to appearance of the third name
for the phenomena, “ghost attractor” [76]. It is possible that the TA is just another example of
the bifurcation memory phenomena. It is hoped that new researches will help to clarify the
validity of this hypothesis.
Besides, another very specific new mechanism of arrhythmia is assumed [41], which is the so-
called splitting of the excitation wave. Passing through the damaged area of the heart, the
excitation wave may split into two following each other component. Investigation using special
blockers has shown that the first component is caused by activation of Na+-current, and the
second is a delayed activation of the Ca2+-current. The auxiliary component, resulting from
this splitting, can be a source of extra cardiac beat.
All these autowave phenomena is supposed to be able act as ectopic foci, resulting in ectopic
beat (or cardiac ectopy). Note that nearly all autowave sources mentioned in this section were
detected in experiments on myocardium only at very specific experimental conditions.
Nevertheless, the physician should bear in mind that the ectopic foci in the myocardium, which
gives the characteristic concentric waves of excitation, can be not only an unregulated latent
pacemaker. This remark is entirely correct also regarding so-called polytopic tachycardias, which
may be based on essentially different mechanisms of ectopia.
3.2. Circulating autowaves (reentry)
The concept of circulation of the excitation wave, which is so important for understanding the
mechanisms of a number of types of high-frequency cardiac arrhythmias (tachycardias), has
been confirmed experimentally in 1926 by D. Scherf and C. Schockhoff [8], and now it is widely
recognized that the circulation of excitation (reentry) is not confined within conducting tissues,
but can occur in any region of the heart.
3.3. A single two-dimensional autowave vortex
It is known that reentrant cardiac arrhythmias are often initiated by forming a discontinuous
propagating wave of excitation. In sufficiently thin layers (i.e., in two-dimensional media, in
mathematical language), it is refractoriness that makes possible the existence of special
circulating autowaves (Figure 4), which evolve from wave fronts with the free tip originating
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from rupture of the wave front. In a thin layer of active medium of sufficiently large extent
(“infinite” from the point of view of mathematics, i.e. a layer of such extent when a further
increase in the size does not affect the behavior of the object under study), the rotating
autowaves take shape of rotating spirals. It was shown already in the axiomatic models of
Wiener-Rosenbluth [40] that the discontinuity of a plane wave of excitation, which results from
its collision with a sufficiently large non-excitable obstacle, makes the excitation wave revolve
around this obstacle. Further studies have shown that the availability of obstacles is not
required without fail and that the rotating autowaves also arises when creating the appropriate
initial conditions. For example, the inhomogeneity of tissue refractoriness may lead to the fact
that at high repetition frequency of the excitation waves the wave front may break on rough‐
ness of the tail of the preceding wave, and the evolution of these ruptures leads to the formation
of rotating autowaves.
Figure 4. Some classic types of reverberator evolution. The inset demonstrates examples of ECG forms for different
types of evolution of reverberator: uniform circular rotation (top), meander (middle), and hyper-meander (bottom).
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It is customary to distinguish four variants of circulating autowaves (see [8, 41], for example):
1. The spiral wave, which is an excitation autowave revolving around an obstacle. An example
of this is atrial flutter due to the autowave moving around cardiac veins.
2. The autowave running around the ring (synonym: one-dimensional circulation regime).
Examples of arrhythmias caused by such type of reentry are: (1) the excitation wave
circulation between the atria and ventricles through additional atrioventricular path
during tachycardia associated with WPW-syndrome; (2) supraventricular tachycardia
caused by the excitation wave circulation in the AV node; (3) intraventricular circulations
of the excitation wave along path consisting of the specialized cardiac conduction system.
3. The autowave reverberator, which is two-dimensional circulation of autowave with its free
tip in the plane of the heart wall in the area of myocardium without anatomic obstacle
(i.e., two-dimensional autowave vortex). In contrast to the circulation around the obstacle,
the position of the center of this type of circulating autowaves in this case can move
through the cardiac tissue (i.e., it can drift) during arrhythmia. With use of both the
multielectrode and optical mapping the existence of such sources of arrhythmias in real
myocardium was demonstrated in the SA node as well as in the atrial and ventricular
cardiac tissue.
4. Autowave fibrillation, which is chaotic regime of autowave propagation.
Figure 5. The critical size of reverberator (based on data from [41] obtained by Pertsov and Panfilov for the FitzHugh-
Nagumo model). A. The relation between the critical size of reverberator and the size of the reverberator core. B. The
dependences of the critical sizes of reverberator and of the critical size of a closed loop (for an autowave running
around the ring) on the conduction of rapid current gf. C. Dependences of the period of the reverberator and of the
autowave running around the ring on gf. D. Dependence of the refractoriness of the medium (R) on gf for the spiral
wave (curvature k=0.83) and for the plane wave.
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It is necessary to pay attention to some of the subtleties of terminology. Various authors can
refer to the rotating in two-dimensional medium autowave as “spiral wave”, “reverberator”,
“rotor”, “autowave vortex” or even “scroll wave”. Note, however, that these terms are not
interchangeable synonymous. Briefly, there are the following differences between them. The
term “spiral wave” refers usually only to the autowave that revolves around non-excitable
obstacle in a medium of sufficiently large extent, that is, in this case, the medium of such size,
comparing with which the obstacle is small, but large enough to result in the wave break. The
tip of the spiral wave moves along the boundary of the non- excitable obstacle. The authors of
[41] pointed out: “The most important difference between a reverberator and a spiral wave
rotating around the hole, which is similar to reverberator in its form, is that the reverberator
is not tied to any structure in the medium. Due to this property, reverberators can appear and
disappear at different locations of the medium.” Moreover, the autowave reverberators have
property to appear not only in the absence of non-excitable obstacles, but also in a completely
homogeneous medium (under appropriate initial conditions).
Furthermore, it proved (Figure 5) that refractory period is longer for waves with nonzero
curvature (i.e., for reverberators) than for a plane autowave (i.e., the autowave running around
the ring), and refractory period of reverberators begins to increase before increase of refractory
period of a plane wave, when the excitability of the medium decreases. These and other
significant differences of reverberator from circular movement of the excitation wave make us
distinguish between these two regimes of reentry.
In the simplest case without drift (i.e., the regime of uniform circular rotation), the tip of a
reverberator rotates around a fixed point along the circumference of a certain radius (the
circular motion of the tip of the reverberator). The autowave cannot penetrate into the circle
bounded by this circumference. As far as it approaches the centre of the reverberator rotation,
the amplitude of the excitation pulse is reduced, and, at a relatively low excitability of the
medium there is a region of finite size in the centre of reverberator, where the amplitude of
the excitation pulse is zero (recall that we speak now about a homogeneous medium, for each
point of which its properties are the same). This area of low amplitude in the centre of the
reverberator is usually called the core of the reverberator. The existence of such a region in the
center of reverberator seems, at first glance, quite incomprehensible, as it borders all the time
with the excited sites. A detailed investigation of this phenomenon showed [41] that resting
area in the centre of reverberator remains of its normal excitability, and the existence of a
quiescent region in the centre of the reverberator is related to the phenomenon of the critical
curvature. In the case of "infinite" homogeneous medium, the core radius and the speed of the
rotor rotation are determined only by the properties of the medium itself, rather than the initial
conditions. The certain size of the core of the reverberator is conditioned by that the excitation
wave, which circulates in a closed path, should completely fit in this path without bumping
into its own refractory tail.
The critical size of reverberator is understood as the minimum size of the active homogeneous
medium in which the reverberator can exist during indefinitely long time. To assess the critical
size of reverberator, some authors (e.g., [61]) used the size of the core of the reverberator,
supposing that the region of the medium that is adjacent to the core is sufficient for the existence
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It is customary to distinguish four variants of circulating autowaves (see [8, 41], for example):
1. The spiral wave, which is an excitation autowave revolving around an obstacle. An example
of this is atrial flutter due to the autowave moving around cardiac veins.
2. The autowave running around the ring (synonym: one-dimensional circulation regime).
Examples of arrhythmias caused by such type of reentry are: (1) the excitation wave
circulation between the atria and ventricles through additional atrioventricular path
during tachycardia associated with WPW-syndrome; (2) supraventricular tachycardia
caused by the excitation wave circulation in the AV node; (3) intraventricular circulations
of the excitation wave along path consisting of the specialized cardiac conduction system.
3. The autowave reverberator, which is two-dimensional circulation of autowave with its free
tip in the plane of the heart wall in the area of myocardium without anatomic obstacle
(i.e., two-dimensional autowave vortex). In contrast to the circulation around the obstacle,
the position of the center of this type of circulating autowaves in this case can move
through the cardiac tissue (i.e., it can drift) during arrhythmia. With use of both the
multielectrode and optical mapping the existence of such sources of arrhythmias in real
myocardium was demonstrated in the SA node as well as in the atrial and ventricular
cardiac tissue.
4. Autowave fibrillation, which is chaotic regime of autowave propagation.
Figure 5. The critical size of reverberator (based on data from [41] obtained by Pertsov and Panfilov for the FitzHugh-
Nagumo model). A. The relation between the critical size of reverberator and the size of the reverberator core. B. The
dependences of the critical sizes of reverberator and of the critical size of a closed loop (for an autowave running
around the ring) on the conduction of rapid current gf. C. Dependences of the period of the reverberator and of the
autowave running around the ring on gf. D. Dependence of the refractoriness of the medium (R) on gf for the spiral
wave (curvature k=0.83) and for the plane wave.
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It is necessary to pay attention to some of the subtleties of terminology. Various authors can
refer to the rotating in two-dimensional medium autowave as “spiral wave”, “reverberator”,
“rotor”, “autowave vortex” or even “scroll wave”. Note, however, that these terms are not
interchangeable synonymous. Briefly, there are the following differences between them. The
term “spiral wave” refers usually only to the autowave that revolves around non-excitable
obstacle in a medium of sufficiently large extent, that is, in this case, the medium of such size,
comparing with which the obstacle is small, but large enough to result in the wave break. The
tip of the spiral wave moves along the boundary of the non- excitable obstacle. The authors of
[41] pointed out: “The most important difference between a reverberator and a spiral wave
rotating around the hole, which is similar to reverberator in its form, is that the reverberator
is not tied to any structure in the medium. Due to this property, reverberators can appear and
disappear at different locations of the medium.” Moreover, the autowave reverberators have
property to appear not only in the absence of non-excitable obstacles, but also in a completely
homogeneous medium (under appropriate initial conditions).
Furthermore, it proved (Figure 5) that refractory period is longer for waves with nonzero
curvature (i.e., for reverberators) than for a plane autowave (i.e., the autowave running around
the ring), and refractory period of reverberators begins to increase before increase of refractory
period of a plane wave, when the excitability of the medium decreases. These and other
significant differences of reverberator from circular movement of the excitation wave make us
distinguish between these two regimes of reentry.
In the simplest case without drift (i.e., the regime of uniform circular rotation), the tip of a
reverberator rotates around a fixed point along the circumference of a certain radius (the
circular motion of the tip of the reverberator). The autowave cannot penetrate into the circle
bounded by this circumference. As far as it approaches the centre of the reverberator rotation,
the amplitude of the excitation pulse is reduced, and, at a relatively low excitability of the
medium there is a region of finite size in the centre of reverberator, where the amplitude of
the excitation pulse is zero (recall that we speak now about a homogeneous medium, for each
point of which its properties are the same). This area of low amplitude in the centre of the
reverberator is usually called the core of the reverberator. The existence of such a region in the
center of reverberator seems, at first glance, quite incomprehensible, as it borders all the time
with the excited sites. A detailed investigation of this phenomenon showed [41] that resting
area in the centre of reverberator remains of its normal excitability, and the existence of a
quiescent region in the centre of the reverberator is related to the phenomenon of the critical
curvature. In the case of "infinite" homogeneous medium, the core radius and the speed of the
rotor rotation are determined only by the properties of the medium itself, rather than the initial
conditions. The certain size of the core of the reverberator is conditioned by that the excitation
wave, which circulates in a closed path, should completely fit in this path without bumping
into its own refractory tail.
The critical size of reverberator is understood as the minimum size of the active homogeneous
medium in which the reverberator can exist during indefinitely long time. To assess the critical
size of reverberator, some authors (e.g., [61]) used the size of the core of the reverberator,
supposing that the region of the medium that is adjacent to the core is sufficient for the existence
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of sustainable reentry. However, accurate quantitative study of the dependence of the
reverberator behavior on conductivity of rapid transmembrane current (which characterizes
the excitability of the medium) has revealed [41] that the critical size and the size of the
reverberator core are its different characteristics (Figure 5), and the critical size of reverberator
is, in many cases, much larger than the size of its core (i.e., reverberator perishes even when
its core easily fit within the boundaries of the medium and its drift is absent). It was shown
also that, for the same local characteristics of an excitable medium (excitability, refractoriness,
etc. given by the nonlinear free member of the base model), there are significant quantitative
differences in dependencies of characteristics of the reverberator and of one-dimensional
circulation of the autowave impulse, although corresponding curves coincide qualitatively. It
is assumed that the earlier growth of the refractory period and of the critical size of reverberator
with a decrease of excitability is caused by the curvature of the wavefront of reverberator.
The one-dimensional circulation regime, which is perhaps the simplest case of circulating
autowaves, has been studied in greatest detail, and the results help to understand more
intricate variants of reentry. In particular, it was shown [55] that the existence of this type of
reentry is only possible on condition that the size of the closed loop in which the circulation
occurs is greater than a minimal size (the critical size of the closed loop). Size of the core of the
reverberator is usually less than the critical size of the closed loop for circular movement, which is
associated with the phenomenon of critical curvature (Figure 5). Note that, in the normal
myocardium (i.e., with normal velocity of excitation autowave, V ≈ 1 m / sec, and with normal
refractory period, R ≈ 0,2 sec), the wavelength (V = R λ) is about 20 centimeters, and, therefore,
it is difficult, even nearly impossible, for circulating wave to fit in the human heart, if there are
not any special conditions. Probability of arising of reverberator in the human heart under
normal state of the myocardium is small, but the decreases of refractory period or of the
excitation wave velocity (under the influence of metabolism, under the pharmacological
influence, etc.) contribute to the appearance of circulating waves in the myocardium.
A reverberator is able to drift freely in medium; besides direction of its drift is caused not only
by the properties of the medium, but also largely by its own properties (i.e., the reverberator
itself “decides” where to move). In the classical works [32, 42, 77], the following basic types of
reverberator behavior in a homogeneous isotropic medium (Figure 4) are distinguished: (1)
the regime of uniform circular rotation (circular movement), which is the simplest case without
drift, with the tip of a reverberator rotating around a fixed point along the circumference of a
certain radius; (2) meander, which is two-periodic motion of the reverberator in which the
trajectory of its tip is similar to a cycloidal curve (epicycloid and hypocycloid); (3) hyper-
meander, which is a complicated reverberator motion with, probably, chaotic trajectory of its
tip. Under special conditions, a vortex with meandering of hypocycloid type can be trans‐
formed to a vortex with linear core [77].
Recently a new form of autowave behavior was found [21], — namely, the transformation of
reverberator motion from a two-periodic meander into one-periodic circular rotation due to
spontaneous deceleration of reverberator drift. The new autowave behavior, which was called
“autowave lacet”, is likely to result from a phenomenon of so called bifurcation memory. When
autowave lacet was discovered, the first question arose: Does the meander exist ever or the
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halt of the reverberator drift can be observed every time in all the cases, which are called
meander, if the observation will be sufficiently long? The comparative quantitative analysis of
the drift velocity of reverberator in the regimes of meander and lacet revealed a clear difference
between these two types of evolution of the reverberator: while the drift velocity quickly goes
to a stationary value during meander, a steady decrease in the drift velocity of the vortex can
be observed during the lacet, in which can be clearly identified the phase of slow deceleration
and phase of rapid deceleration of the drift velocity.
The revealing of autowave lacet may be important for cardiology, because the autowave theory
predicts the existence of special type of ventricular arrhythmias, conditionally called “lacetic”
[1, 2], which cardiologists do not still distinguish in diagnostics.
When an autowave propagates in a medium and collides with an obstacle containing a slit,
propagation beyond the slit depends on the relationship between the width of the slit and the
liminal region. When the slit dimensions are greater than the liminal region, then the wave
fragment passing through the slit will continue to propagate. In addition, the ends of the newly
formed wave fragment will curl and form counter-rotating autowave vortices, which can
results in cardiac tachycardia or fibrillation. [47].
Even more interesting phenomenon caused by the critical curvature effects is unidirectional
conduction of excitation autowave through a narrow gap in a non-excitable partition arising in
the case if the partition edges are arranged at an angle to one another [52].
Variety of forms of behavior of autowave vortices leads to the variety of cardiac arrhythmias,
which can be quite ambiguous reflected in the electrocardiograms [1].
At this point, this brief overview of two-dimensional circulating autowaves must be stopped,
and more detailed information about their multifarious behavior can be found in the extensive
literature.
3.4. Three-dimensional autowave vortices
Even more intricate types of reentry arise “in the three-dimensional case”, in the parlance of
mathematicians [13, 78–80]. Figure 6 gives examples of three-dimensional organization of
reentrant propagation. Direct generalization of an autowave reverberator for the case of three-
dimensional space is a simple scroll, which rotation occurs around a straight line, called
“filament”. In addition to such a simple three-dimensional autowave reentry, the filament can
be arbitrarily curved and possibly even closed (in the latter case, the scroll turns into an
autowave scroll ring). If the rotational phase of the scroll varies along its filament, the vortex is
called “twisted scroll”. Despite the much greater variety of three-dimensional autowave
regimes in comparison with two-dimensional case, it was mathematically proven that there
are certain topological restrictions, which reduce significantly the variety of three-dimensional
autowave structures. For example, a single twisted scroll ring is impossible; topologically there
must be another filament passing through the center of the filament ring [81].
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of sustainable reentry. However, accurate quantitative study of the dependence of the
reverberator behavior on conductivity of rapid transmembrane current (which characterizes
the excitability of the medium) has revealed [41] that the critical size and the size of the
reverberator core are its different characteristics (Figure 5), and the critical size of reverberator
is, in many cases, much larger than the size of its core (i.e., reverberator perishes even when
its core easily fit within the boundaries of the medium and its drift is absent). It was shown
also that, for the same local characteristics of an excitable medium (excitability, refractoriness,
etc. given by the nonlinear free member of the base model), there are significant quantitative
differences in dependencies of characteristics of the reverberator and of one-dimensional
circulation of the autowave impulse, although corresponding curves coincide qualitatively. It
is assumed that the earlier growth of the refractory period and of the critical size of reverberator
with a decrease of excitability is caused by the curvature of the wavefront of reverberator.
The one-dimensional circulation regime, which is perhaps the simplest case of circulating
autowaves, has been studied in greatest detail, and the results help to understand more
intricate variants of reentry. In particular, it was shown [55] that the existence of this type of
reentry is only possible on condition that the size of the closed loop in which the circulation
occurs is greater than a minimal size (the critical size of the closed loop). Size of the core of the
reverberator is usually less than the critical size of the closed loop for circular movement, which is
associated with the phenomenon of critical curvature (Figure 5). Note that, in the normal
myocardium (i.e., with normal velocity of excitation autowave, V ≈ 1 m / sec, and with normal
refractory period, R ≈ 0,2 sec), the wavelength (V = R λ) is about 20 centimeters, and, therefore,
it is difficult, even nearly impossible, for circulating wave to fit in the human heart, if there are
not any special conditions. Probability of arising of reverberator in the human heart under
normal state of the myocardium is small, but the decreases of refractory period or of the
excitation wave velocity (under the influence of metabolism, under the pharmacological
influence, etc.) contribute to the appearance of circulating waves in the myocardium.
A reverberator is able to drift freely in medium; besides direction of its drift is caused not only
by the properties of the medium, but also largely by its own properties (i.e., the reverberator
itself “decides” where to move). In the classical works [32, 42, 77], the following basic types of
reverberator behavior in a homogeneous isotropic medium (Figure 4) are distinguished: (1)
the regime of uniform circular rotation (circular movement), which is the simplest case without
drift, with the tip of a reverberator rotating around a fixed point along the circumference of a
certain radius; (2) meander, which is two-periodic motion of the reverberator in which the
trajectory of its tip is similar to a cycloidal curve (epicycloid and hypocycloid); (3) hyper-
meander, which is a complicated reverberator motion with, probably, chaotic trajectory of its
tip. Under special conditions, a vortex with meandering of hypocycloid type can be trans‐
formed to a vortex with linear core [77].
Recently a new form of autowave behavior was found [21], — namely, the transformation of
reverberator motion from a two-periodic meander into one-periodic circular rotation due to
spontaneous deceleration of reverberator drift. The new autowave behavior, which was called
“autowave lacet”, is likely to result from a phenomenon of so called bifurcation memory. When
autowave lacet was discovered, the first question arose: Does the meander exist ever or the
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halt of the reverberator drift can be observed every time in all the cases, which are called
meander, if the observation will be sufficiently long? The comparative quantitative analysis of
the drift velocity of reverberator in the regimes of meander and lacet revealed a clear difference
between these two types of evolution of the reverberator: while the drift velocity quickly goes
to a stationary value during meander, a steady decrease in the drift velocity of the vortex can
be observed during the lacet, in which can be clearly identified the phase of slow deceleration
and phase of rapid deceleration of the drift velocity.
The revealing of autowave lacet may be important for cardiology, because the autowave theory
predicts the existence of special type of ventricular arrhythmias, conditionally called “lacetic”
[1, 2], which cardiologists do not still distinguish in diagnostics.
When an autowave propagates in a medium and collides with an obstacle containing a slit,
propagation beyond the slit depends on the relationship between the width of the slit and the
liminal region. When the slit dimensions are greater than the liminal region, then the wave
fragment passing through the slit will continue to propagate. In addition, the ends of the newly
formed wave fragment will curl and form counter-rotating autowave vortices, which can
results in cardiac tachycardia or fibrillation. [47].
Even more interesting phenomenon caused by the critical curvature effects is unidirectional
conduction of excitation autowave through a narrow gap in a non-excitable partition arising in
the case if the partition edges are arranged at an angle to one another [52].
Variety of forms of behavior of autowave vortices leads to the variety of cardiac arrhythmias,
which can be quite ambiguous reflected in the electrocardiograms [1].
At this point, this brief overview of two-dimensional circulating autowaves must be stopped,
and more detailed information about their multifarious behavior can be found in the extensive
literature.
3.4. Three-dimensional autowave vortices
Even more intricate types of reentry arise “in the three-dimensional case”, in the parlance of
mathematicians [13, 78–80]. Figure 6 gives examples of three-dimensional organization of
reentrant propagation. Direct generalization of an autowave reverberator for the case of three-
dimensional space is a simple scroll, which rotation occurs around a straight line, called
“filament”. In addition to such a simple three-dimensional autowave reentry, the filament can
be arbitrarily curved and possibly even closed (in the latter case, the scroll turns into an
autowave scroll ring). If the rotational phase of the scroll varies along its filament, the vortex is
called “twisted scroll”. Despite the much greater variety of three-dimensional autowave
regimes in comparison with two-dimensional case, it was mathematically proven that there
are certain topological restrictions, which reduce significantly the variety of three-dimensional
autowave structures. For example, a single twisted scroll ring is impossible; topologically there
must be another filament passing through the center of the filament ring [81].
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Figure 6. Examples of autowave 3D-vortices: A — a simple scroll, B — a simple vortex ring.
Although the scroll filament is a bit of a virtual object, it was shown [79] that it has a special
property, which has been called tension of filaments. A filament with positive tension tends to
shorten, similar to an elastic band, and, for example, the autowave scroll ring “shrinks” as a
result. When being with negative tension, it increases in size, which eventually ends in multiple
twisting of the filament, in its ruptures and in total chaotization of the autowave behavior, —
and it looks like ventricular fibrillation (inasmuch as the atrial walls are much thinner, an
intricate autowave three-dimensional structure cannot be placed there). The reader should
give attention to the fact that the filament tension is a phenomenon caused by the properties
of the active medium, and not by the properties of the autowave vortex arising in this medium.
A new mechanism of stabilizing the motion of an autowave vortex was described in the same
work for the case of three-dimensional excitable medium with a positive tension of filament;
the stabilization occurs due to shortening of the filament attached to the transverse walls of
model media. Although ECG manifestations of such stabilization of a vortex motion are not
considered in [79], the obvious conclusion in this case is that there would be observed a
spontaneous transition of tachycardia from polymorphic to monomorphic type. Thus,
stabilization of an autowave three-dimensional vortex with positive tension due to shortening
its filament is today the third possible mechanism of such electrocardiographic transformation
(the two others are anchoring the autowave vortex in an obstacle and tachycardia of the lacetic
type [1]). Note that the anchoring and the lacetic tachycardia are still hypothetical, and their
detection in real myocardium requires further research.
3.5. Multiple reverberators and autowave fibrillation
One of the most important results of the study of autowave processes is disclosure of a new
mechanism of instability in the active media [30, 42] associated with reproduction of rever‐
berators. As mentioned earlier, wave-fronts sent by reverberator follow closely to each other,
and therefore a subsequent wave-front may be broken on the irregularities of the tail of the
previous wave-front. It is recognized that (1) reverberators cannot reproduce themselves in a
homogeneous medium, and (2) the waves give rise to a new reverberator in an inhomogeneous
medium only if the period of these waves is sufficiently small (roughly equal to the relative
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refractory period). The latter circumstance is used in physiological experiments to provoke
tachycardia: two consecutive pulses are sent through the stimulating electrode, and if the
second pulse falls within the "window of vulnerability" (i.e., at the time of relative refractori‐
ness), then an experimental reentrant arrhythmia occurs [34]. It is also assumed that a similar
mechanism (collision of an extra wave of excitation to the refractory tail of the previous wave)
underlies clinical paroxysmal tachycardias, such as atrial flutter, paroxysmal supraventricular
or ventricular tachycardia [8].
It was shown in theoretical studies with use of axiomatic models [41] that another significant
property of the reverberator is a finite time of his life in heterogeneous environments. Causes
of destruction of reverberator are the same as the causes for its rise, and consist in the inability
of steady propagation of excitation waves with high frequency in heterogeneous media. These
conclusions are well confirmed in experiments: a reverberator in a homogeneous chemical
medium has "infinite" lifetime (limited by depletion of reagents), but in the heart, where there
is large heterogeneity, an arising accidentally reverberator usually have time to send only a
few wave-fronts.
Thus, there are two competing processes in an inhomogeneous medium: reproduction of
reverberators and their death. When the reproduction rate is less than the rate of death, then
chaos is impossible, and the medium works in regular mode. In the opposite case, the number
of autowave sources begins to grow, leading to chaos. This process reproduces well all main
phenomena observed in the heart during fibrillation [41, 42]. Here, similar to the phenomenon
of critical mass in the chain reactions, some critical characteristic values appear, above which
there is an unlimited reproduction of reverberators. One of these characteristics is the so-called
critical mass of fibrillation, which is the minimum mass of cardiac tissue, above which fibrillation
becomes possible.
The historically first point of view on ventricular fibrillation was that it is a passive process:
the jaded heart cannot longer conduct the excitation through the myocardium and only a few
Purkinje fibers, after losing control from the pacemaker of higher hierarchy, continue sponta‐
neously to cause asynchronous excitation of myocardial fibers. Currently, though multifocal
ectopic activity of ventricular myocardium remains still being considered as a possible
mechanism of fibrillation, the main mechanism of ventricular fibrillation is widely recognized
to be reentry within the ventricles, which may occur for one cause or another [7, 8, 60,].
Development of ideas about myocardium as an active medium led to significantly different
views on the nature of ventricular fibrillation. For example, it has been shown that the ECG
that is typical for ventricular fibrillation can be observed resulting from at least two different
autowave mechanisms: as a result of coexistence multiple autowave vortices or of a single
vortex due to Wenckebach-like frequency division, which in turn is due to some peculiarities
inhomogeneity of the active medium [80].
However, such an interesting hypothesis about the nature of ventricular fibrillation as a
competing chain reactions of birth and death of reverberators is not received still the merited
popularity among researchers and remains without its further development. It is hoped that
new researches will give a new development for this hypothesis.
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Figure 6. Examples of autowave 3D-vortices: A — a simple scroll, B — a simple vortex ring.
Although the scroll filament is a bit of a virtual object, it was shown [79] that it has a special
property, which has been called tension of filaments. A filament with positive tension tends to
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model media. Although ECG manifestations of such stabilization of a vortex motion are not
considered in [79], the obvious conclusion in this case is that there would be observed a
spontaneous transition of tachycardia from polymorphic to monomorphic type. Thus,
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medium only if the period of these waves is sufficiently small (roughly equal to the relative
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refractory period). The latter circumstance is used in physiological experiments to provoke
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reverberators and their death. When the reproduction rate is less than the rate of death, then
chaos is impossible, and the medium works in regular mode. In the opposite case, the number
of autowave sources begins to grow, leading to chaos. This process reproduces well all main
phenomena observed in the heart during fibrillation [41, 42]. Here, similar to the phenomenon
of critical mass in the chain reactions, some critical characteristic values appear, above which
there is an unlimited reproduction of reverberators. One of these characteristics is the so-called
critical mass of fibrillation, which is the minimum mass of cardiac tissue, above which fibrillation
becomes possible.
The historically first point of view on ventricular fibrillation was that it is a passive process:
the jaded heart cannot longer conduct the excitation through the myocardium and only a few
Purkinje fibers, after losing control from the pacemaker of higher hierarchy, continue sponta‐
neously to cause asynchronous excitation of myocardial fibers. Currently, though multifocal
ectopic activity of ventricular myocardium remains still being considered as a possible
mechanism of fibrillation, the main mechanism of ventricular fibrillation is widely recognized
to be reentry within the ventricles, which may occur for one cause or another [7, 8, 60,].
Development of ideas about myocardium as an active medium led to significantly different
views on the nature of ventricular fibrillation. For example, it has been shown that the ECG
that is typical for ventricular fibrillation can be observed resulting from at least two different
autowave mechanisms: as a result of coexistence multiple autowave vortices or of a single
vortex due to Wenckebach-like frequency division, which in turn is due to some peculiarities
inhomogeneity of the active medium [80].
However, such an interesting hypothesis about the nature of ventricular fibrillation as a
competing chain reactions of birth and death of reverberators is not received still the merited
popularity among researchers and remains without its further development. It is hoped that
new researches will give a new development for this hypothesis.
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4. Basic mechanisms of adaptation and their abnormalities
Earlier in this chapter we have attempted to show how significantly opportunities of research‐
ers in the interpretation of various phenomena of cardiac action were expanded with using
biophysical language, which constitutes a substantial generalization of the experience of two
centuries of studies of the heart. But it must be also recognized that the cybernetic language,
the basis of which was provided by Norbert Wiener in his classic work [82], is equally useful
generalization for aims of cardiology. This section of the chapter is intended for outlining the
fundamental cybernetic ideas about the cardiac action and its disorders, with the subsequent
text based mainly on Fedorov’s11 work [83], which is scarcely known for English readers.
In the tradition of biophysics, the regulation of heart rate is modeled in isolation; in other
words, the heart is assumed to be an autonomous organ, in which its own rhythmic contraction
is determined by spontaneous activity of the sinus node myocardiocytes (as it was described
above in this chapter), although it is assumed a number of both humoral and neural factors
that can modulate this spontaneous activity. In contrast to the pure biophysical approach,
cyberneticists used to simulate the regulation of cardiac rhythm as a part of certain regulatory
circuits in a more general model of the cardiovascular system rather than isolated.12 Biological
systems contain many types of regulatory circuits, both positive and negative; and construction
of a scheme of regulatory circuits, i.e. a typical for traditional physiology descriptive model of
regulation, is certainly based on considerations about purpose of functioning of a mechanism
or a system that is under studying. Instead the word “purpose”, the fixed expression
“physiological role” (of the system or of the mechanism) is accepted to use in biological sources,
the term “target function” corresponding with it in the frames of the cybernetic approach.
It is recognized that the most important purpose of functioning of the blood circulatory system
(including also external respiration), i.e. the most important “physiological role” of the blood
circulation, is the timely delivery of oxygen, nutritious and other substances to all the cells of
the body, as well as removal of accumulated metabolites and heat from the tissues; and this
ensures maintenance of the internal environment, which surrounds the cells and is necessary
for implementation of their metabolism and their biological functions. Open- and closed-loop
control as well as a good number of guidance loops is involved in the inherent regulation 13 of
circulation. It is accepted that the inherent circulatory regulation includes all changes in the
cardiovascular system which are directed to preventing or reducing every threatening
alteration of the internal environment and metabolism of cells. Consideration of separate
mechanisms of the inherent circulatory regulation reveals that the regulation provides it also
with achieving an additional goal, which is maintenance of the blood circulation as itself and
economization of the blood flow reserve. This substantiates the assignment of the cardiovas‐
cular apparatus to the category of a separate functional system of the organism. Besides the
11 Viktor FedorovichFedorov carried out this investigation during his work on PhD thesis on the base of the Department
of Telemedicine of Medical Center attached to the Presidential Property Management Directorate.
12 By the way, this is one of the reasons why the modern “cardiophysics” is not synonymous with the modern
“cardiovascular biophysics”.
13 In the original [83]:«автоматическое управление кровообращением».
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tasks of control of maintaining the internal environment at the chosen level, the biological
inherent regulation includes also mechanisms of self-adjustment (adaptation) of the control
systems in accordance with changes in the parameters of the biological object or of external
influences, as well as mechanisms of automatic selection of the best modes. In view of this the
broader term “inherent guidance” (or “self-guidance”) is believed to be more appropriate to
describe the functioning of living systems. It should be noted that a human being is charac‐
terized with a very complex mental activity; on this occasion, P.K Anokhin, a famous Russian
physiologist who developed the theory of functional systems [84, 85], pointed out a significant
influence of motivation and memory on the result of afferent synthesis, i.e. not physical, but
purely informational in its nature stimuli are important for results of inherent circulatory
regulation. Hence, the sinus rhythm of the human heart reflects the work of many body systems
in normal and pathological conditions, and therefore it is quite reasonable to recognize the
possibility of making use of its parameters for constructing a quantitative measure of the
quality of individual health.
However, we must here pay attention to the paradoxical situation existing in theoretical
medicine today, when any disease (except for the most exotic) is fully described and classified
by its stages as well as is easily scaled by its severity, but at the same time a scaling (a set of
standardized quantitative measures of the quality) of health is absent, although people widely
use in everyday life words of comparing people's health.
According to the new conception of measuring human health [86] that was developed at the
Department of Medical and Biological Cybernetics of the Russian State Medical University
(Moscow) and was approved by Russian Ministry of Health about two decades ago, the health
is understood as “the system's ability to achieve its aims through its adequate behavior”. Analysis of
the ultimate goals of the diverse forms of behavior of living systems can reduce all of these
goals to two aims, which are self-reproduction and self-preservation (and keen rivalry between
them in the nature is usually resolved in favor of the first). The main idea which was advanced
in this connection is to make “an assessment of individual health or social health (health of a
population) on the base of the ability of the living systems to self-development, to self-preservation, to
reproduction of offspring as well as to reproduction of the means for implementation of their goals and
adequate forms of their behavior”. In the same paradigm, adequate forms of behavior of living
systems are grouped as follows:
• self-organization, understood as ability of the system to implement process of dynamic
structural and functional self-development with differentiation of some collections of
elements for a function;
• adaptability, i.e. the system's ability to adjust itself to changing environmental conditions
while retaining its identity and its main functional properties;
• active transformation of the environment (i.e., natural habitat) as a form of adaptation,
consequences for the social system should be to create harmony of the noosphere (according
to V.I. Vernadsky).
It is easy to see in this construction that self-organization, and active habitat transformation is
based on adaptive properties, which are typical for all living things.
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4. Basic mechanisms of adaptation and their abnormalities
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the basis of which was provided by Norbert Wiener in his classic work [82], is equally useful
generalization for aims of cardiology. This section of the chapter is intended for outlining the
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text based mainly on Fedorov’s11 work [83], which is scarcely known for English readers.
In the tradition of biophysics, the regulation of heart rate is modeled in isolation; in other
words, the heart is assumed to be an autonomous organ, in which its own rhythmic contraction
is determined by spontaneous activity of the sinus node myocardiocytes (as it was described
above in this chapter), although it is assumed a number of both humoral and neural factors
that can modulate this spontaneous activity. In contrast to the pure biophysical approach,
cyberneticists used to simulate the regulation of cardiac rhythm as a part of certain regulatory
circuits in a more general model of the cardiovascular system rather than isolated.12 Biological
systems contain many types of regulatory circuits, both positive and negative; and construction
of a scheme of regulatory circuits, i.e. a typical for traditional physiology descriptive model of
regulation, is certainly based on considerations about purpose of functioning of a mechanism
or a system that is under studying. Instead the word “purpose”, the fixed expression
“physiological role” (of the system or of the mechanism) is accepted to use in biological sources,
the term “target function” corresponding with it in the frames of the cybernetic approach.
It is recognized that the most important purpose of functioning of the blood circulatory system
(including also external respiration), i.e. the most important “physiological role” of the blood
circulation, is the timely delivery of oxygen, nutritious and other substances to all the cells of
the body, as well as removal of accumulated metabolites and heat from the tissues; and this
ensures maintenance of the internal environment, which surrounds the cells and is necessary
for implementation of their metabolism and their biological functions. Open- and closed-loop
control as well as a good number of guidance loops is involved in the inherent regulation 13 of
circulation. It is accepted that the inherent circulatory regulation includes all changes in the
cardiovascular system which are directed to preventing or reducing every threatening
alteration of the internal environment and metabolism of cells. Consideration of separate
mechanisms of the inherent circulatory regulation reveals that the regulation provides it also
with achieving an additional goal, which is maintenance of the blood circulation as itself and
economization of the blood flow reserve. This substantiates the assignment of the cardiovas‐
cular apparatus to the category of a separate functional system of the organism. Besides the
11 Viktor FedorovichFedorov carried out this investigation during his work on PhD thesis on the base of the Department
of Telemedicine of Medical Center attached to the Presidential Property Management Directorate.
12 By the way, this is one of the reasons why the modern “cardiophysics” is not synonymous with the modern
“cardiovascular biophysics”.
13 In the original [83]:«автоматическое управление кровообращением».
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tasks of control of maintaining the internal environment at the chosen level, the biological
inherent regulation includes also mechanisms of self-adjustment (adaptation) of the control
systems in accordance with changes in the parameters of the biological object or of external
influences, as well as mechanisms of automatic selection of the best modes. In view of this the
broader term “inherent guidance” (or “self-guidance”) is believed to be more appropriate to
describe the functioning of living systems. It should be noted that a human being is charac‐
terized with a very complex mental activity; on this occasion, P.K Anokhin, a famous Russian
physiologist who developed the theory of functional systems [84, 85], pointed out a significant
influence of motivation and memory on the result of afferent synthesis, i.e. not physical, but
purely informational in its nature stimuli are important for results of inherent circulatory
regulation. Hence, the sinus rhythm of the human heart reflects the work of many body systems
in normal and pathological conditions, and therefore it is quite reasonable to recognize the
possibility of making use of its parameters for constructing a quantitative measure of the
quality of individual health.
However, we must here pay attention to the paradoxical situation existing in theoretical
medicine today, when any disease (except for the most exotic) is fully described and classified
by its stages as well as is easily scaled by its severity, but at the same time a scaling (a set of
standardized quantitative measures of the quality) of health is absent, although people widely
use in everyday life words of comparing people's health.
According to the new conception of measuring human health [86] that was developed at the
Department of Medical and Biological Cybernetics of the Russian State Medical University
(Moscow) and was approved by Russian Ministry of Health about two decades ago, the health
is understood as “the system's ability to achieve its aims through its adequate behavior”. Analysis of
the ultimate goals of the diverse forms of behavior of living systems can reduce all of these
goals to two aims, which are self-reproduction and self-preservation (and keen rivalry between
them in the nature is usually resolved in favor of the first). The main idea which was advanced
in this connection is to make “an assessment of individual health or social health (health of a
population) on the base of the ability of the living systems to self-development, to self-preservation, to
reproduction of offspring as well as to reproduction of the means for implementation of their goals and
adequate forms of their behavior”. In the same paradigm, adequate forms of behavior of living
systems are grouped as follows:
• self-organization, understood as ability of the system to implement process of dynamic
structural and functional self-development with differentiation of some collections of
elements for a function;
• adaptability, i.e. the system's ability to adjust itself to changing environmental conditions
while retaining its identity and its main functional properties;
• active transformation of the environment (i.e., natural habitat) as a form of adaptation,
consequences for the social system should be to create harmony of the noosphere (according
to V.I. Vernadsky).
It is easy to see in this construction that self-organization, and active habitat transformation is
based on adaptive properties, which are typical for all living things.
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In this regard, it is extremely important to remember that adaptive properties of a natural
living system is aimed at survival of the biological population14 as a whole rather than to
survival of the single individual in the population, which is conditioned by the process of
biological evolution (for instance, by means of natural selection). P.V. Simonov, another
illustrious Russian physiologist, has written [87] on this subject: “mechanism of myocardial
infarction has been formed already in the evolution of the relict salmon. As a working hypothesis, we
tend to consider cardiovascular pathology of neurogenic origin as a result of a long evolution of one of
the mechanisms that enforce the stability and qualitative improvement of the population through the
elimination of those individuals that adapts poorly in certain conditions of the existence of our distant
ancestors. (...) Since passive animals are often better protected from external dangers (predators, traps,
etc.) than individuals with active-searching behavior, natural selection could lead to the accumulation
of passive cowards in the population, which would denote regression of the species while increasing its
sustainability. This risk of degeneration seems to have been eliminated by means of genetic linkage
between the tendency to passive-defensive behavior and susceptibility to cardiovascular and some other
psychosomatic diseases. An extreme but striking example of such behavior is suicidal tendency among
the subjects with chronic depressive syndrome.” It seems that the recent investigations [88] prove
such conclusions. Despite the fact that this context generates a number of ethical issues, which
are known as moral dilemmas15, any ignoring of such biological mechanisms would be a huge
mistake.
In the adaptive responses of a biological system (an organism), it is useful to distinguish the
ability to implement the process of adaptation, the process itself and its result. Therefore, with
respect to adaptive reactions of a human individual, from our point of view, we can formulate
the following definitions. Adaptation of a human is the process of such adjusting changes of
the organism and of the personality under the influence of totality of conditions of habitat that
provide an approximation to the optimal values of the efficiency and reliability of implemen‐
tation of adequate patterns of human behavior. Adaptedness is understood as the state of having
been adapted, which is also the measure the current result of adaptation. Adaptability is the
measure that reflects the ability of a biological system to change its adaptedness per unit of
time.
Practical experience shows that a high level of adaptedness to certain specific conditions (i.e.,
high specialization) leads to a loss of adaptability (universality), and vice versa. Consequently,
either extreme reduces the reliability of functioning of the organism. On the basis of these
theses an individual human health can be defined as follows.
Individual health is a measure that expresses the ratio between adaptedness and adaptability of the
individual. At that, the optimal state of health should be understood as a state of satisfactory
adaptedness to the specific conditions of the individual existence while maintaining sufficient
adaptability (adaptive readiness to a sudden change of conditions).
14 A biological species can be considered as a set (in the mathematical meaning) of consanguineous (closely-related)
biological populations.
15 In-depth analysis of moral dilemmas was given in [89] recently, so we will not dwell on this issue here.We should only
note that similar problems are encountered when finding the optimal balance between the values of the unity of a nation
and the values of liberal freedoms.
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Consequently, the character of the deviations in the action of the heart from its normal action
must be considered from the standpoint of assessment of deviations in state of a human from
his or her optimal state of health. How this should be done?
When considering a practically healthy person with the saved in varying degrees adaptive
mechanisms, the process of adaptation to functioning in conditions of permissible physical or
mental exertion is taking the form of a quasi-linear increase of the corresponding function with
an increase in exertion. The linear dependence in coordinates of “stress-response” is broken
only in the areas of imperceptible (i.e., while having a subthreshold level of stress) or extreme
exertions (i.e., when exhaustion of the reserve of adaptation occurs). In other words, the whole
curve “stress-response” reveals a sort of S-shaped dependence (i.e., the logistic sigmoid
function). There are five sites that can be identified on this curve (Figure 7). It is obvious that
the nature of the load as well as parameters of response may vary in description of the different
systems or organs of the human body. It may be a special load, which has an influence only
on a number of certain parameters of the organism (e.g., the influence of illumination on the
pupil diameter), or a sort of universal load, in response to which the parameters of all or most
of the organs and the systems become changed (such as hypoxia). The response parameters
need not be primary (measured directly). As those, in some cases, one may make use of the
results of mathematical processing of time series of individual primary parameters or even
different mathematical combinations of several primary parameters that characterize a
particular function of the body. The main requirement for the choice of such parameters is that
each parameter showing the response of the organism should change with increasing load like
the logistic function and should conform to physiological functions.
It is obvious that the various organs and systems of the body are not necessarily to be in the
same functional state. So the pathology of certain organs or systems may result in not only
functional, but also structural change of other organs for compensating the reduced function.
Therefore, to describe the whole organism by the proposed method, it is required to develop
a system of tests that assess separate responses of different organs and systems on a load which
is typical for each of them. A specific component of quantitative assessment of the health
quality of a particular person can be obtained by making comparison of the slope and the level
of saturation of the logistic curve, which corresponds to the response on an adequate load, in
a specific plane, which conforms with a specific organ or a specific system, with the average
statistical parameters of healthy individuals of the corresponding sex and age group. A set of
such “response-planes”, each of these with its own parameters (A, B, C, D), enables us to build
a system of quantitative assessment of the quality of individual health. By tracking the
dynamics of change of the parameters of the curves in each plane simultaneously, we can assess
the level of total individual health.
The medical examination should be fulfilled as a three-phase test, comprising the successive
phases: 1) initial phase of rest, 2) phase of the individually metered load, and 3) recovery phase.
This is caused by the following circumstances.
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the following definitions. Adaptation of a human is the process of such adjusting changes of
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provide an approximation to the optimal values of the efficiency and reliability of implemen‐
tation of adequate patterns of human behavior. Adaptedness is understood as the state of having
been adapted, which is also the measure the current result of adaptation. Adaptability is the
measure that reflects the ability of a biological system to change its adaptedness per unit of
time.
Practical experience shows that a high level of adaptedness to certain specific conditions (i.e.,
high specialization) leads to a loss of adaptability (universality), and vice versa. Consequently,
either extreme reduces the reliability of functioning of the organism. On the basis of these
theses an individual human health can be defined as follows.
Individual health is a measure that expresses the ratio between adaptedness and adaptability of the
individual. At that, the optimal state of health should be understood as a state of satisfactory
adaptedness to the specific conditions of the individual existence while maintaining sufficient
adaptability (adaptive readiness to a sudden change of conditions).
14 A biological species can be considered as a set (in the mathematical meaning) of consanguineous (closely-related)
biological populations.
15 In-depth analysis of moral dilemmas was given in [89] recently, so we will not dwell on this issue here.We should only
note that similar problems are encountered when finding the optimal balance between the values of the unity of a nation
and the values of liberal freedoms.
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mental exertion is taking the form of a quasi-linear increase of the corresponding function with
an increase in exertion. The linear dependence in coordinates of “stress-response” is broken
only in the areas of imperceptible (i.e., while having a subthreshold level of stress) or extreme
exertions (i.e., when exhaustion of the reserve of adaptation occurs). In other words, the whole
curve “stress-response” reveals a sort of S-shaped dependence (i.e., the logistic sigmoid
function). There are five sites that can be identified on this curve (Figure 7). It is obvious that
the nature of the load as well as parameters of response may vary in description of the different
systems or organs of the human body. It may be a special load, which has an influence only
on a number of certain parameters of the organism (e.g., the influence of illumination on the
pupil diameter), or a sort of universal load, in response to which the parameters of all or most
of the organs and the systems become changed (such as hypoxia). The response parameters
need not be primary (measured directly). As those, in some cases, one may make use of the
results of mathematical processing of time series of individual primary parameters or even
different mathematical combinations of several primary parameters that characterize a
particular function of the body. The main requirement for the choice of such parameters is that
each parameter showing the response of the organism should change with increasing load like
the logistic function and should conform to physiological functions.
It is obvious that the various organs and systems of the body are not necessarily to be in the
same functional state. So the pathology of certain organs or systems may result in not only
functional, but also structural change of other organs for compensating the reduced function.
Therefore, to describe the whole organism by the proposed method, it is required to develop
a system of tests that assess separate responses of different organs and systems on a load which
is typical for each of them. A specific component of quantitative assessment of the health
quality of a particular person can be obtained by making comparison of the slope and the level
of saturation of the logistic curve, which corresponds to the response on an adequate load, in
a specific plane, which conforms with a specific organ or a specific system, with the average
statistical parameters of healthy individuals of the corresponding sex and age group. A set of
such “response-planes”, each of these with its own parameters (A, B, C, D), enables us to build
a system of quantitative assessment of the quality of individual health. By tracking the
dynamics of change of the parameters of the curves in each plane simultaneously, we can assess
the level of total individual health.
The medical examination should be fulfilled as a three-phase test, comprising the successive
phases: 1) initial phase of rest, 2) phase of the individually metered load, and 3) recovery phase.
This is caused by the following circumstances.
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Figure 7. Typical response curves obtained during the testing process with linear increase and subsequent linear de‐
crease of load. Five sections can be identified on each curve: OA — the zone of areactivity, when the load is so small
that the response is inexpedient; AB — the initial nonlinear part of the response, when the specific reaction grows
with load increases (can be approximated by a power or exponential functions); BC — the zone of linear regulation,
when the reaction increase is proportional to the load growth; CD — the final non-linear section, when the respond‐
ing system is approaching exhaustion of resources for adaptation; the section right of D corresponds with resource
exhaustion response. Arrows show the direction of the process. The projection of the distance between linear sections
of the load curve (ascending part of the loop) and the recovery curve (its descending part) on the axis of reactions is
taken as the “width of the hysteresis loop”.
Figure 8. The general scheme of the two approaches (black and gray boxes). X — vector of input influences; Y —
vector of output measured parameters; Z — vector uncontrolled influences.
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When investigating the complex system (and many researchers are inclined to reckon human
organism among supercomplex systems) about the internal structure of which is not known
everything that is required to know for predicting its behavior under different conditions, the
approaches of “black box” or of “gray box” (Figure 8) are taken to use in cybernetics. Either
approach provides for an impact on the studied object by a number of certain controllable
factors (the vector of the input parameters) with subsequent registration of the vector of the
output parameters. While changing the quantitative levels of the input vector or composition
of these parameters, one can observe some changes of the output vector with the aim to find







), i.e. the output parameters are a function of both the input
(controlled) impacts and a complex of uncontrolled influences. In our particular case, a doctor
or a researcher has a number of certain ideas about the form of the function (or more precisely,
a set of models that approximately describe it); in other words, our box is “gray”, not “black”.
However, even when the form of the function F  is known exactly, but we do not know anything
about the vector Z
→
, the correct prediction of how the system behavior changes with changing
the vector X
→
 can scarcely be done. As long as the task of a detailed description of the vector
Z
→
, seems to be unsolvable in principle when the cardiovascular system is under the study
(since, for example, emotionally significant reflections of the patient have a significant effect
on the cardiac rhythm as well as on blood pressure, but they cannot be put under an external
control), the only way to solve the problem of revealing the transition function is the way of





(in the appropriate meaning). To reach the situation, one can either
transfer some of the factors from the Z
→
 to the X
→
 (if it is possible), or raise the components of
the vector X
→
 to such values when the control system of the biological object being studied will
be forced to neglect the influence of Z
→
 for reasons of self-preservation.
Hence, the testing of a complex system the sufficient information about which is not available
should be carried out under the influence of a set of controlled factors (the load) the total effect
of which is much higher than that of the unrecorded influences. In other words, the medical
examination of the cardiac action should always be performed with the phase of such level of
the individually metered load that is physiologically significant for the organism of the
examined individual.
No matter how little the test influence is applied, the cardiovascular system, as well as the
organism as a whole, functions in a “background mode” nevertheless, in accordance with a
great number of the natural laws. So the information about the level of functioning of the
organism at rest (at below-threshold loads) is also required, and, therefore, every part of the
dependence in coordinates of “stress-response” provides some useful information about the
organism.
After canceling any significant load, the system can not instantly jump to its original state
because of its inertial properties associated primarily with changes in concentrations of various
substances (both hormones and metabolites) in response to the foregoing load. For bringing
the substances to their initial concentration, their diffusion, transport and metabolism require
some time and energy costs. Hence, the recovery process contains not less information about
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the system than its actual response to the load. To assess the response of the load, one of the
most convenient models is that one in which a linear increase of load up to a predetermined
level followed by a linear decline of load to zero (for example, using veloergometry) is
implemented. Curves obtained in this way are reminiscent of the hysteresis loop in descrip‐
tions of the magnetization reversal of ferromagnets with high coercivity. The curves from tests
with increasing load to a submaximal level have the form shown in Figure 7. The width of the
hysteresis loop in this case reflects the adaptability of the reacting system.
The basic mechanisms of cardiovascular regulation, as well as methods for assessing their
integrity in the cases when spatial-temporal organization of the heart remains near normality,
have been described briefly in this section of the chapter. In such cases, the methods recom‐
mended will help more effectively identify persons with weakened adaptive ability at
maintenance of normal heart functioning. According to the well-known joke, “healthy people
do not exist, there are only people that did still not get the sufficiently full checkup”; and it
looks like a great truth.
5. Conclusion: Arrhythmic action of the heart
It has been believed for centuries that cardiac arrhythmia is a sort of pathology, excepting a
few variants, caused by these or those disorders of cardiac activity. However, the facts that is
set out in this chapter make us become engrossed in our thoughts about many cases when
arrhythmia may be a specific sort of normal activity of the heart (and the cardiovascular system
in whole), which should be regarded as a normal adaptive response of an organism either on
some other health problems, which are different from cardiac problem, or on some specific
external signals. And medical treatment in either situation seems to be harmful, and accord‐
ingly increases the overall mortality rate from treated cases of arrhythmia (the problem that
was addressed in the beginning of the chapter).
In some cases, it has the character of a reversible adaptive response, in other cases it is a
compensatory response aimed at replacement of certain lost functions of the organism, and all
such cases should be taken as a normal arrhythmic functioning of the heart. Certain types of
arrhythmias are dangerous to life of the whole organism, because they call forth hemodynamic
disturbances, which in turn lead to dysfunction of various vital organs. This group of arrhyth‐
mias includes also those that are started up by certain natural hereditary mechanisms of the
population dynamics regulation, which should also be recognized, from the viewpoint of the
biomedical sciences, as a sort of the normal arrhythmic functioning of the heart. Recall that,
according to the hypothesis expressed by P.K Anokhin, even myocardial infarction, at least in
some cases, should be considered as a specific adaptive reaction realized through certain
mechanisms of intra-population self-regulation. Developing Anokhin’s hypothesis, we
propose a new special term “arrhythmic action of the heart”, which should be comprehended as
the normal arrhythmic functioning of the heart that is aimed at maintenance of physiological
homeostasis under certain specific conditions.
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In some other cases, we are often faced with pathological arrhythmic functioning of the heart, of
course. Therefore, the actual problem of modern medicine is the development of objective
methods for discerning arrhythmic action of the heart and arrhythmic disorders of the action of
the heart
Note that the evaluation of serious cardiac arrhythmias associated with the change in location
of the source of excitation waves is even more difficult. For example, the case reported
previously [1] engenders thoughts that even the atrioventricular nodal reentrant tachycardia
(AVNRT) should be considered in the certain cases as a variant of the normal adaptive
response. To observe and to study the normal variants of the AVNRT is harder for two obvious
reasons. Firstly, when a human is moving very actively, taking measurements of his or her
physiological parameters becomes a very difficult task. Secondly, there are a relatively small
number of people in populations of modern societies, who are able to undergo very high
physical loads. But it must be assumed that in ancient times, when living conditions were much
more rigorous, the normal type of AVNRT could play a vitally important role in providing
physiological needs of an actively moving human (during an extremely quick run, for
example). It is reasonable to assume that the biological evolution has given our ancestors this
normal type of AVNRT as a reserve mechanism for increasing cardiac rate during extremely
high physical loads, when it is needed more frequent rhythm of cardiac contraction than the
highest possible rhythm of the sinoatrial node. If this hypothesis will be confirmed, clinical
cases of AVNRT should be seen rather as a disease resulting from decrease of control from the
side of the functional system that regulates the cardiac action, than as pathology of the
atrioventricular node.
Another important point is concerned with the widespread conception in the medical com‐
munity that the arrhythmia must be understood as some abnormalities in the electrical activity
of the heart or in conduction of excitation waves through the myocardium. Under this
conception, disturbance of other cardiac functions, such as the contractile function, does not
relate to cardiac arrhythmias, although can result in arrhythmia of this or that type. This
understanding of cardiac arrhythmia is based on traditional rough notions of cause-and-effect
relations between processes that underlie the cardiac action. It is traditionally accepted that
the process of excitation of the membranes of cardiomyocytes causes contraction of these cells,
which in turn leads to the ejection of blood from the heart. Everything here is seems to be
simple, logical and understandable, but...
Recent studies [90–92] have demonstrated that the nature in this case also proved to be
“smarter” than the human logic built within the frames of the mechanistic approach. The new
experimental results reveal the existence of negative feedback, in the terms of cybernetics,
between the contractile function of the heart and the process of its electrical excitation, as well
as the substantial effect of the mechanical conditions of cardiac contraction on the process of
cardiac excitation. In contrast to the rather well-studied nature of the coupling between
excitation and contraction, the molecular-cellular mechanisms of mechanoelectrical feedback and
its physiological and pathophysiological significance are still not completely understood. The
authors assert that the mechanoelectrical coupling is physiologically significant for regulation
of functioning of normal myocardium, because it provides coordinated changes of the action
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potential and of the kinetics of intracellular calcium depending on the mechanical conditions,
which is an additional contributing factor of the cardiac muscle adaptation to changing
external conditions of mechanical contraction. The same authors acknowledge that arrhyth‐
mogenic effects of mechanical impacts are well-known; for example, a sharp shortening or
quick mechanical stretches of cardiomyocytes under certain conditions lead to extra action
potentials.
Moreover, after studying influence of myocardial heterogeneity on the efficiency of its
mechanical function, the same authors come also to unexpected findings. It proved that
“different types of mechanical heterogeneity (...) can play a positive or negative role depending
on the distribution of heterogeneous properties and on the order the elements of the system
are activated” [90]. In pathology, fine coordination of individual characteristics of cardiomyo‐
cytes and sequence of their activation can be broken, so that myocardial system becomes
disorganized, and its function deteriorates. For example, parts with casual inclusions of
hypoxic, hypertrophic and normal cardiomyocytes were observed in the mature myocardium,
and therefore it happened that the functional properties of the cells in such a system (partic‐
ularly, their electromechanical characteristics) were randomly distributed with respect to a
sequence of excitation. As a result, the strength of cardiac contraction decreases sharply in such
a system, while arrhythmogenic dispersion of repolarization increases. It has been shown that
derangement of the accurate sequence of activation of the myocardium can lead to a sharp
deterioration in its contractile function, and this fact helps to explain why so often the clinic
use of artificial pacemaker does not improve the quality of life of patients. In that way, the
complex and diversified investigation brought out clearly that cardiac arrhythmias can result
not only from the disorder of the electrical activity of the heart, but also from disorder of its
contractile function, and that the most important cause of arrhythmias is a disarrangement in
the mechanisms of synchronous interaction between the electrical and mechanical processes
in the myocardium.
Consequently, the term “pathological cardiac arrhythmia” should be understood not only as these or
those disorders in electrical activity of the heart, but it is disorders of its functioning as the whole
organ, which is a part of the entire cardiovascular system with its complex regulatory mecha‐
nisms.
If disorders in electrical organization of the heart are well compensated by the mechanical
properties of multi-cellular system of the myocardium, the heart continues to perform its pump
function effectively. On the contrary, very serious disorders of the pump function of the heart,
caused by disorders in the accurate organization of the mechanical properties of the myocardial
multi-cellular system, can occur even during the “normal” sequence of propagation of electric
(i.e. autowave) excitation in the heart. Scientific observation of the heart from this new
standpoint of biophysics and cybernetics makes us re-ask the question, in what cases changing
the position of the source of excitation waves should be seen as a failure of adaptive mecha‐
nisms (i.e., as the disease), and in what cases such sorts of arrhythmia should still considered
as a normal effect of adaptive mechanisms or as their side effect. In case of pathological
arrhythmias, another task associated with revealing the exact location of failure of adaptation
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remains: whether it finds itself in the myocardium or in one of the control loops and guidance
loops that serve the cardiac action.
Hence, according to the conception presented here, we must distinguish at least the following
groups of pathological arrhythmias:
• arrhythmias that are ranked among normal reactions of adaptation, but, nevertheless, lead
to hemodynamic disorders, dangerous for the whole organism (the mechanisms of regula‐
tion of population dynamics, for example);
• arrhythmias that result from disorders of adaptation because of disorganization in the
chains of regulation of cardiac action;
• arrhythmias that result from disorders of adaptation because of disorganization of the
autowave function of the heart.
It must be assumed that these new results will help finally to begin effective treatment of
cardiac arrhythmias by restoring the accurate organization of such a complex system which
the heart is indeed.
The biophysical language provides a better understanding of the causes of cardiac disorders,
because it offers a number of integral characteristics of biological objects, and this is what gives
him additional power. The physiological language has become actually a linguistic subset of
the biophysical language, and it is quite a natural process in the development of knowledge.
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1. Introduction
The most commonly diagnosed sleep disordered breathing is obstructive (OSA) and central
(CSA) sleep apnea. However, establishing the pathogenic mechanisms are not clear and precise
contribution of OSA or CSA in the development of cardiovascular disease is not fully under‐
stood (Arias and Sanchez, 2007). Increased sympathetic activity induced by hypoxia, blood
viscosity, inflammation (Chowdhuri et al., 2007; Patel and Rosen, 2007) or increased oxidative
stress (Schulz et al., 2006) may mediate establishing pathogenesis. In both of these disorders
are described serious complications significantly increasing the risk of arterial hypertension,
coronary heart disease, heart rhythm disorders, including myocardial infarction. Similarly,
CSA is accompanied by a variety of disorders of the heart, such as right ventricular dysfunction
(afterload) (Bugress, 1998).
Apnea episodes produce not only short-term systemic hypoxia as well as hypercapnia and
acidosis, where not only the myocardium is suffering disorders (Budhiraja and Quan, 2005;
Schulz et al., 2006; Aronow, 2007; Patel and Rosen, 2007; Arias and Sanchez, 2007), but also the
central nervous system. These clinical trials unambiguously ascribe the increased risk of
cardiac events to apneic episodes occuring during sleep. In addition, respiratory alkalosis is
also an extremely common and complicated problem affecting virtually every organ system
in the body, the etiology of which may be related to pulmonary or extrapulmonary factors.
However, not at all consider the effect of the recovery of oxygen delivery (reoxygenation) after
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contribution of OSA or CSA in the development of cardiovascular disease is not fully under‐
stood (Arias and Sanchez, 2007). Increased sympathetic activity induced by hypoxia, blood
viscosity, inflammation (Chowdhuri et al., 2007; Patel and Rosen, 2007) or increased oxidative
stress (Schulz et al., 2006) may mediate establishing pathogenesis. In both of these disorders
are described serious complications significantly increasing the risk of arterial hypertension,
coronary heart disease, heart rhythm disorders, including myocardial infarction. Similarly,
CSA is accompanied by a variety of disorders of the heart, such as right ventricular dysfunction
(afterload) (Bugress, 1998).
Apnea episodes produce not only short-term systemic hypoxia as well as hypercapnia and
acidosis, where not only the myocardium is suffering disorders (Budhiraja and Quan, 2005;
Schulz et al., 2006; Aronow, 2007; Patel and Rosen, 2007; Arias and Sanchez, 2007), but also the
central nervous system. These clinical trials unambiguously ascribe the increased risk of
cardiac events to apneic episodes occuring during sleep. In addition, respiratory alkalosis is
also an extremely common and complicated problem affecting virtually every organ system
in the body, the etiology of which may be related to pulmonary or extrapulmonary factors.
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apneic episodes on the onset or development of ventricular arrhythmias. Reoxygenation after
apneic episodes does not automatically normalize myocardial properties (electrophysiological
and mechanical), but can also increase the risk of reoxygenation arrhythmias (Mubagwa et al.,
1997; Shinmura et al., 1997). There are many cardiac effects of pulmonary hyperventilation-
induced respiratory alkalosis including tachycardia, heart rhythm disorders (Foster et al.,
2001) and supraventricular tachycardia caused by altered atrioventricular nodal conduction
(Chen et al., 2001). Disorders of pulmonary ventilation are clearly considered to be proar‐
rhythmogenic.
The timing of the transient risk state is dependent upon the synchronisation of the patient and
not upon the time per se. After a transmeridian flight over several time zones, individuals will
be out of phase for at least a short duration of time with their new surroundings. Information
on the speed of the adjustment of the human circadian system is not available, but the system
is probably in a transient state of internal desynchronisation for several days, depending on
the magnitude of the longitudinal transmeridian displacement. It is commonly stated that it
takes one day for every change in meridian. In shift workers, the degree of disturbance of
circadian desynchronisation of physiological functions is in relation to its surroundings and
may vary with the type of working hour shift. Also, the interaction of endogenous rhythms
with environmental factors must be considered.
2. Chronobiology of the electrophysiological myocardial properties under
apnoic episode and reoxygenation
It has been shown that all cardiac functions as well as the symptoms of cardiovascular diseases,
including the various types of ventricular arrhythmias, morbidity and mortality, show
circadian dependence (rhythmicity (Henry et al., 1990; Gilpin et al., 1990; Waterhouse et al.,
2000). Knowledge regarding circadian variations of the electrophysiological myocardial
properties of the heart and autonomic nervous system activity may help to more precisely
evaluate the risk of ventricular arrhythmia incidence. The evidence in the literature regarding
circadian patterns in arrhythmias is complicated by the fact that nearly all of the studies are
confounded by a variety of factors independent of the intrinsic arrhythmogenic activity
(Portaluppi and Hermida, 2007).
But, the circadian system is the foundation of the sleep-wake cycle, disorders and abnormalities
in sleep are often connected with disorders or abnormalities in the circadian system. Circadian
rhythm sleep disorders, such as jet lag syndrome (Auger and Morgenthaler, 2009) and shift
work sleep disorder (Akerstedt and Wright, 2009), are those specifically attributed to dys‐
functions or insufficiencies in the circadian system. Taking into consideration the preeminence
of the circadian clock in timing sleep, it is likely that other sleep disorders are also linked to
circadian system abnormalities (Richardson, 2005).
There are the clinical trials, which refer to fact that connection of the circadian rhythmicity of
the cardiovascular events with apnoic episodes may have practical relevance in screening for
patients with OSA and may have prognostic clinical value in predicting future cardiovascular
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events. The risk of sudden death from cardiac causes has peak from 06:00h to noon and a nadir
from midnight to 06:00h. OSA is associated with neurohormonal and electrophysiological
abnormalities that may increase the risk of sudden death from cardiac causes, especially during
sleep. Gami et al. (2005) followed this dependence in 112 people, who died suddenly from
cardiac causes. They found that from midnight to 06:00h, sudden death from cardiac causes
occurred in 46% of people with OSA, as compared with 21% of people without OSA. People
with sudden death from cardiac causes from midnight to 06:00h had a significantly higher
apnea-hypopnea index than those with sudden death from cardiac causes during other
intervals, and the apnea-hyponea index correlated directly with the relative risk of sudden
death from cardiac causes from midnight to 06:00h. Thus, people with OSA have a peak in
sudden death from cardiac causes during the sleeping hours, which contrasts strikingly with
the nadir of sudden death from cardiac causes during this period in people without OSA. The
different variation in onset of myocardial infarction was found in patients with and without
OSA. Myocardial infarction occurred between 12:00h and 06:00h in 32% of OSA patients and
7% of non/OSA patients. Of all patients having myocardial infarction between 12:00h and
06:00h, 91% had OSA. These findings suggest that OSA may be a trigger for myocardial
infarction and patients having nocturnal onset of myoacardial infarction should be evaluated
for OSA. Future research should address the effects of OSA therapy for prevention of nocturnal
cardiac events (Kuniyoshi et al., 2008).
Besides humans, almost all animals are exposed to periodic repetitions of light and dark cy‐
cles during a 24-hour (circadian) period to which virtually all physiological functions are
synchronized. Disturbance of the internal synchronization of rhythms with the periodicity
of the external environment may manifest by increased susceptibility to disease. Surprising‐
ly, there are only few works describing day-time of the experiment running or synchroniza‐
tion of animals to the external environmental periodicity, such as the light-dark (LD) cycle.
It can be a problem, because the LD cycle is given for one of the strongest circadian synchro‐
nizators of the animal endogenous rhythms. Therefore, the creation of experimental, in vivo,
chronobiological animal models may help reveal some of the relationships between circadi‐
an time and biological function, which is sometimes very difficult to study in humans. From
this reason, the circadian variability should be considered as important factor especially in
the cardiovascular studies.
For example, the 24h course of the myocardial vulnerability showed the highest susceptibility
of the rat ventricular myocardium to arrhythmias between 12:00h and 15:00h and highest
resistance between 24:00h and 03:00h under normooxic conditions (Svorc et al., 1994; 2012). In
hypoventilatory rat model, hypoventilation-induced systemic hypoxia, hypercapnia and
acidosis increased the myocardial vulnerability and decreased heart rate values throughout
the 24-hour period. Circadian rhythm of the electrical stability of the heart was changed to
biphasic with smaller peak between 15:00h and 18:00h and higher peak between 24:00h and
03:00h. The hypoventilatory circadian rhythm of the electrical stability of the heart was not
significant as revealed by the population mean cosinor (Svorc et al., 1997, 2000). Hyperventi‐
lation does not disturb, but likely only modifies the circadian rhythm of the electrical stability
of the heart. The hyperventilatory 24h rhythm of the myocardial vulnerability shows a
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nizators of the animal endogenous rhythms. Therefore, the creation of experimental, in vivo,
chronobiological animal models may help reveal some of the relationships between circadi‐
an time and biological function, which is sometimes very difficult to study in humans. From
this reason, the circadian variability should be considered as important factor especially in
the cardiovascular studies.
For example, the 24h course of the myocardial vulnerability showed the highest susceptibility
of the rat ventricular myocardium to arrhythmias between 12:00h and 15:00h and highest
resistance between 24:00h and 03:00h under normooxic conditions (Svorc et al., 1994; 2012). In
hypoventilatory rat model, hypoventilation-induced systemic hypoxia, hypercapnia and
acidosis increased the myocardial vulnerability and decreased heart rate values throughout
the 24-hour period. Circadian rhythm of the electrical stability of the heart was changed to
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nonsignificant pattern, with higher myocardial resistance during the dark (active) period of
the LD cycle.
On the basis of these facts, it is clear that the disorders of pulmonary ventilation (hypoventi‐
lation, hyperventilation) not only change the electrophysiological properties of the myocar‐
dium, but also circadian rhythm of the myocardial vulnerability to the ventricular arhythmias.
This includes also apnoic episodes, which are also arrhythmogenicly. Problems of connection
of the circadian rhythmicity of the cardiovascular system with apnoic episodes is not study in
more detail, although clinical studies suggest a connection between sudden death from cardiac
causes and OSA dependent on circadian timing. The question remains whether there also a
reverse connection? Could patients with OSA, without obvious cardiac diseases, be more
susceptible to heart-rhythm disorders during sleep after a change in synchronisation with local
time? We evaluated if apneic episodes and subsequent reoxygenation changed the electrical
predisposition of the heart to ventricular arrhythmias, heart rate (HR), activity of the auto‐
nomic nervous system and acid–base balance by the same manner in active (dark) and non-
active (light) part of the day.
The present study conformed with the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH publication number 85-23, revised
1996). The study protocol was also approved by the Ethics Committee of the Medical Faculty
of Safarik University (Kosice, Slovak Republic) (permission number 2/05).
The experiments were performed in ketamine/xylazine anaesthetized female Wistar rats
(ketamine [Narkamon] 100 mg/kg [SPOFA Prague] + xylazine [Rometar] 15 mg/kg, intra‐
muscularly). Anaesthesia was maintained at a level such that painful stimuli and surgery did
not evoke noticeable motor or cardiovascular responses. On completion of the experiments,
rats were sacrificed by cardiac administration of an overdose of ketamine. The effect of the
light period (light phase) on electrophysiological properties of the heart, acid-base balance,
ions and heart rate variability (HRV) were followed after adaptation to an LD cycle (12h light,
12h dark, 40%-60% humidity, room temperature 24 °C, two animals/cage with access to food
and water ad libitum) for four weeks, with the dark part of the cycle from 18:00h to 06:00h. The
effect of the dark period (dark phase) was followed after adaptation to the inverse setting of
the LD cycle (12h dark, 12h light), with the dark period from 06:00h to 18:00h. The experiments
were performed twice (the first animal between 09:00h and 10:00h and the second animal
between 12:00h and 13:00h) (scheme 1).
2.1. Ventilation
The trachea was exposed at the mid-cervical level and cannulated using a plastic tube. A
tracheal cannula was attached to a volume-rate-regulated artificial ventilator (UGO Basile,
Comerio-Varese, Italy) and animals ventilated by room air. The parameters of the initial
ventilation and reoxygenation were a respiratory rate of 50 breaths/min and a tidal volume of
1 ml/100 g body weight. The parameters of ventilation were chosen on the basis of validated
methods of artificial controlled ventilation using room air for pentobarbital-anaesthetised rats,
which can be applied for the preservation of normal acid–base balance. Apneic episode was
simulated by switching off the ventilator for 2 min. The respiratory effect of the pulmonary
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ventilatory changes was monitored by the analysis of the acid-base balance from blood samples
taken from the femoral artery unrepeatedly at the end of experiment in the single groups.
2.2. Experimental protocol
Animals were randomly divided into seven groups (14 animals in each group) for the light
and dark parts of the day to evaluate the acid–base balance in single experimental steps. Group
1 contained intact rats before surgical interventions, spontaneous breathing under ketamine/
xylazine anaesthesia (Intact). Group 2 contained rats after tracheotomy, thoracotomy and 5
min of normal artificial ventilation (Stabil). Group 3 contained rats who underwent 2 min of
apnoea (Apnoea). Group 4 had rats that underwent 5 min of reoxygenation (5 reoxy). Group
5 had rats that underwent 10 min of reoxygenation (10 reoxy). Group 6 involved rats who had
15 min of reoxygenation (15 reoxy). Group 7 contained animals that had 20 min of reoxyge
nation (20 reoxy) after 2 min. apneic episode. The experiment was completed by taking blood
samples (scheme 2).
2.3. Measurements
ECG parameters, acid-base balance and HRV measurements were performed in the supine
position on a preheated table. Body temperature was maintained at a level equivalent to the
rectal temperature measured before anaesthetic agent administration. Heat provided by an
infrared lamp was used to prevent any hypothermic effects on heart rate.
The chest was opened via a parasternal thoracotomy for elimination of nervous breathing
control mechanisms and measurement of the electrical stability of the heart (measured by the
ventricular arrhythmia threshold - VAT). The VAT was estimated as the minimal amount of
dark, 12h light), with the dark period from 06:00h to 18:00h. The experiments were performed 
twice (the first animal between 09:00h and 10:00h and the second animal between 12:00h and 
13:00h) (scheme 1).   
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Scheme 1. Adaptation of rats to the LD cycle (12h : 12h) in a special room. Light stripe - the 
light part of the rat regime day, dark stripe - the dark part of the rat regime day. Arrows 
indicate the time of the experiment running. 
Ventilation
 The trachea was exposed at the mid-cervical level and cannulated using a plastic tube. A 
tracheal cannula was attached to a volume-rate-regulated artificial ventilator (UGO Basile, 
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ventilation and reoxygenation were a respiratory rate of 50 breaths/min and a tidal volume of 
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methods of artificial controlled ventilation using room air for pentobarbital-anaesthetised rats, 
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reoxy). Group 6 involved rats who had 15 min of reoxygenation (15 reoxy). Group 7 
contained animals that had 20 min of reoxygenation (20 reoxy). The experiment was 
completed by taking bl od samples (scheme 2). 
Scheme 2. Experimental protocol. Arrows denote single steps of the experiment with 
measurement of the ventricular arrhythmia threshold for evaluation of the electrical stability 
of the heart. 
Measurements
     ECG parameters, aci -base balance and HRV measurements were performed in the supine 
position on a preheated table. Body temperature was maintained at a level equivalent to the 
rectal temperature measured before anaesthetic agent administration. Heat provided by an 
infrared lamp was used to prevent any hypothermic effects o  hea t rate.        
      The chest was opened via a parasternal thoracotomy for elimination of nervous breathing 
control mechanisms and measurement of the electrical stability of the heart (measured by the 
ventricular arrhythmia threshold - VAT). The VAT was estimated as the minimal amount of 
electrical current (mA) needed for elicitation of ventricular arrhythmias. The heart was 
protected from changes in temperature and humidity by administering physiological solution, 
dropwise, to the heart, with temperature equal to rectal temperature measured before the 
anaesthetic agent application. The stimulating platinum electrodes (diameter 1 mm and 5 mm 
interelectrode distance, temperatura equal to rectal temperature) were placed at the base of 
right ventricle. Parameters of the electrical stimulation were 400 ms series of rectangular 
pulses; frequency, 30 Hz; impulse length, 10 ms). Stimuli were triggered by onset of the R 
wave in the II lead of electrocardiography (ECG) on the base of synchronization of ECG with 
stimu tor. The current intensity was increas d progres ively by increments of 0.2 mA until 
ventricular arrhythmias were obtained. Recovery of the sinus rhythm was spontaneous.   
 The bipolar electrodes were attached to the upper and lower limbs and served for recording 
of the heart rate (HR), ECG and heart rate variability (HRV). ECG was further analysed using 
Scheme 2. Experimental protocol. Arrows denote single steps of the experiment with measurement of the ventricular
arrhythmia threshold for evaluation of the electrical stability of the heart.
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nonsignificant pattern, with higher myocardial resistance during the dark (active) period of
the LD cycle.
On the basis of these facts, it is clear that the disorders of pulmonary ventilation (hypoventi‐
lation, hyperventilation) not only change the electrophysiological properties of the myocar‐
dium, but also circadian rhythm of the myocardial vulnerability to the ventricular arhythmias.
This includes also apnoic episodes, which are also arrhythmogenicly. Problems of connection
of the circadian rhythmicity of the cardiovascular system with apnoic episodes is not study in
more detail, although clinical studies suggest a connection between sudden death from cardiac
causes and OSA dependent on circadian timing. The question remains whether there also a
reverse connection? Could patients with OSA, without obvious cardiac diseases, be more
susceptible to heart-rhythm disorders during sleep after a change in synchronisation with local
time? We evaluated if apneic episodes and subsequent reoxygenation changed the electrical
predisposition of the heart to ventricular arrhythmias, heart rate (HR), activity of the auto‐
nomic nervous system and acid–base balance by the same manner in active (dark) and non-
active (light) part of the day.
The present study conformed with the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH publication number 85-23, revised
1996). The study protocol was also approved by the Ethics Committee of the Medical Faculty
of Safarik University (Kosice, Slovak Republic) (permission number 2/05).
The experiments were performed in ketamine/xylazine anaesthetized female Wistar rats
(ketamine [Narkamon] 100 mg/kg [SPOFA Prague] + xylazine [Rometar] 15 mg/kg, intra‐
muscularly). Anaesthesia was maintained at a level such that painful stimuli and surgery did
not evoke noticeable motor or cardiovascular responses. On completion of the experiments,
rats were sacrificed by cardiac administration of an overdose of ketamine. The effect of the
light period (light phase) on electrophysiological properties of the heart, acid-base balance,
ions and heart rate variability (HRV) were followed after adaptation to an LD cycle (12h light,
12h dark, 40%-60% humidity, room temperature 24 °C, two animals/cage with access to food
and water ad libitum) for four weeks, with the dark part of the cycle from 18:00h to 06:00h. The
effect of the dark period (dark phase) was followed after adaptation to the inverse setting of
the LD cycle (12h dark, 12h light), with the dark period from 06:00h to 18:00h. The experiments
were performed twice (the first animal between 09:00h and 10:00h and the second animal
between 12:00h and 13:00h) (scheme 1).
2.1. Ventilation
The trachea was exposed at the mid-cervical level and cannulated using a plastic tube. A
tracheal cannula was attached to a volume-rate-regulated artificial ventilator (UGO Basile,
Comerio-Varese, Italy) and animals ventilated by room air. The parameters of the initial
ventilation and reoxygenation were a respiratory rate of 50 breaths/min and a tidal volume of
1 ml/100 g body weight. The parameters of ventilation were chosen on the basis of validated
methods of artificial controlled ventilation using room air for pentobarbital-anaesthetised rats,
which can be applied for the preservation of normal acid–base balance. Apneic episode was
simulated by switching off the ventilator for 2 min. The respiratory effect of the pulmonary
Cardiac Arrhythmias - Mechanisms, Pathophysiology, and Treatment48
ventilatory changes was monitored by the analysis of the acid-base balance from blood samples
taken from the femoral artery unrepeatedly at the end of experiment in the single groups.
2.2. Experimental protocol
Animals were randomly divided into seven groups (14 animals in each group) for the light
and dark parts of the day to evaluate the acid–base balance in single experimental steps. Group
1 contained intact rats before surgical interventions, spontaneous breathing under ketamine/
xylazine anaesthesia (Intact). Group 2 contained rats after tracheotomy, thoracotomy and 5
min of normal artificial ventilation (Stabil). Group 3 contained rats who underwent 2 min of
apnoea (Apnoea). Group 4 had rats that underwent 5 min of reoxygenation (5 reoxy). Group
5 had rats that underwent 10 min of reoxygenation (10 reoxy). Group 6 involved rats who had
15 min of reoxygenation (15 reoxy). Group 7 contained animals that had 20 min of reoxyge
nation (20 reoxy) after 2 min. apneic episode. The experiment was completed by taking blood
samples (scheme 2).
2.3. Measurements
ECG parameters, acid-base balance and HRV measurements were performed in the supine
position on a preheated table. Body temperature was maintained at a level equivalent to the
rectal temperature measured before anaesthetic agent administration. Heat provided by an
infrared lamp was used to prevent any hypothermic effects on heart rate.
The chest was opened via a parasternal thoracotomy for elimination of nervous breathing
control mechanisms and measurement of the electrical stability of the heart (measured by the
ventricular arrhythmia threshold - VAT). The VAT was estimated as the minimal amount of
dark, 12h light), with the dark period from 06:00h to 18:00h. The experiments were performed 
twice (the first animal between 09:00h and 10:00h and the second animal between 12:00h and 
13:00h) (scheme 1).   
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Scheme 1. Adaptation of rats to the LD cycle (12h : 12h) in a special room. Light stripe - the 
light part of the rat regime day, dark stripe - the dark part of the rat regime day. Arrows 
indicate the time of the experiment running. 
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methods of artificial controlled ventilation using room air for pentobarbital-anaesthetised rats, 
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simulated by switching off the ventilator for 2 min. The respiratory effect of the pulmonary 
ventilatory changes was monitored by the analysis of the acid-base balance from blood 
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thoracotomy and 5 min of normal artificial ventilation (Stabil). Group 3 contained rats who 
underwent 2 min of apnoea (Apnoea). Group 4 had rats that underwent 5 min of 
reoxygenation (5 reoxy). Group 5 had rats that underwent 10 min of reoxygenation (10 
reoxy). Group 6 involved rats who had 15 min of reoxygenation (15 reoxy). Group 7 
contained animals that had 20 min of reoxygenation (20 reoxy). The experiment was 
completed by taking bl od samples (scheme 2). 
Scheme 2. Experimental protocol. Arrows denote single steps of the experiment with 
measurement of the ventricular arrhythmia threshold for evaluation of the electrical stability 
of the heart. 
Measurements
     ECG parameters, aci -base balance and HRV measurements were performed in the supine 
position on a preheated table. Body temperature was maintained at a level equivalent to the 
rectal temperature measured before anaesthetic agent administration. Heat provided by an 
infrared lamp was used to prevent any hypothermic effects o  hea t rate.        
      The chest was opened via a parasternal thoracotomy for elimination of nervous breathing 
control mechanisms and measurement of the electrical stability of the heart (measured by the 
ventricular arrhythmia threshold - VAT). The VAT was estimated as the minimal amount of 
electrical current (mA) needed for elicitation of ventricular arrhythmias. The heart was 
protected from changes in temperature and humidity by administering physiological solution, 
dropwise, to the heart, with temperature equal to rectal temperature measured before the 
anaesthetic agent application. The stimulating platinum electrodes (diameter 1 mm and 5 mm 
interelectrode distance, temperatura equal to rectal temperature) were placed at the base of 
right ventricle. Parameters of the electrical stimulation were 400 ms series of rectangular 
pulses; frequency, 30 Hz; impulse length, 10 ms). Stimuli were triggered by onset of the R 
wave in the II lead of electrocardiography (ECG) on the base of synchronization of ECG with 
stimu tor. The current intensity was increas d progres ively by increments of 0.2 mA until 
ventricular arrhythmias were obtained. Recovery of the sinus rhythm was spontaneous.   
 The bipolar electrodes were attached to the upper and lower limbs and served for recording 
of the heart rate (HR), ECG and heart rate variability (HRV). ECG was further analysed using 
Scheme 2. Experimental protocol. Arrows denote single steps of the experiment with measurement of the ventricular
arrhythmia threshold for evaluation of the electrical stability of the heart.
Chronobiological Aspects of Impact of Apnoic Episode and Reoxygenation on the Electrical...
http://dx.doi.org/10.5772/57168
49
electrical current (mA) needed for elicitation of ventricular arrhythmias. The heart was
protected from changes in temperature and humidity by administering physiological solution,
dropwise, to the heart, with temperature equal to rectal temperature measured before the
anaesthetic agent application. The stimulating platinum electrodes (diameter 1 mm and 5 mm
interelectrode distance, temperatura equal to rectal temperature) were placed at the base of
right ventricle. Parameters of the electrical stimulation were 400 ms series of rectangular
pulses; frequency, 30 Hz; impulse length, 10 ms). Stimuli were triggered by onset of the R wave
in the II lead of electrocardiography (ECG) on the base of synchronization of ECG with
stimulator. The current intensity was increased progressively by increments of 0.2 mA until
ventricular arrhythmias were obtained. Recovery of the sinus rhythm was spontaneous.
The bipolar electrodes were attached to the upper and lower limbs and served for recording
of the heart rate (HR), ECG and heart rate variability (HRV). ECG was further analysed using
computer software (ECG Practic Veterinary, Prague, Czech Republic). Measurement of the
ECG and HR (mean value of the last four cycles) were carried out: in intact animals; after
tracheotomy (Tr); thoracotomy (To); after each minute of the 5-min stabilization; after each 30
s of the apneic episode; and after each minute of the 20-min reoxygenation. HRV was analysed
from ECG using computer software (Varia Pulse TF4, Sima, Olomouc, Czech Republic).
Analysis of HRV was performed by scoring 600 RR intervals needed for calculation of HRV
parameters. The following HRV parameters were measured: RR interval duration (ms), very
low frequency (VLF) power (corresponding to sympathetic activity), low frequency (LF) power
(baroreceptor activity, or sympathetic and parasympathetic activity together), high-frequency
(HF) power (corresponding to parasympathetic activity) (ms2) and relative VLF power, relative
LF power and relative HF power (%).
2.4. Statistical analysis
The data are presented as the means ± SD. A non-paired t - test was used for statistical
evaluation. Differences of p < 0,05 were considered significant. The relationship between the
evaluated parameters was determined by calculating correlation coefficients. The interval –0,4
> r > +0,4 was considered to be significant. The data were processed from trials that were
conducted independent of the season because circannual variation can also occur in the
parameters that were examined.
2.5. Limitations of study
Absence of the reference ECG values, acid-base balance parameters and HRV parameters (also
literary current data) from animals without anaesthesia and in the LD dependence can be a
limitation in our study. The next limitation can be a relatively large dispersion of the measured
values. The ECG, acid-base and HRV values showed intra- and interindividual variability,
which is a problem, mainly concerning in vivo studies. The discrepancy can be explained by
the production of spontaneous, unpredictible alterations in the electrophysiologic properties
of the heart induced by anaesthesia, or hormonal and homeostatic reflexes in the animals. The
third limitation was that rats were in systemic asphyxia from the start to the end of the
experiment independent of the LD cycle. This state has been described by other authors in rats
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(Sumitra et al., 2004; Alva et al., 2006) and reflects the changes in cardiovascular (Sumitra et
al., 2004) and respiratory (Farver et al., 1986) systems.
In the first moment, we have focused on the assessment of the changes in heart rate and
electrical stability of the heart. The disruptive effect of acute hypoxia on the LD-dependent
differences in the HR–response curve was not confirmed, as suggested by other authors
(Mortola and Seifert, 2000; Bishop et al., 2001; Bosco et al., 2003; Kaplan et al., 2003; Mortola,
2007). However, it is known that ketamine/xylazine anaesthesia decreases heart rate (Hsu et
al., 1986; Morita et al., 1997; Cope et al., 1997) which has been connected with systemic asphyxia
after administration of anaesthetic agent (Švorc et al., 2009).
One of the main conclusions is that the HR was significantly and systematically higher in the
dark part than in the light part of the day during apneic episode-induced acute systemic
asphyxia. Start of apneic episode significantly (p<0,001) decreased the HR only in the dark part
of the day compared with the HR value from the end of the period of stabilization, not in the
light part. The HR decreased gradually until the end of the apneic episode in both lighted parts
of the day. Although reoxygenation significantly (p<0,001) increased the HR in both lighted
parts of the day, surprising was the finding that the LD differences were eliminated during
reoxygenation.
Figure 1. HR changes in single experimental steps. White circles represent the light part of the day and black circles
the dark part. Int: intact animals under ketamine/xylazine anaesthesia before surgical intervention allowing for spon‐
taneous breathing in the supine position. Tr: tracheotomy. To: thoracotomy.*** p < 0,001; ** p < 0,01 * p < 0,05 statis‐
tically significant HR differences between the light and dark part of the day (Svorc Jr. et al., 2011).
Twenty minutes of reoxygenation recovered the HR approximately to the HR levels of
spontaneously breathing animals. Decrease of HR can be explained by effect of hypoxia
(Hinojosa-Laborde and Mifflin, 2005) or a larger parasympathetic influence (Hayashida et al.,
1996; Svorc Jr. et al. 2013) (figure 1).
The electrical stability of the heart after the period of stabilization showed significant (p<0,001)
LD differences with the higher values during the active (dark) part of the regimen day. Apneic
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electrical current (mA) needed for elicitation of ventricular arrhythmias. The heart was
protected from changes in temperature and humidity by administering physiological solution,
dropwise, to the heart, with temperature equal to rectal temperature measured before the
anaesthetic agent application. The stimulating platinum electrodes (diameter 1 mm and 5 mm
interelectrode distance, temperatura equal to rectal temperature) were placed at the base of
right ventricle. Parameters of the electrical stimulation were 400 ms series of rectangular
pulses; frequency, 30 Hz; impulse length, 10 ms). Stimuli were triggered by onset of the R wave
in the II lead of electrocardiography (ECG) on the base of synchronization of ECG with
stimulator. The current intensity was increased progressively by increments of 0.2 mA until
ventricular arrhythmias were obtained. Recovery of the sinus rhythm was spontaneous.
The bipolar electrodes were attached to the upper and lower limbs and served for recording
of the heart rate (HR), ECG and heart rate variability (HRV). ECG was further analysed using
computer software (ECG Practic Veterinary, Prague, Czech Republic). Measurement of the
ECG and HR (mean value of the last four cycles) were carried out: in intact animals; after
tracheotomy (Tr); thoracotomy (To); after each minute of the 5-min stabilization; after each 30
s of the apneic episode; and after each minute of the 20-min reoxygenation. HRV was analysed
from ECG using computer software (Varia Pulse TF4, Sima, Olomouc, Czech Republic).
Analysis of HRV was performed by scoring 600 RR intervals needed for calculation of HRV
parameters. The following HRV parameters were measured: RR interval duration (ms), very
low frequency (VLF) power (corresponding to sympathetic activity), low frequency (LF) power
(baroreceptor activity, or sympathetic and parasympathetic activity together), high-frequency
(HF) power (corresponding to parasympathetic activity) (ms2) and relative VLF power, relative
LF power and relative HF power (%).
2.4. Statistical analysis
The data are presented as the means ± SD. A non-paired t - test was used for statistical
evaluation. Differences of p < 0,05 were considered significant. The relationship between the
evaluated parameters was determined by calculating correlation coefficients. The interval –0,4
> r > +0,4 was considered to be significant. The data were processed from trials that were
conducted independent of the season because circannual variation can also occur in the
parameters that were examined.
2.5. Limitations of study
Absence of the reference ECG values, acid-base balance parameters and HRV parameters (also
literary current data) from animals without anaesthesia and in the LD dependence can be a
limitation in our study. The next limitation can be a relatively large dispersion of the measured
values. The ECG, acid-base and HRV values showed intra- and interindividual variability,
which is a problem, mainly concerning in vivo studies. The discrepancy can be explained by
the production of spontaneous, unpredictible alterations in the electrophysiologic properties
of the heart induced by anaesthesia, or hormonal and homeostatic reflexes in the animals. The
third limitation was that rats were in systemic asphyxia from the start to the end of the
experiment independent of the LD cycle. This state has been described by other authors in rats
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(Sumitra et al., 2004; Alva et al., 2006) and reflects the changes in cardiovascular (Sumitra et
al., 2004) and respiratory (Farver et al., 1986) systems.
In the first moment, we have focused on the assessment of the changes in heart rate and
electrical stability of the heart. The disruptive effect of acute hypoxia on the LD-dependent
differences in the HR–response curve was not confirmed, as suggested by other authors
(Mortola and Seifert, 2000; Bishop et al., 2001; Bosco et al., 2003; Kaplan et al., 2003; Mortola,
2007). However, it is known that ketamine/xylazine anaesthesia decreases heart rate (Hsu et
al., 1986; Morita et al., 1997; Cope et al., 1997) which has been connected with systemic asphyxia
after administration of anaesthetic agent (Švorc et al., 2009).
One of the main conclusions is that the HR was significantly and systematically higher in the
dark part than in the light part of the day during apneic episode-induced acute systemic
asphyxia. Start of apneic episode significantly (p<0,001) decreased the HR only in the dark part
of the day compared with the HR value from the end of the period of stabilization, not in the
light part. The HR decreased gradually until the end of the apneic episode in both lighted parts
of the day. Although reoxygenation significantly (p<0,001) increased the HR in both lighted
parts of the day, surprising was the finding that the LD differences were eliminated during
reoxygenation.
Figure 1. HR changes in single experimental steps. White circles represent the light part of the day and black circles
the dark part. Int: intact animals under ketamine/xylazine anaesthesia before surgical intervention allowing for spon‐
taneous breathing in the supine position. Tr: tracheotomy. To: thoracotomy.*** p < 0,001; ** p < 0,01 * p < 0,05 statis‐
tically significant HR differences between the light and dark part of the day (Svorc Jr. et al., 2011).
Twenty minutes of reoxygenation recovered the HR approximately to the HR levels of
spontaneously breathing animals. Decrease of HR can be explained by effect of hypoxia
(Hinojosa-Laborde and Mifflin, 2005) or a larger parasympathetic influence (Hayashida et al.,
1996; Svorc Jr. et al. 2013) (figure 1).
The electrical stability of the heart after the period of stabilization showed significant (p<0,001)
LD differences with the higher values during the active (dark) part of the regimen day. Apneic
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episodes significantly (p<0,001) decreased the VAT in both light parts of the day and eliminated
LD differences. The results clearly demonstrate and confirm the pro-arrhythmogenic effects
of apneic episodes (Budhiraja and Quan, 2005; Schulz et al., 2006; Aronow, 2007; Patel and
Rosen, 2007; Arias and Sanchez, 2007). In our model, we initially stated that the pro-arrhyth‐
mogenic effects of apneic episodes act in the same manner regardless of whether they are in
the light (non-active) or dark (active) part of the day for rats (figure 2).
Figure 2. VAT changes in single experimental steps. White columns represent the light part of the day, and black col‐
umns the dark part. Stabil: animals after tracheotomy, toracotomy and 5 min artificial ventilation. Apnoae: after a 2-
min apneic episode. 5 reoxy, 10 reoxy, 15 reoxy and 20 reoxy: after 5, 10, 15 and 20 min of reoxygenation,
respectively. *** p < 0,001; ** p < 0,01 statistically significant VAT differences between the light and dark part of the
day (Svorc Jr. et al., 2011).
The decreased the electrical stability of the heart also in the course of whole 24h period (Svorc
et al., 1994, 1997) confirm results from other electrophysological studies about the effect of
hypoxia on myocardium. The reason of disorders of the heart rhythm in the hypoxic state is a
sudden increase of the extracellular K+ concentration, which play the crucial role in the changes
of the rest membrane potential and can produce the ectopic activity as well as inhibition of the
rapid reaction (Opie et al., 1979). The rapid increase of the extracellular K+ concentration is
result of KATP channel activation. It is inactivated in the normooxic conditions, but it is activated
in the hypoxic or anoxic conditions (Noma and Shibasaki, 1985; Sanguinetti et al., 1988; Daut
et al., 1990; Billman et al., 1993). Thus, the blockade of KATP channels acts antiarrhythmic
(Wolleben et al., 1989). We can suppose that mechanism of the K+ current activation by hypoxia
can be responsible for change in the electrical stability of the heart also in the circadian
dependence, although biphasic course of the VAT is not perspicuously explained by this
mechanism.
However, it seems that recovery of the pulmonary ventilation after apneic episodes can also
contribute to heart rhythm disorders, but this is dependent upon the light (non-active)-dark
(active) cycle. In the dark part of the day, the gradual increase in the VAT is associated with
the duration of reoxygenation (anti-arrhythmogenic effect) compared with the light part of the
Cardiac Arrhythmias - Mechanisms, Pathophysiology, and Treatment52
day, where the contrary tendency was observed (pro-arrhythmogenic effect). This suggests
that synchronisation of the organism to a particular enviromental periodicity could be a crucial
factor influencing myocardial vulnerability to ventricular arrhythmias mainly in the process
of recovery of the pulmonary ventilation after an apneic episode. Our model suggests that
synchronisation to local time may be an important factor for evaluation of cardiovascular risk
in patients suffering from OSA. Analyses of myocardial reactions to acute systemic asphyxia
induced by apneic episodes (as well as to reoxygenation) is very important in experimental
respirology and cardiology because the myocardium reacts differently depending on the
external environmental periodicity.
3. Chronobiology of the ECG parameters during apnoic episode and
reoxygenation
Therefore, myocardial vulnerability changes depend on the breathing as well as on the lighted
mode of the rat regime day. In addition, number of electrophysiological properties of the
cardiac structures are recognized as essential for the triggering and maintenance of heart
rhythm disorders and show dependence on the time of day (Portaluppi and Hermida, 2007).
The question remains, which electrophysiological properties play a role in the myocardial
sensitivity to the ventricular arrhythmias during apnoic episode and recovery of the pulmo‐
nary ventilation (reoxygenation) depending on the cycle of the light and the darkness succes‐
sion. Ventilatory disorders act arrhythmogenicly and the chronophysiological view on the
functional interconnection between disorders of pulmonary ventilation and changes in the
electrophysiologic properties of the heart are also important. We got from the fact that
ventricular arrhythmias may arise either from the disorders of the impulse formation and
conduction (presented by PQ interval), or from a enlarged dispersion of the refractory periods
(presented by QT interval).
We analyzed the PQ and QT interval changes (Bacova et al., 2010) in the single experimental
steps. In intact animals, higher values of PQ interval duration during in the light (inactive,
sleep) phase of the rat regime day suggest that ventricular myocardium is more susceptible to
arrhythmias originating from impulse production and conduction compare to the active part
of the day. The speed of the impulse conduction from atria to ventricles (PQ interval) depends
from action potential amplitude, reflecting the active role of Na+ channels (Carmeliet, 1986;
Amitzur et al., 2000). It can mean that ketamine/xylazine anaesthesia with associated systemic
asphyxia as well as with subsequent surgical interventions do not affect the kinetics of the Na
+ channels, which are likely to be different in the light and dark part of the rat regime day. It
seems that PQ interval is the relative stable electrophysiological parameter of the heart and it
is directly influenced by the LD cycle (figure 3). Mechanisms of such different effect of
ketamine/xylazine anaesthesia are still unknown and were not analyzed in detail.
Apneic episodes, obstructive or central, often in a connection with the sleep apnea syndrome,
are linked with disorders of the cardiac rhythm (Cutler et. al., 2002; Yamashita et al., 2004;
Bounhoure et al., 2005; Dunai et al., 2006; Bayram and Diker, 2008; Grešová et al., 2009). In our
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episodes significantly (p<0,001) decreased the VAT in both light parts of the day and eliminated
LD differences. The results clearly demonstrate and confirm the pro-arrhythmogenic effects
of apneic episodes (Budhiraja and Quan, 2005; Schulz et al., 2006; Aronow, 2007; Patel and
Rosen, 2007; Arias and Sanchez, 2007). In our model, we initially stated that the pro-arrhyth‐
mogenic effects of apneic episodes act in the same manner regardless of whether they are in
the light (non-active) or dark (active) part of the day for rats (figure 2).
Figure 2. VAT changes in single experimental steps. White columns represent the light part of the day, and black col‐
umns the dark part. Stabil: animals after tracheotomy, toracotomy and 5 min artificial ventilation. Apnoae: after a 2-
min apneic episode. 5 reoxy, 10 reoxy, 15 reoxy and 20 reoxy: after 5, 10, 15 and 20 min of reoxygenation,
respectively. *** p < 0,001; ** p < 0,01 statistically significant VAT differences between the light and dark part of the
day (Svorc Jr. et al., 2011).
The decreased the electrical stability of the heart also in the course of whole 24h period (Svorc
et al., 1994, 1997) confirm results from other electrophysological studies about the effect of
hypoxia on myocardium. The reason of disorders of the heart rhythm in the hypoxic state is a
sudden increase of the extracellular K+ concentration, which play the crucial role in the changes
of the rest membrane potential and can produce the ectopic activity as well as inhibition of the
rapid reaction (Opie et al., 1979). The rapid increase of the extracellular K+ concentration is
result of KATP channel activation. It is inactivated in the normooxic conditions, but it is activated
in the hypoxic or anoxic conditions (Noma and Shibasaki, 1985; Sanguinetti et al., 1988; Daut
et al., 1990; Billman et al., 1993). Thus, the blockade of KATP channels acts antiarrhythmic
(Wolleben et al., 1989). We can suppose that mechanism of the K+ current activation by hypoxia
can be responsible for change in the electrical stability of the heart also in the circadian
dependence, although biphasic course of the VAT is not perspicuously explained by this
mechanism.
However, it seems that recovery of the pulmonary ventilation after apneic episodes can also
contribute to heart rhythm disorders, but this is dependent upon the light (non-active)-dark
(active) cycle. In the dark part of the day, the gradual increase in the VAT is associated with
the duration of reoxygenation (anti-arrhythmogenic effect) compared with the light part of the
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day, where the contrary tendency was observed (pro-arrhythmogenic effect). This suggests
that synchronisation of the organism to a particular enviromental periodicity could be a crucial
factor influencing myocardial vulnerability to ventricular arrhythmias mainly in the process
of recovery of the pulmonary ventilation after an apneic episode. Our model suggests that
synchronisation to local time may be an important factor for evaluation of cardiovascular risk
in patients suffering from OSA. Analyses of myocardial reactions to acute systemic asphyxia
induced by apneic episodes (as well as to reoxygenation) is very important in experimental
respirology and cardiology because the myocardium reacts differently depending on the
external environmental periodicity.
3. Chronobiology of the ECG parameters during apnoic episode and
reoxygenation
Therefore, myocardial vulnerability changes depend on the breathing as well as on the lighted
mode of the rat regime day. In addition, number of electrophysiological properties of the
cardiac structures are recognized as essential for the triggering and maintenance of heart
rhythm disorders and show dependence on the time of day (Portaluppi and Hermida, 2007).
The question remains, which electrophysiological properties play a role in the myocardial
sensitivity to the ventricular arrhythmias during apnoic episode and recovery of the pulmo‐
nary ventilation (reoxygenation) depending on the cycle of the light and the darkness succes‐
sion. Ventilatory disorders act arrhythmogenicly and the chronophysiological view on the
functional interconnection between disorders of pulmonary ventilation and changes in the
electrophysiologic properties of the heart are also important. We got from the fact that
ventricular arrhythmias may arise either from the disorders of the impulse formation and
conduction (presented by PQ interval), or from a enlarged dispersion of the refractory periods
(presented by QT interval).
We analyzed the PQ and QT interval changes (Bacova et al., 2010) in the single experimental
steps. In intact animals, higher values of PQ interval duration during in the light (inactive,
sleep) phase of the rat regime day suggest that ventricular myocardium is more susceptible to
arrhythmias originating from impulse production and conduction compare to the active part
of the day. The speed of the impulse conduction from atria to ventricles (PQ interval) depends
from action potential amplitude, reflecting the active role of Na+ channels (Carmeliet, 1986;
Amitzur et al., 2000). It can mean that ketamine/xylazine anaesthesia with associated systemic
asphyxia as well as with subsequent surgical interventions do not affect the kinetics of the Na
+ channels, which are likely to be different in the light and dark part of the rat regime day. It
seems that PQ interval is the relative stable electrophysiological parameter of the heart and it
is directly influenced by the LD cycle (figure 3). Mechanisms of such different effect of
ketamine/xylazine anaesthesia are still unknown and were not analyzed in detail.
Apneic episodes, obstructive or central, often in a connection with the sleep apnea syndrome,
are linked with disorders of the cardiac rhythm (Cutler et. al., 2002; Yamashita et al., 2004;
Bounhoure et al., 2005; Dunai et al., 2006; Bayram and Diker, 2008; Grešová et al., 2009). In our
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model, short-term asphyxia increases vulnerability to the arrhythmias originating from
disorders of the impulse production and conduction more in the light (inactive) than in the
dark (active) part but does not disturb LD dependence. Long-term apneic episode, connected
with more serious asphyxia, henceforth prolonges PQ interval and increases vulnerability to
the arrhythmias but probably independently on the LD cycle. Reoxygenation recovered PQ
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Loss of the LD differences in the dispersion of the refractory period durations (QT interval)
can be a result of the effect of the initial asphyxia, which has distracting influence on the LD
differences in QT interval. A similar situation was described by Gunes et al. (2008) in clinical
study, where the loss of diurnal variation of the dispersion of the refractory periods was also
present in patients having either an ischemic or non-ischemic origin of heart failure treated
with optimal drug therapy. Although dispersion of the refractory period duration (QT interval)
is the result of the action of more ion currents (Ca2+, Na+, Cl- and inward rectifying K+ current)
(Amitzur et al., 2000), depends mainly from intracellular K+ concentration (Froldi et al., 1994).
This suggests that ketamine/xylazine anaesthesia together with initial asphyxia probably
influence mainly K+ ion current by the same manner in the both lighted parts of the day and
disturb the light-dark dependence.
The opposite situation is true of the QT interval. Short-term apneic episode increased vulner‐
ability to the arrhythmias originating from dispersion of the refractory period independently
on the LD cycle, but long-term apneic episode facilitated the LD differences with the higher
dispersion during the dark (active) than light (nonactive) part of the rat daily regime. The next
LD difference was seen at the end of asphyxic period. Slightly decreased the QT interval
duration was only during the light (nonactive) part, but not during the dark (active) one.
These changes may be caused by changes in ion channel sensitivities regarding duration and
gravity of asphyxia. Hypoxia exacerbated the atrioventricular conduction by reduction of the
slow inward Na+ current and by rectifying K+ current and depressed automaticity by the
increase of the outward K+ current and in the certain range by reduction of the slow inward
Na+ current in the isolated rabbit AV node (Nishimuraet al., 1989). Sinus interval, AH and HV
interval are gradually prolonged with the duration of the hypoxia. These effects are attributed
to the K+ ATP channel (Sawanobori 1995), which is probably activated by the endogenous
adenosine released from the hypoxic myocardium (Xu et al., 1994; Leone Jr. and Merrill,
1995). Our results suggest that above mentioned changes can be modified also by the LD cycle.
Interesting is fact that the average values of QT interval were slightly and nonsignicantly
longer in the dark part of the day after reoxygenation compared to the light one, while the
opposite tendency was observed in the intact animals and after stabilization. These slight
differences probably do not have any biological significance because they may be a result of
the relatively large variation in dispersion of the refractory periods, what corresponds with
second limitation (Lubbe et al., 1975). Similarly, there are contrary conclusions about the effect
of reoxygenation on the changes of the electrophysiological myocardial properties. Our results
affirm the opinion of some authors about the antiarrhythmogenic effect of reoxygenation
(Perchenet and Kreher, 1995; Bugge et al., 1997). There are papers however, which describe
the serious injury of the heart by the reoxygenation (Griffiths et al., 2000; Mukai et al., 2000).
What is known about the effects of hypoxia on circadian patterns is still quite limited, especially
with respect to the causative mechanistic sequence of the hypoxic effects. It appears that the
most common effect of prolonged hypoxia is to decrease, and in come cases to abolish, the
amplitudes of the daily oscillations, irrespective of the state of arousal or activity level. On the
other hand, the evidence is that hypoxia causes only minimal and transient perturbation of the
period of the rhythm. The fact that hypoxia modifies the circadian oscillations of variables as
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model, short-term asphyxia increases vulnerability to the arrhythmias originating from
disorders of the impulse production and conduction more in the light (inactive) than in the
dark (active) part but does not disturb LD dependence. Long-term apneic episode, connected
with more serious asphyxia, henceforth prolonges PQ interval and increases vulnerability to
the arrhythmias but probably independently on the LD cycle. Reoxygenation recovered PQ
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the active part of the day. The speed of the impulse conduction from atria to ventricles (PQ 
interval) depends from action potential amplitude, reflecting the active role of Na+ channels 
(Carmeliet, 1986; Amitzur et al., 2000). It can mean that ketamine/xylazine anaesthesia with 
associated systemic asphyxia as well as with subsequent surgical interventions do not affect 
the kinetics of the Na+ channels, which are likely to be different in the light and dark phase of 
the rat regime day. It seems that PQ interval is the relative stable electrophysiological 
parameter of the heart and it is directly influenced by the LD cycle (figure 3). Mechanisms of 
such different effect of ketamine/xylazine anaesthesia are still unknown and were not 
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Figure 3. Mean ± SD values of the PQ interval duration in intact animals (Int), after 
tracheotomy (Tr), thoracotomy (To), 5 min. stabilization (Stabil), in each 30 sec. of 2 minutes 
apneic episode and after 5., 10., 15. and 20 minute of artefitial reoxygenation.. Empty and 
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Loss of the LD differences in the dispersion of the refractory period durations (QT interval)
can be a result of the effect of the initial asphyxia, which has distracting influence on the LD
differences in QT interval. A similar situation was described by Gunes et al. (2008) in clinical
study, where the loss of diurnal variation of the dispersion of the refractory periods was also
present in patients having either an ischemic or non-ischemic origin of heart failure treated
with optimal drug therapy. Although dispersion of the refractory period duration (QT interval)
is the result of the action of more ion currents (Ca2+, Na+, Cl- and inward rectifying K+ current)
(Amitzur et al., 2000), depends mainly from intracellular K+ concentration (Froldi et al., 1994).
This suggests that ketamine/xylazine anaesthesia together with initial asphyxia probably
influence mainly K+ ion current by the same manner in the both lighted parts of the day and
disturb the light-dark dependence.
The opposite situation is true of the QT interval. Short-term apneic episode increased vulner‐
ability to the arrhythmias originating from dispersion of the refractory period independently
on the LD cycle, but long-term apneic episode facilitated the LD differences with the higher
dispersion during the dark (active) than light (nonactive) part of the rat daily regime. The next
LD difference was seen at the end of asphyxic period. Slightly decreased the QT interval
duration was only during the light (nonactive) part, but not during the dark (active) one.
These changes may be caused by changes in ion channel sensitivities regarding duration and
gravity of asphyxia. Hypoxia exacerbated the atrioventricular conduction by reduction of the
slow inward Na+ current and by rectifying K+ current and depressed automaticity by the
increase of the outward K+ current and in the certain range by reduction of the slow inward
Na+ current in the isolated rabbit AV node (Nishimuraet al., 1989). Sinus interval, AH and HV
interval are gradually prolonged with the duration of the hypoxia. These effects are attributed
to the K+ ATP channel (Sawanobori 1995), which is probably activated by the endogenous
adenosine released from the hypoxic myocardium (Xu et al., 1994; Leone Jr. and Merrill,
1995). Our results suggest that above mentioned changes can be modified also by the LD cycle.
Interesting is fact that the average values of QT interval were slightly and nonsignicantly
longer in the dark part of the day after reoxygenation compared to the light one, while the
opposite tendency was observed in the intact animals and after stabilization. These slight
differences probably do not have any biological significance because they may be a result of
the relatively large variation in dispersion of the refractory periods, what corresponds with
second limitation (Lubbe et al., 1975). Similarly, there are contrary conclusions about the effect
of reoxygenation on the changes of the electrophysiological myocardial properties. Our results
affirm the opinion of some authors about the antiarrhythmogenic effect of reoxygenation
(Perchenet and Kreher, 1995; Bugge et al., 1997). There are papers however, which describe
the serious injury of the heart by the reoxygenation (Griffiths et al., 2000; Mukai et al., 2000).
What is known about the effects of hypoxia on circadian patterns is still quite limited, especially
with respect to the causative mechanistic sequence of the hypoxic effects. It appears that the
most common effect of prolonged hypoxia is to decrease, and in come cases to abolish, the
amplitudes of the daily oscillations, irrespective of the state of arousal or activity level. On the
other hand, the evidence is that hypoxia causes only minimal and transient perturbation of the
period of the rhythm. The fact that hypoxia modifies the circadian oscillations of variables as
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important as body temperature and metabolism leads to the expectation that the daily rhythms
of many other functions are perturbed by hypoxia, according to their link to the primary
variables (Mortola, 2007). This modification can be probably seen also in our experimental
model, where the definite loss of the LD dependence was not demonstrated in followed
parameters of ECG.
4. Chronobiology and autonomic nervous system during apnoic episode
and reoxygenation
Circadian rhythms in autonomic nervous system activity are well known that directly controls
circadian thythm in cardiovascular system and constitute major triggers of cardiac arrhyth‐
mias. Increased sympathetic activity accelerates heart rate, favors spontaneous depolarization,
shortens the ventricular effective refractory period, and decrease the threshold for ventricular
fibrillation. In contrast, increased parasympathetic activity slows heart rate, decreases AV
nodal conduction, and in the presence of baseline sympathetic neural activity, increases both
the ventricular refractory period and the ventricular fibrillation threshold (review of references
in Portaluppi and Hermida, 2007). This direct and clear dependence, described in people and
in larger experimental animals, was not confirmed in rats (Svorc et al., 1994, 1997).
OSA is associated with increased daytime and nocturnal sympathetic activity, what can be the
risk factor of cardiovascular disease. It is associated with a significant worsening in heart-rate
variability, heart rate turbulence and QT dynamicity parameters (Aytemir et al., 2007). Its
mechanism can be explained by the observation that the sympathetic tone increases due to
repetitive apneas accompanied by hypoxias and arousals during sleep. Heart rate variability
representing cardiac autonomic function is mediated by respiratory sinus arrhythmia,
baroreflex-related fluctuation and thermoregulation-related fluctuation. The LF/HF ratio was
higher in the severe OSA syndrome group to that of the moderate group (Park et al., 2008).
Structural changes occur in the airway to obstruct airflow during OSA, and the resulting apnea
activates hypoxic and hypercapnic reflexes, wich in turn lead to profound elevation in
sympathetic nerve activity and cyclical changes in parasympathetic nerve activity. These
autonomic effects are though to contribute to the associated cardiovascular diseases (eg,
hypertension) and frequently observed brady- and tachyarrhythmias (Cutler et al., 2002).
Autonomic abnormalities seen in pacient with OSA include increased resting heart rate,
decreased RR interval variability and increased blood pressure variability (Parish and Somers,
2004). Using heart rate variability analysis, nocturnal sinusal dysfunction contrasted with a
blunted diurnal parasymathetic modulation of the sinus node. Frequent nocturnal nonsus‐
tained supraventricular tachycardias were predominantly found in patients with severe sleep
related breathing disorders; however, an increased risk of ventricular arrhythmias was not
found. (Roche et al., 2003).
Apneic episodes influence the autonomic nervous system activity (Aydin et al., 2004), but little
is know about the effect on circadian variation in this system activities. The circadian rhythm
of the LF, HF and LF/HF ratio differed significantly in the group of patients with mild OSA
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(group 2, apnea index AI > or = 20) compared with group of patients with severe OSA (group
1, apnea index AI < 20) and control group. The mean HF from 04:00h to 12:00h was significantly
lower in group2 than in group1 and the control group, and it correlated significantly with the
lowest nocturnal O2 saturation (r = 0,58). The mean LF/HF ratio during the same period was
significantly higher in group2 than in group1 and the control group, and it correlated signifi‐
cantly with total time of the nocturnal oxygen saturation < 90% (r = 0,64) and the lowest
nocturnal O2 saturation (r = 0,56). These findings suggest that sleep-disordered breathing
associated with severe oxygen desaturation might influence heart rate variability not only
sleep but also during daytime. OSA per se might contribute to altered circadian rhythm in
autonomic activity leading to the development of cardiovascular diseases (Noda et al., 1998)
also in the absence of hypertension, heart failure, or other disease states, and that it is linked
to the severity of OSA (Aydin et al., 2004). These conclusions were supported by Tükek et al.
(2003) in study, where examined the possible effect of diurnal variability of heart rate on the
development of arrhythmias in patients with chronic obstructive pulmonary disease. They
concluded that patients with chronic obstructive pulmonary disease with arrhythmia had
circadian disturbances in heart rate variability such as unchanged night-time parasympathetic
tone and disturbed sympathovagal balance in favour of the sympathetic system all day long,
which may explain the increased frequency of arrhythmia.
The next step in the analysis of the effect of apnoic episode and reoxygenation on the electrical
stability of the heart was assessment of the changes in the activity of the autonomic nervous
system in LD dependence. The HRV was applied to assess these changes. HRV was not
evaluated during apnoic episode because the changes in the duration of the RR intervals
drastically have been extended, resulting in a high dispersion of the values.
The first 5 minutes of recovery pulmonary ventilation has been associated with significant
turbulence in the heart rhythm, especially in the light part of the day (time range of R-R interval
ranged from 0.025 to ms 0,717 ms). In a dark part of the day, so a significant dispersion was
not observed. Although the LD differences were not maintained during the 20-minute
reoxygenation, in the light part has been observed nonsignificant the tendency of the short‐
ening compare to the dark part, where the duration of the RR interval was prolonged. These
results coincide with heart rate changes. Reoxygenation recovered RR interval duration to the
values from intact animals only in the dark (active) part (figure 5).
Significant LD differences in power HF were seen in the intact animals with the higher value
in the light part compared to the dark one. Effect of reoxygenation on the power HF has been
dependent on the LD cycle. Power HF gradually increased and reached a level of intact animals
with the time of the reoxygenation but only in the dark part of the rat regime day. In the light
part of the day, the changes in the power HF were nesignificant and fluctuated randomly,
without any tendency of decrease or increase. Significant LD differences were maintained
throughout the period of reoxygenation, up to the 20th minute, where the elimination of this
difference has been observed. In each interval evaluation of power HF, the value was higher
in the dark compare to light part of the day (figure 6). Reoxygenation did not recover power
HF, but preserved the dominant position of the parasympathetic division in the both lighted
periods.
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important as body temperature and metabolism leads to the expectation that the daily rhythms
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model, where the definite loss of the LD dependence was not demonstrated in followed
parameters of ECG.
4. Chronobiology and autonomic nervous system during apnoic episode
and reoxygenation
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mias. Increased sympathetic activity accelerates heart rate, favors spontaneous depolarization,
shortens the ventricular effective refractory period, and decrease the threshold for ventricular
fibrillation. In contrast, increased parasympathetic activity slows heart rate, decreases AV
nodal conduction, and in the presence of baseline sympathetic neural activity, increases both
the ventricular refractory period and the ventricular fibrillation threshold (review of references
in Portaluppi and Hermida, 2007). This direct and clear dependence, described in people and
in larger experimental animals, was not confirmed in rats (Svorc et al., 1994, 1997).
OSA is associated with increased daytime and nocturnal sympathetic activity, what can be the
risk factor of cardiovascular disease. It is associated with a significant worsening in heart-rate
variability, heart rate turbulence and QT dynamicity parameters (Aytemir et al., 2007). Its
mechanism can be explained by the observation that the sympathetic tone increases due to
repetitive apneas accompanied by hypoxias and arousals during sleep. Heart rate variability
representing cardiac autonomic function is mediated by respiratory sinus arrhythmia,
baroreflex-related fluctuation and thermoregulation-related fluctuation. The LF/HF ratio was
higher in the severe OSA syndrome group to that of the moderate group (Park et al., 2008).
Structural changes occur in the airway to obstruct airflow during OSA, and the resulting apnea
activates hypoxic and hypercapnic reflexes, wich in turn lead to profound elevation in
sympathetic nerve activity and cyclical changes in parasympathetic nerve activity. These
autonomic effects are though to contribute to the associated cardiovascular diseases (eg,
hypertension) and frequently observed brady- and tachyarrhythmias (Cutler et al., 2002).
Autonomic abnormalities seen in pacient with OSA include increased resting heart rate,
decreased RR interval variability and increased blood pressure variability (Parish and Somers,
2004). Using heart rate variability analysis, nocturnal sinusal dysfunction contrasted with a
blunted diurnal parasymathetic modulation of the sinus node. Frequent nocturnal nonsus‐
tained supraventricular tachycardias were predominantly found in patients with severe sleep
related breathing disorders; however, an increased risk of ventricular arrhythmias was not
found. (Roche et al., 2003).
Apneic episodes influence the autonomic nervous system activity (Aydin et al., 2004), but little
is know about the effect on circadian variation in this system activities. The circadian rhythm
of the LF, HF and LF/HF ratio differed significantly in the group of patients with mild OSA
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evaluated during apnoic episode because the changes in the duration of the RR intervals
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dependent on the LD cycle. Power HF gradually increased and reached a level of intact animals
with the time of the reoxygenation but only in the dark part of the rat regime day. In the light
part of the day, the changes in the power HF were nesignificant and fluctuated randomly,
without any tendency of decrease or increase. Significant LD differences were maintained
throughout the period of reoxygenation, up to the 20th minute, where the elimination of this
difference has been observed. In each interval evaluation of power HF, the value was higher
in the dark compare to light part of the day (figure 6). Reoxygenation did not recover power
HF, but preserved the dominant position of the parasympathetic division in the both lighted
periods.
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 The first 5 minutes of recovery pulmonary ventilation has been associated with significant turbulence 
in the heart rhythm, especially in the light period of the day (time range of R-R interval ranged from 
0.025 to ms 0,717 ms). In a dark period of the day, so a significant dispersion was not observed. 
Although the LD differences were not maintained during the 20-minute reoxygenation, in the light 
part has been observed nonsignificant the tendency of the shortening compare to the dark period, 
where the duration of the RR interval was prolonged. These results coincide with heart rate changes. 
Reoxygenation recovered RR interval duration to the values from intact animals only in the dark 
(active) period (figure 5). 
 Figure 5. Mean ± SD values of the RR interval duration in intact animals (Intact), after 
tracheotomy, thoracotomy and 5 min. stabilization (Stabil) and after 20 minute of artefitial 
reoxygenation. Empty and black columns refer to light and dark parts of the day, respectively. 
The level of significance of differences between the light and dark part of the rat regime day 
is indicated by the symbol (*** p < 0,001). 
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Figure 6. Mean ± SD values of the power HF in intact animals (Intact), after tracheotomy, 
thoracotomy and 5 min. stabilization (Stabil) and after 20 minute of artefitial reoxygenation. 
Empty and black columns refer to light and dark parts of the day, respectively. The level of 
significance of differences between the light and dark part of the rat regime day is indicated 
by the symbol (** p < 0,01, *** p < 0,001). 
Figure 7. Mean ± SD values of the power LF in intact animals (Intact), after tracheotomy, 
thoracotomy and 5 min. stabilization (Stabil) and after 20 minute of artefitial reoxygenation. 
Empty and black columns refer to light and dark parts of the day, respectively. The level of 
significance of differences between the light and dark part of the rat regime day is indicated 
by the symbol (* p < 0,05, *** p < 0,001). 
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Figure 7. Mean ± SD values of the power LF in intact animals (Intact), after tracheotomy, thoracotomy and 5 min. sta‐
bilization (Stabil) and after 20 minute of artificial reoxygenation. Empty and black columns refer to light and dark
parts of the day, respectively. The level of significance of differences betwee  th  light and dark part of the rat regime
day is indicated by the symbol (* p < 0,05, *** p < 0,001).
LF and VLF components of the HRV did not show any regular and predictable changes in the
duration of the experiment. Although significant LD differences was found in intact animals
with longer duration in the light part, changes in these component practically did not depend
























     LF and VLF components of the HRV did not show any regular and predictable changes in the 
duration of the experiment. Although significant LD differences was found in intact animals with 
longer duration in the lig t period, changes in these compo ent practically did not depend on the LD 
cycle during the recovery of pulmonary ventilation (figure 7 and 8). 
Figure 8. Mean ± SD values of the power VLF in intact animals (Intact), after tracheotomy, 
thoracotomy and 5 min. stabilization (Stabil) and after 20 minute of artefitial reoxygenation. 
Empty and black columns refer to light and dark parts of the day, respectively. The level of 
significance of differences between the light and dark part of the rat regime day is indicated 
by the symbol (*** p < 0,001). 
 Ketamine/xylazine anaesthesia significantly increases the parasympathetic activity and 
decreases sympathetic and baroreceptor activity independently of the cycle of light and dark 
alternation. Under ketamine/xylazine anaesthesia, the RR interval duration preserves the 
significant LD differences resulting of the parasympathetic and baroreceptor activities as well 
in a dark (active) as well as in the light (inactive) mode on the rat day. Share of RR intervals 
is negligible to the sympathetic activity. 
 Reoxygenation the following immediately after the apnoic episode does not alter the relative 
abundance of the individual divissions of the ANS, but it is preserved the dominant 
parasympathetic activity (figure 9 and 10). During the light period of the day, the activity of 
the parasympathetic fluctuates randomly, but in a dark period of the day, we can see an 
increasing trend with time the duration of the reoxygenation. This tendency is comparable to 
the changes in the heart's electrical stability, which increases with the duration of the 
reoxygenation. Baroreceptor activity in the light period of the day fluctuates randomly, but in 
a dark part of the growing trend, which is probably associated with the predominant activity 
Figure 8. Mean ± SD values of the power VLF in intact animals (Intact), after tracheotomy, thoracotomy and 5 min.
stabilization (Stabil) and after 20 minute of artificial reoxygenation. Empty and black columns refer to light and dark
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day is indicated by the symbol (*** p < 0,001).
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Chronobiological Aspects of Impact of Apnoic Episode and Reoxygenation on the Electrical...
http://dx.doi.org/10.5772/57168
59
 The first 5 minutes of recovery pulmonary ventilation has been associated with significant turbulence 
in the heart rhythm, especially in the light period of the day (time range of R-R interval ranged from 
0.025 to ms 0,717 ms). In a dark period of the day, so a significant dispersion was not observed. 
Although the LD differences were not maintained during the 20-minute reoxygenation, in the light 
part has been observed nonsignificant the tendency of the shortening compare to the dark period, 
where the duration of the RR interval was prolonged. These results coincide with heart rate changes. 
Reoxygenation recovered RR interval duration to the values from intact animals only in the dark 
(active) period (figure 5). 
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tracheotomy, thoracotomy and 5 min. stabilization (Stabil) and after 20 minute of artefitial 
reoxygenation. Empty and black columns refer to light and dark parts of the day, respectively. 
The level of significance of differences between the light and dark part of the rat regime day 
is indicated by the symbol (*** p < 0,001). 
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Figure 6. Mean ± SD values of the power HF in intact animals (Intact), after tracheotomy, 
thoracotomy and 5 min. stabilization (Stabil) and after 20 minute of artefitial reoxygenation. 
Empty and black columns refer to light and dark parts of the day, respectively. The level of 
significance of differences between the light and dark part of the rat regime day is indicated 
by the symbol (** p < 0,01, *** p < 0,001). 
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is negligible to the sympathetic activity. 
 Reoxygenation the following immediately after the apnoic episode does not alter the relative 
abundance of the individual divissions of the ANS, but it is preserved the dominant 
parasympathetic activity (figure 9 and 10). During the light period of the day, the activity of 
the parasympathetic fluctuates randomly, but in a dark period of the day, we can see an 
increasing trend with time the duration of the reoxygenation. This tendency is comparable to 
the changes in the heart's electrical stability, which increases with the duration of the 
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significant LD differences resulting of the parasympathetic and baroreceptor activities as well
in a dark (active) as well as in the light (inactive) mode on the rat day. Share of RR intervals is
negligible to the sympathetic activity.
Reoxygenation the following immediately after the apnoic episode does not alter the relative
abundance of the individual divissions of the ANS, but it is preserved the dominant para‐
sympathetic activity (figure 9 and 10). During the light part of the day, the activity of the
parasympathetic fluctuates randomly, but in a dark part of the day, we can see an increasing
trend with time the duration of the reoxygenation. This tendency is comparable to the changes
in the heart's electrical stability, which increases with the duration of the reoxygenation.
Baroreceptor activity in the light part of the day fluctuates randomly, but in a dark part of the
growing trend, which is probably associated with the predominant activity of the parasym‐
pathetic. Sympathetic activity during the reoxygenation shows no predictable changes in either




































































of the parasympathetic. Sympathetic activity during the reoxygenation shows no predictable 
changes in either of the light periods of the day.   
Figure 9. Relative power of the single components of HRV during the light period of the rat 
regime day. Black shadow – power HF, middle shadow – power LF and light shadow – power 
VLF.
Figure 9. Relative power of the single components of HRV during the dark period of the rat 
regime day. Black shadow – power HF, middle shadow – power LF and light shadow – power 
VLF.
Figure 9. Relative power of the single components of HRV during the light part of the rat regime day. Black shadow –
power HF, middle shadow – power LF and light shadow – power VLF.
In intact animals, correlation coefficients revealed that durations of RR intervals is influenced
by parasympathetic and baroreceptor activities in both lighted parts of the day. Reoxygenation
eliminated this dependence (table 1). We concluded that proarrythmogenic or antiarrhyth‐
mogenic effect of reoxygenation is probably connected with the changes in the parasympa‐
thetic activity and is dependent on the rat active or passive period in a ketamine/xylazine
anaesthesia.
In ketamine/xylazine-anaesthetized rats, significant LD differences were preserved, in contrast
to pentobarbital-anaesthetized rats (Svorc Jr. et al., 2013). Although the disruptive effect of
ketamine n circadian rhythms has been described by others (Prudian et al., 1997; Pelissier et
al., 1998), this effect was associated with modification of acrophase, amplitude or mesor, but
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without loss of daily rhythmicity. Ketamine/xylazine anaesthesia reduces heart rate in isolated
rat heart preparations (Aronson and Hanno, 1978) and also in in vivo conditions (Salerno and
vanTienhoven, 1976; Sapru and Krieger, 1979; Brown et al., 1994; Hoque et al., 1996; Maignan
et al., 2000). It prolongs RR and QT intervals (Aronson and Hanno, 1978), decreases blood
pressure (Sapru and Krieger, 1979), renal sympathetic activity and attenuates baroreflex
sensitivity in vivo (Akine et al., 2001). On the other hand, Reid et al. (2003), described a
stimulating effect on cardiac function during resuscitation. Unfortunately, in the above-
mentioned studies, the clock time of the experiment was not reported, nor was the synchro‐




































































of the parasympathetic. Sympathetic activity during the reoxygenation shows no predictable 
changes in either of the light periods of the day.   
Figure 9. Relative power of the single compo ents of HRV during the light period of the rat 
regime day. Black shadow – power HF, middle shadow – power LF and light shadow – power 
VLF.
Figure 9. Relative power of the single components of HRV during the dark period of the rat 
regime day. Black shadow – power HF, middle shadow – power LF and light shadow – power 
VLF.
Figure 10. Relative power of the single components of HRV during the dark part of the rat regime day. Black shadow
– power HF, middle shadow – power LF and light shadow – power VLF.
Intact Stabil 20 reoxy
light dark light dark light dark
HF-RR r = 0,48 r = 0,44 r = 0,43 r = 0,37 r = 0,05 r = 0,5
LF-RR r = 0,46 r = 0,45 r = 0,57 r = 0,56 r = - 0,1 r = 0,1
VLF-RR r = 0,19 r = 0,14 r = 0,53 r = 0,19 r = - 0,27 r = - 0,02
Table 1. Correlation coefficients between RR intervals duration and single parameters of HRV in the single
experimental steps.
Results demostrate that ketamine/xylazine anaesthesia preferably increases parasympathetic
activity and suppresses sympathetic and baroreceptor activity, resulting in marked bradycar‐
dia independently of the LD cycle. Presence of LD differences refers to the fact that this type
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significant LD differences resulting of the parasympathetic and baroreceptor activities as well
in a dark (active) as well as in the light (inactive) mode on the rat day. Share of RR intervals is
negligible to the sympathetic activity.
Reoxygenation the following immediately after the apnoic episode does not alter the relative
abundance of the individual divissions of the ANS, but it is preserved the dominant para‐
sympathetic activity (figure 9 and 10). During the light part of the day, the activity of the
parasympathetic fluctuates randomly, but in a dark part of the day, we can see an increasing
trend with time the duration of the reoxygenation. This tendency is comparable to the changes
in the heart's electrical stability, which increases with the duration of the reoxygenation.
Baroreceptor activity in the light part of the day fluctuates randomly, but in a dark part of the
growing trend, which is probably associated with the predominant activity of the parasym‐
pathetic. Sympathetic activity during the reoxygenation shows no predictable changes in either
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without loss of daily rhythmicity. Ketamine/xylazine anaesthesia reduces heart rate in isolated
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pressure (Sapru and Krieger, 1979), renal sympathetic activity and attenuates baroreflex
sensitivity in vivo (Akine et al., 2001). On the other hand, Reid et al. (2003), described a
stimulating effect on cardiac function during resuscitation. Unfortunately, in the above-
mentioned studies, the clock time of the experiment was not reported, nor was the synchro‐
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Table 1. Correlation coefficients between RR intervals duration and single parameters of HRV in the single
experimental steps.
Results demostrate that ketamine/xylazine anaesthesia preferably increases parasympathetic
activity and suppresses sympathetic and baroreceptor activity, resulting in marked bradycar‐
dia independently of the LD cycle. Presence of LD differences refers to the fact that this type
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of anaesthesia may be applicable in chronobiological studies. However, it may be problematic
for cardiovascular research owing to serious bradycardia.
5. Conclusions
We concluded that the electrical myocardial properties are influenced by the changing cycles
of light and darkness also in ketamine/xylazine anaesthesia.
• heart rate and electrical stability of the heart are significantly reduced by apneic episode
regardless of the lighted period (proarrhythmogenic effect). Electrocardiographic parame‐
ters (PQ and QT interval) prolong with the duration of apneic episode regardless of the LD
cycle. Possible cause of ventricular arrhythmias (ventricular arrhythmias originating from
disorders of the impulse production and conduction or ventricular arrhythmias originating
from an enlarged dispersion of refractory periods) probably depends not only on the
duration of apneic episode, but also on the LD cycle. Short-term asphyxia increases
vulnerability to the arrhythmias originating from disorders of the impulse production and
conduction but does not disturb LD dependence. Long-term apneic episode, connected with
more serious asphyxia continue increases vulnerability to this type of arrhythmias but
independently on the LD cycle. The opposite situation is true of the QT interval.
• recovery of the pulmonary ventilation after apneic episodes can also contribute to heart
rhythm disorders, but this is dependent upon the light (non-active)-dark (active) cycle. In
the dark part of the day, the gradual decrease of the myocardial vulnerability is associated
with the duration of reoxygenation (anti-arrhythmogenic effect) compared with the light
part of the day, where the contrary tendency was observed (pro-arrhythmogenic effect).
Reoxygenation disturbs LD differences in the heart rate as well as in QT interval duration,
but recovers PQ interval duration to the pre-asphyxic values with preservation of the LD
differences observed in intact animals.
• ketamine/xylazine anaesthesia increases parasympathetic activity, inhibits baroreceptor
and sympathetic activity in the same way in both lighted periods. Dominant influence of
parasympathetic autonomic nervous system was preserved during experiment. In these
conditions, the heart is controled by the parasympathetic divission without the influence of
the sympathetic autonomic nervous system.
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of anaesthesia may be applicable in chronobiological studies. However, it may be problematic
for cardiovascular research owing to serious bradycardia.
5. Conclusions
We concluded that the electrical myocardial properties are influenced by the changing cycles
of light and darkness also in ketamine/xylazine anaesthesia.
• heart rate and electrical stability of the heart are significantly reduced by apneic episode
regardless of the lighted period (proarrhythmogenic effect). Electrocardiographic parame‐
ters (PQ and QT interval) prolong with the duration of apneic episode regardless of the LD
cycle. Possible cause of ventricular arrhythmias (ventricular arrhythmias originating from
disorders of the impulse production and conduction or ventricular arrhythmias originating
from an enlarged dispersion of refractory periods) probably depends not only on the
duration of apneic episode, but also on the LD cycle. Short-term asphyxia increases
vulnerability to the arrhythmias originating from disorders of the impulse production and
conduction but does not disturb LD dependence. Long-term apneic episode, connected with
more serious asphyxia continue increases vulnerability to this type of arrhythmias but
independently on the LD cycle. The opposite situation is true of the QT interval.
• recovery of the pulmonary ventilation after apneic episodes can also contribute to heart
rhythm disorders, but this is dependent upon the light (non-active)-dark (active) cycle. In
the dark part of the day, the gradual decrease of the myocardial vulnerability is associated
with the duration of reoxygenation (anti-arrhythmogenic effect) compared with the light
part of the day, where the contrary tendency was observed (pro-arrhythmogenic effect).
Reoxygenation disturbs LD differences in the heart rate as well as in QT interval duration,
but recovers PQ interval duration to the pre-asphyxic values with preservation of the LD
differences observed in intact animals.
• ketamine/xylazine anaesthesia increases parasympathetic activity, inhibits baroreceptor
and sympathetic activity in the same way in both lighted periods. Dominant influence of
parasympathetic autonomic nervous system was preserved during experiment. In these
conditions, the heart is controled by the parasympathetic divission without the influence of
the sympathetic autonomic nervous system.
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1. Introduction
The adjective ‘cardiac’ signifies ‘related to the heart’ and it originates from the Greek word
‘kardia’ meaning ‘heart’. The human heart is a muscular pump roughly the size of a fist. It pumps
blood continuously through the circulatory system. The average human heart will beat at 72
beats per minute, and beat 2.5 billion times during a 66 year lifespan. Further, the heart pumps
an average 5.2 liters of blood per minute. It weighs approximately 250 to 300 grams in females
and 300 to 350 grams in males [1].
The heart’s electrical system includes three parts (see Figure 1):
1. S-A node (sinoatrial node)− known as the heart's natural pacemaker, the S-A node has
special cells that create the electricity that makes your heart beat.
2. A-V node (atrioventricular node)− the bridge between the atria and ventricles. Electrical
signals pass from the atria down to the ventricles through the A-V node.
3. His-Purkinje system− carries the electrical signals throughout the ventricles via conduction
pathways to make them contract.
Severe disorders of the heart rhythm can lead to sudden cardiac death (SCD), which is a sudden
and unexpected death. Not to be confused with heart attacks which occur because of coronary
artery blockage, sudden cardiac death happens when the electrical system of the heart becomes
very irregular leading the heart to beat dangerously fast. At the outset of such a scenario, the
greatest concern becomes blood flow to the brain being reduced, and unless treated rapidly
patient death ensues.
In 2012, a review of the epidemiology of SCD was disseminated [3]. For brevity, we provide
only a short summary of its highlights. In the United States alone, the incidence rate ranges
© 2014 Fallavollita; licensee InTech. This is a paper distributed under the terms of the Creative Commons
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distribution, and reproduction in any medium, provided the original work is properly cited.
[78] Svorc, P. Jr.; Svorc, P. & Fulton, B.L. (2011). Chronobiological aspects of reoxygena‐
tion impact on the heart rhythm disorders in Wistar rat model. Trends in Comp Bio‐
chem Physiol, Vol. 15, pp. 55-61, ISSN: 0972-4540.
[79] Svorc, P.; Marossy, A.; Svorc, P. Jr; Gresova, S.; Buzga, M. & Fulton, B.J. (2012). Chro‐
nobiological aspects of the heart rhythm disorders at the change of pulmonary venti‐
lation in rat model. In: Cardiac arrhythmias. New Considerations, Breijo-Marquez, F.R,
pp. 193-226, InTech, ISBN: 978-953-51-0126-0, Rijeka, Croatia
[80] Svorc, P. Jr.; Bacova, I.; Svorc, P. & Buzga, M. (2013). Autonomic nervous system un‐
der ketamine/xylazine and pentobarbital anaesthesia in a Wistar rat model: Chrono‐
biological view. Prague Medical Report, Vol. 114, No. 2, (Apr. 2013), pp. 72-80, ISSN
1214-6994.
[81] Tukek, T.; Yildiz, P.; Atilgan, D.; Tuzcu, V.; Eren, M.; Erk, O.; Demirel, S.; Akkaya, V.;
Dilmener, M. & Korkut, F. (2003). Effect of diurnal variability of heart rate on devel‐
opment of arrhythmia in patients with chronic obstructive pulmonary disease. Inter‐
national Journal of Cardiology, Vol. 88, No. 2-3, (Apr 2003), pp. 199-206, ISSN:
0167-5273.
[82] Waterhouse, J.; Witte, K.; Huser, L.; Nevill, A.; Atkinson, G.; Reilly, T. & Lemmer, B.
(2000). Sensitivity of heart rate and blood pressure to spontaneous activity in trans‐
genic rats. Biological Rhythm Research, Vol. 31, No. 2, (Apr 2000), pp. 146-159, ISSN:
0929-1016.
[83] Wolleben, C.D.; Sanguinetti, M.C. & Siegl, P.K.S. (1989). Influence of ATP-sensitive
potassium channel modulators on ischemia-induced fibrillation in isolated rat hearts.
Journal of Molecular and Cellular Cardiology, Vol. 21, No. 8, (Aug 1989), 783-788, ISSN:
0022-2828.
[84] Xu, J.; Wang, L.; Hurt, C.M. & Pelleg, A. (1994). Endogenous adenosine does not acti‐
vate ATPsensitive pottasium channels in the hypoxic guinea pig ventricle in vivo.
Circulation, Vol. 89, No. 3, (Mar 1994), pp. 1209-1216, ISSN: 1524-4539.
[85] Yamashita, J.; Nomura, M.; Uehara, K.; Nakaya, Y.; Uemura, E.; Iga, A.; Sawa, Y.;
Nishikado, A.; Saito, K. & Ito, S. (2004). Influence of sleep apnea on autonomic nerv‐
ous activity and QT dispersion in patients with essential hypertension and old myo‐
cardial infarction. Journal of Electrocardiology, Vol. 37, No. 1, (Jan 2004), pp. 31-40, doi:
10.1016/j.jelectrocard.2003.10.009
Cardiac Arrhythmias - Mechanisms, Pathophysiology, and Treatment70
Chapter 3
Detection, Tracking and Related Costs of Ablation
Catheters in the Treatment of Cardiac Arrhythmias
Pascal  Fallavollita
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/57424
1. Introduction
The adjective ‘cardiac’ signifies ‘related to the heart’ and it originates from the Greek word
‘kardia’ meaning ‘heart’. The human heart is a muscular pump roughly the size of a fist. It pumps
blood continuously through the circulatory system. The average human heart will beat at 72
beats per minute, and beat 2.5 billion times during a 66 year lifespan. Further, the heart pumps
an average 5.2 liters of blood per minute. It weighs approximately 250 to 300 grams in females
and 300 to 350 grams in males [1].
The heart’s electrical system includes three parts (see Figure 1):
1. S-A node (sinoatrial node)− known as the heart's natural pacemaker, the S-A node has
special cells that create the electricity that makes your heart beat.
2. A-V node (atrioventricular node)− the bridge between the atria and ventricles. Electrical
signals pass from the atria down to the ventricles through the A-V node.
3. His-Purkinje system− carries the electrical signals throughout the ventricles via conduction
pathways to make them contract.
Severe disorders of the heart rhythm can lead to sudden cardiac death (SCD), which is a sudden
and unexpected death. Not to be confused with heart attacks which occur because of coronary
artery blockage, sudden cardiac death happens when the electrical system of the heart becomes
very irregular leading the heart to beat dangerously fast. At the outset of such a scenario, the
greatest concern becomes blood flow to the brain being reduced, and unless treated rapidly
patient death ensues.
In 2012, a review of the epidemiology of SCD was disseminated [3]. For brevity, we provide
only a short summary of its highlights. In the United States alone, the incidence rate ranges
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between 180,000 and 450,000 cases annually [3, 4]. These estimates vary owing to differences
in SCD definitions and surveillance methods [3, 5]. Prospective studies using multiple centers
within the United States [3, 6-7], Netherlands [3, 8], Ireland [3, 9] and China [3, 10] showed
SCD rates ranging from 50 to 100 per 100,000 general populations. From these, it is clear that
the overall burden in the population remains high. Improvements in primary and secondary
prevention have resulted in substantial declines in overall coronary heart disease (CHD)
mortality over the past 30 years [3, 11-12], whereas SCD rates specifically have declined to a
lesser extent [3, 13-16]. SCD still accounts for 50% of all CHD deaths and up to 20% of all deaths
[3, 17]. For some segments of the population, rates are not decreasing and may actually be
increasing [3, 14, 18]. As such, SCD prevention represents a major opportunity to further reduce
mortality from CHD [3].
Figure 1. The electrical activity of the heart − image taken from [2].
i. Radiofrequency catheter ablation
Cardiac arrhythmias have been linked to SCD and the handling of these has been facilitated
by the ability to definitively treat many patients with radiofrequency (RF) catheter ablation.
Two very common arrhythmias treated are atrial fibrillation (AF) and ventricular tachycardia
(VT). The first originates by impulses beginning and spreading through the atria, competing
for a chance to travel through the AV node. The heart rhythm becomes disorganized, rapid,
and irregular resulting in loss of coordinated atrial contraction. On the other hand, VT is a
rapid rhythm originating from the lower chambers of the heart. It prevents the heart from
filling adequately with blood, thereby less blood is able to pump through the body. VT is
considered a more serious arrhythmia.
Authors in [19] provide an excellent review on the history and evolution of RF ablation.
Catheter ablation with direct current from a standard external defibrillator began to supersede
surgery in the 1980’s. A shock was delivered between the distal catheter electrode and a
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cutaneous surface electrode [19]. However, this high-voltage discharge was difficult to control
and could cause tissue damage. As clinicians became more skilled and electrophysiological
mapping improved, direct current (DC) ablation was used to treat cases of Wolff-Parkinson-
White, ventricular tachycardia and atrial tachycardia [19, 20-25]. By the 1990’s, radiofrequency
energy had supplanted direct current [19, 26] since there was high incidence of complications
associated with the high-energy discharge. In addition to this, RF ablation could be performed
on conscious patients [19, 27-29].
Today, catheter ablation procedures are performed in an electrophysiology laboratory. RF
electrode catheters are most commonly inserted percutaneously into the femoral veins and
orientated within the heart to allow pacing stimulation and intracardiac electrical signal
recording at key sites: such as the right atrium, right ventricle, the area of the His bundle or
the coronary sinus [19, 30]. The efficacy of catheter ablation is highly dependent on accurate
identification of the site of origin of the arrhythmia. Once this site has been identified, an
ablation catheter (typically 7-11 French in size, see Figure 2) is positioned in direct contact with
it and radiofrequency energy is delivered to ablate it. After one minute, a lesion of 5-mm depth
is formed, which is enough to destroy the full thickness of the atrial myocardium in that
location [19, 30].
Figure 2. Left) Radiofrequency cardiac ablation catheters of different sizes - image taken from [36]. (Right) The cathe‐
ter tip delivers the bursts of high-energy waves that destroy the abnormal areas - image taken from [37].
Current ablation systems allow for temperature monitoring and control [31]. These are
valuable tools during RF ablation procedures as they: (i) provide important information
regarding the adequacy of tissue heating, (ii) minimize the development of coagulum, and (iii)
maximize the lesion size. Newer technical modifications, such as a larger distal electrode and
saline cooling of this electrode, have helped to minimize impedance rises and allow creation
of larger and deeper lesions [19, 32–35].
ii. Radiation exposure
Catheter ablation is often a long procedure requiring fluoroscopy exposure. RF ablation
usually can routinely be accomplished with <20 min of fluoroscopy for most arrhythmias [19].
In 2012, a task force led by prominent cardiologists defined guidelines and recommendations
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(VT). The first originates by impulses beginning and spreading through the atria, competing
for a chance to travel through the AV node. The heart rhythm becomes disorganized, rapid,
and irregular resulting in loss of coordinated atrial contraction. On the other hand, VT is a
rapid rhythm originating from the lower chambers of the heart. It prevents the heart from
filling adequately with blood, thereby less blood is able to pump through the body. VT is
considered a more serious arrhythmia.
Authors in [19] provide an excellent review on the history and evolution of RF ablation.
Catheter ablation with direct current from a standard external defibrillator began to supersede
surgery in the 1980’s. A shock was delivered between the distal catheter electrode and a
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cutaneous surface electrode [19]. However, this high-voltage discharge was difficult to control
and could cause tissue damage. As clinicians became more skilled and electrophysiological
mapping improved, direct current (DC) ablation was used to treat cases of Wolff-Parkinson-
White, ventricular tachycardia and atrial tachycardia [19, 20-25]. By the 1990’s, radiofrequency
energy had supplanted direct current [19, 26] since there was high incidence of complications
associated with the high-energy discharge. In addition to this, RF ablation could be performed
on conscious patients [19, 27-29].
Today, catheter ablation procedures are performed in an electrophysiology laboratory. RF
electrode catheters are most commonly inserted percutaneously into the femoral veins and
orientated within the heart to allow pacing stimulation and intracardiac electrical signal
recording at key sites: such as the right atrium, right ventricle, the area of the His bundle or
the coronary sinus [19, 30]. The efficacy of catheter ablation is highly dependent on accurate
identification of the site of origin of the arrhythmia. Once this site has been identified, an
ablation catheter (typically 7-11 French in size, see Figure 2) is positioned in direct contact with
it and radiofrequency energy is delivered to ablate it. After one minute, a lesion of 5-mm depth
is formed, which is enough to destroy the full thickness of the atrial myocardium in that
location [19, 30].
Figure 2. Left) Radiofrequency cardiac ablation catheters of different sizes - image taken from [36]. (Right) The cathe‐
ter tip delivers the bursts of high-energy waves that destroy the abnormal areas - image taken from [37].
Current ablation systems allow for temperature monitoring and control [31]. These are
valuable tools during RF ablation procedures as they: (i) provide important information
regarding the adequacy of tissue heating, (ii) minimize the development of coagulum, and (iii)
maximize the lesion size. Newer technical modifications, such as a larger distal electrode and
saline cooling of this electrode, have helped to minimize impedance rises and allow creation
of larger and deeper lesions [19, 32–35].
ii. Radiation exposure
Catheter ablation is often a long procedure requiring fluoroscopy exposure. RF ablation
usually can routinely be accomplished with <20 min of fluoroscopy for most arrhythmias [19].
In 2012, a task force led by prominent cardiologists defined guidelines and recommendations
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for ablation procedural techniques, patient management and follow-up [38]. One concern
raised was that an important complication of ablation is the delayed effect of the radiation
received by the patients which yield [39] malignancy, and genetic abnormalities [40]. Many of
the described studies in [38] demonstrated that catheter ablation of atrial fibrillation required
significantly greater fluoroscopy duration and radiation exposure than simpler catheter
ablation procedures. Thus, increasing availability and familiarity of electrophysiologists with
3D mapping systems [41] may significantly reduce fluoroscopy time. The task force recom‐
mendation is that this can only be achieved by an awareness of the importance of reducing
fluoroscopy time, and therefore radiation exposure, by the operator. Although it is hypothe‐
sized that use of remote 3D navigation systems will reduce radiation exposure to patients and
operators, this remained unproven until recently [38].
iii. 3D Mapping systems
An overview of cardiac mapping technologies is presented in [42]. The use of non-fluoroscopic
techniques, using either magnetic or electrical fields for mapping of catheter position, has
reduced fluoroscopy time and radiation dose to both patient and staff.
The common mapping technologies that combine 3D anatomy and electrophysiological data
are: CARTO and CARTOMerge (Biosense Webster), NavX (St.Jude Medical), and RPM (Cardiac
Pathways-Boston Scientific). Other technologies that provide continuous data of all electro‐
physiogical events include Ensite 3000 (St. Jude Medical) and Basket (Cardiac Pathways-EP
Technologies) [43-44]. More sophisticated mapping technologies that involve the fusion of
imaging modalities (i.e. using preoperative MRI/CT, to fluoroscopy) are also discussed [45].
Two sample visualizations of the above technologies are seen in Figure 3.
Figure 3. BioSense Webster has recently released (left) a multi-electrode mapping version of its 3D cardiac mapping
system, and (right) a platform to merge ultrasound data of the heart [37].
An alternative technology is the intracardiac echocardiography (ICE) which has become the
imaging modality of choice in many interventional settings primarily due to its flexibility and
ease of use. The most commonly used ICE transducer is the ACUNAV (Siemens Medical
Solution) which provides real-time visualization of structural anatomy. Another advantage of
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such a transducer is that it delivers precise information about catheter position and adjacent
structures. The first report of the various uses of ICE in atrial fibrillation is outlined in [42].
These include but are not limited to: (i) facilitating transseptal puncture, (ii) assisting catheter
positioning prior to ablation, and (iii) identifying pulmonary vein structure. Also reported is
the efficacy of ICE during the treatment of ventricular tachycardia [46]. Here, ICE is used to
monitor catheter position and stability, and additionally is used to visualize the aortic cusp
region. Lastly, registration between ICE and a 3D reconstruction of the left atria, performed
using rotational fluoroscopy, is reported and shown to be an alternative technique to support
atrial fibrillation ablation [47].
Robotic cardiac catheter ablation has been recently developed to eliminate potential errors in
catheter manipulation. Also, the use of robots could systematically decrease clinician fatigue
and fluoroscopy exposure. Some electrophysiologists agree that areas between mitral valves
and pulmonary veins are typically difficult to reach and position correctly the mapping
catheter. Robotics can thus provide more accuracy in these cases. Yet, initial studies show
complications can occur at about the same rate as manual ablation. Currently there are two
robotic systems – the Stereotaxis Magnetic Navigation System (Stereotaxis, Inc.) and the Hansen
Sensei Robotic Catheter System (Hansen Medical). Both systems allow the physician to perform
the mapping and ablation procedure while sitting in a control room remote from the patient
[48]. Ongoing robotic developments use a magnetic tracking device to track the distal part of
the ablation catheter in real time, and a master-slave robot-assisted system for actuation of a
steerable catheter [49].
iv. Hospital induced costs
In 2013, an exhaustive study was released that evaluated the cost of special equipment chosen
by physicians to perform cardiac ablations [50]. More specifically, the costs associated with the
treatment of atrial fibrillation procedures were investigated. A synopsis of the relevant costs
follows.
Cost of mapping technology: the 5-year cost for the mapping systems and maintenance is
$375,000 (Biosense Webster Carto 3) and $495,000 (St. Jude EnSite Velocity). Phased array
ICE catheters use standard ultrasound machines. The rotational ultrasound catheter (Ultra
ICE, Boston Scientific, Natick, MA, USA) requires a special machine (iLab®) with a 5-year
cost of $131,400. Lastly, the 5-year cost ranged from $33,000–$67,000 for the traditional RF
generators [50].
Cost of catheters:  Catheters compatible with the St.  Jude Ensite Velocity system ranged
from $1,500–$1,900, and the special navigation catheters required by Carto 3 cost $2,800–
$3,000. The lowest cost ICE catheter is the Boston Scientific Ultra ICE™ rotational catheter
costing $1,050.  The most  expensive are the phased-array catheters costing $2,640–$2,800.
Although the rotational ICE catheter costs $1,590 less than the phased array, it requires a
separate ultrasound processor (iLab®); therefore, it takes 82.6 cases to begin saving on each
rotational ICE catheter [50].
Cost of Robotic Systems: The manufacturer’s list price for the Stereotaxis NIROBE Robotic
magnetic navigation system (MNS) is $2,875,000 with an annual maintenance contract of
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An alternative technology is the intracardiac echocardiography (ICE) which has become the
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region. Lastly, registration between ICE and a 3D reconstruction of the left atria, performed
using rotational fluoroscopy, is reported and shown to be an alternative technique to support
atrial fibrillation ablation [47].
Robotic cardiac catheter ablation has been recently developed to eliminate potential errors in
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complications can occur at about the same rate as manual ablation. Currently there are two
robotic systems – the Stereotaxis Magnetic Navigation System (Stereotaxis, Inc.) and the Hansen
Sensei Robotic Catheter System (Hansen Medical). Both systems allow the physician to perform
the mapping and ablation procedure while sitting in a control room remote from the patient
[48]. Ongoing robotic developments use a magnetic tracking device to track the distal part of
the ablation catheter in real time, and a master-slave robot-assisted system for actuation of a
steerable catheter [49].
iv. Hospital induced costs
In 2013, an exhaustive study was released that evaluated the cost of special equipment chosen
by physicians to perform cardiac ablations [50]. More specifically, the costs associated with the
treatment of atrial fibrillation procedures were investigated. A synopsis of the relevant costs
follows.
Cost of mapping technology: the 5-year cost for the mapping systems and maintenance is
$375,000 (Biosense Webster Carto 3) and $495,000 (St. Jude EnSite Velocity). Phased array
ICE catheters use standard ultrasound machines. The rotational ultrasound catheter (Ultra
ICE, Boston Scientific, Natick, MA, USA) requires a special machine (iLab®) with a 5-year
cost of $131,400. Lastly, the 5-year cost ranged from $33,000–$67,000 for the traditional RF
generators [50].
Cost of catheters:  Catheters compatible with the St.  Jude Ensite Velocity system ranged
from $1,500–$1,900, and the special navigation catheters required by Carto 3 cost $2,800–
$3,000. The lowest cost ICE catheter is the Boston Scientific Ultra ICE™ rotational catheter
costing $1,050.  The most  expensive are the phased-array catheters costing $2,640–$2,800.
Although the rotational ICE catheter costs $1,590 less than the phased array, it requires a
separate ultrasound processor (iLab®); therefore, it takes 82.6 cases to begin saving on each
rotational ICE catheter [50].
Cost of Robotic Systems: The manufacturer’s list price for the Stereotaxis NIROBE Robotic
magnetic navigation system (MNS) is $2,875,000 with an annual maintenance contract of
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$104,000 per year for a total 6-year cost of $3,395,000. Assuming 200 patient cases per year, the
robotic MNS costs $2,829 per case. It requires a disposable $1,200/case ablation catheter
advancement system and $250/case circular mapping catheter drive. The system requires
special catheters which cost $3,590 including cables and irrigation tubing and can only utilize
the Carto 3 mapping system. The lowest- and highest-cost scenarios for a MNS ablation are
$12,261 and $15,464. These costs for MNS ablation are 84.7 and 133 % higher than the lowest-
cost RF equipment [50].
Cost of The Medtronic Arctic Front® cryoballoon cost is $6,500.The costs of a cryoballoon
ablation with focal cryoablation touch-up for the lowest- or highest-cost scenarios is similar to
that for the balloon-only ablation, but requires the addition of a Freezor® MAX focal cryoa‐
blation catheter for $3,095. The lowest cost estimate requires repeated removal of the cryobal‐
loon and insertion of the focal ablation catheter through the same sheath. The highest-cost
estimate assumes the addition of a variable-diameter circular mapping catheter used inde‐
pendently of the cryoballoon through a steerable sheath. The total lowest and highest costs of
$15,942 and $22,284 were 140 % and 236 % higher than the lowest-cost RF ablation [50].
The conclusions of the study [50] are that hospitals and clinicians have many choices of ablation
equipment. These equipment costs ranged from $6,637 to $22,284 per case. In the end, the
development of more expensive technologies should demonstrate an increase in the efficiency
of cardiac ablation procedures as well as positive patient outcomes.
2. Detection and tracking of cardiac ablation catheters
There are several reasons as to why detecting and tracking the position of ablation catheters
relative to the patient anatomy is important. They are related to interventional guidance
aspects: (i) accounting for heart motion compensation, (ii) easing positioning & navigation
during cardiac ablation, (iii) planning the ablation procedure by (iv) registration to preopera‐
tive data such as CT and MRI. To achieve detection and tracking, there are two primary options
available: (a) hardware solutions that include mechanical and optical systems or the previously
mentioned mapping systems, and (b) software and image-based solutions that make use of
intraoperative images such as X-ray fluoroscopy.
We observe notable differences when comparing mapping systems with image-based solu‐
tions. First, although mapping solutions are expensive, they provide high accuracy and
robustness and their clinical usage is getting popular. However, there is a notable learning
curve for clinicians to get used to this technology. As for image-guided solutions, these require
dealing with high data variation and involve the acquisition of a large amount of X-ray images.
Their usage is still very limited since there is a high performance requirement for a practical
clinical solution.
Whether using mapping systems or conventional RF ablation techniques, clinicians still rely
on X-ray images to position and guide catheters. Thus, exploiting X-ray image information is
crucial for providing additional information to clinicians during cardiac ablation procedures.
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Hence, there has been a trend lately of researchers investigating image-based solutions since
these would also provide inexpensive and simple assistance to clinicians and could alleviate
some of the burdens involved with the commercially available expensive technologies. We
have identified three recent works that focus on the detection and tracking aspects of catheters
visible in X-ray images [51-53].
These works address some of the inherent properties associated with the acquisition of X-ray
images: (i) low quality and characterized by low signal to noise ratios, (ii) the non-rigid
catheters visible in them have foreshortening artifacts due to X-ray projection principles, (iii)
catheters may be occluded or overlapped by other catheters or background artifacts, and (iv)
specifically during real-time fluoroscopic guidance, one can also observe motion blur artifacts.
i. Detection of catheters
The goal of any algorithm is to find all potential catheter electrode candidates in the X-ray
images. The key is to perform these detections without the requirement of user interactivity
or algorithm re-initialization. Once candidate electrodes are estimated these need to be
subsequently filtered to remove false positives (outliers).
In current research practice, the ‘blob detector’ formulation is used to detect electrodes. We
recall that electrodes appearances are not always the same in X-ray images due to foreshort‐
ening and projective effects. They can appear larger or smaller and their shape can change
from rectangular → elliptical → circular over consecutive frames. It should be noted that for
an individual X-ray image, the appearance of the electrodes belonging to the same catheter are
very similar: if one of them appears as a circle it is very likely that the others share the same
appearance. The candidate electrodes are obtained from a blobness measure influenced by
non-maximum suppression. This blobness measure is implicitly greater than one since we are
using a scale-space approach to detect electrodes at different scales. In other words, a catheter
tip electrode will appear larger than the other electrodes.
Authors in [51, 53] investigated different methods that yield different performances both w.r.t.
the detection rate and execution time. These approaches are based respectively on the usage
of a “laplacian of gaussian” (LoG) and a “difference of gaussian” (DoG). The (LoG) blob
detector [54] is a non-separable linear filter capable of finding blob-like structures while having
low responses to edge-like structures. For each X-ray image it is necessary to run three linear
filters and to evaluate the blobness measure:
Blobness LoG(x, y, t0)=  t0(L xx L yy - L xy2 ) (1)
where Lxx, Lyy, Lxy are respectively the convolution of the X-ray image I(x,y) with Gxx, Gyy, Gxy
being the second derivatives of the gaussian filter and t0 = σ2 is used for normalization purposes
equal to the variance of the gaussian filter.
The (DoG) blob detector [55] is an approximation of the “laplacian of gaussian” filter and is
based only on the usage of gaussian filters that are linearly separable. A scale-space represen‐
tation of the image is obtained by filtering the image with a gaussian kernel using increasing
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that for the balloon-only ablation, but requires the addition of a Freezor® MAX focal cryoa‐
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loon and insertion of the focal ablation catheter through the same sheath. The highest-cost
estimate assumes the addition of a variable-diameter circular mapping catheter used inde‐
pendently of the cryoballoon through a steerable sheath. The total lowest and highest costs of
$15,942 and $22,284 were 140 % and 236 % higher than the lowest-cost RF ablation [50].
The conclusions of the study [50] are that hospitals and clinicians have many choices of ablation
equipment. These equipment costs ranged from $6,637 to $22,284 per case. In the end, the
development of more expensive technologies should demonstrate an increase in the efficiency
of cardiac ablation procedures as well as positive patient outcomes.
2. Detection and tracking of cardiac ablation catheters
There are several reasons as to why detecting and tracking the position of ablation catheters
relative to the patient anatomy is important. They are related to interventional guidance
aspects: (i) accounting for heart motion compensation, (ii) easing positioning & navigation
during cardiac ablation, (iii) planning the ablation procedure by (iv) registration to preopera‐
tive data such as CT and MRI. To achieve detection and tracking, there are two primary options
available: (a) hardware solutions that include mechanical and optical systems or the previously
mentioned mapping systems, and (b) software and image-based solutions that make use of
intraoperative images such as X-ray fluoroscopy.
We observe notable differences when comparing mapping systems with image-based solu‐
tions. First, although mapping solutions are expensive, they provide high accuracy and
robustness and their clinical usage is getting popular. However, there is a notable learning
curve for clinicians to get used to this technology. As for image-guided solutions, these require
dealing with high data variation and involve the acquisition of a large amount of X-ray images.
Their usage is still very limited since there is a high performance requirement for a practical
clinical solution.
Whether using mapping systems or conventional RF ablation techniques, clinicians still rely
on X-ray images to position and guide catheters. Thus, exploiting X-ray image information is
crucial for providing additional information to clinicians during cardiac ablation procedures.
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Hence, there has been a trend lately of researchers investigating image-based solutions since
these would also provide inexpensive and simple assistance to clinicians and could alleviate
some of the burdens involved with the commercially available expensive technologies. We
have identified three recent works that focus on the detection and tracking aspects of catheters
visible in X-ray images [51-53].
These works address some of the inherent properties associated with the acquisition of X-ray
images: (i) low quality and characterized by low signal to noise ratios, (ii) the non-rigid
catheters visible in them have foreshortening artifacts due to X-ray projection principles, (iii)
catheters may be occluded or overlapped by other catheters or background artifacts, and (iv)
specifically during real-time fluoroscopic guidance, one can also observe motion blur artifacts.
i. Detection of catheters
The goal of any algorithm is to find all potential catheter electrode candidates in the X-ray
images. The key is to perform these detections without the requirement of user interactivity
or algorithm re-initialization. Once candidate electrodes are estimated these need to be
subsequently filtered to remove false positives (outliers).
In current research practice, the ‘blob detector’ formulation is used to detect electrodes. We
recall that electrodes appearances are not always the same in X-ray images due to foreshort‐
ening and projective effects. They can appear larger or smaller and their shape can change
from rectangular → elliptical → circular over consecutive frames. It should be noted that for
an individual X-ray image, the appearance of the electrodes belonging to the same catheter are
very similar: if one of them appears as a circle it is very likely that the others share the same
appearance. The candidate electrodes are obtained from a blobness measure influenced by
non-maximum suppression. This blobness measure is implicitly greater than one since we are
using a scale-space approach to detect electrodes at different scales. In other words, a catheter
tip electrode will appear larger than the other electrodes.
Authors in [51, 53] investigated different methods that yield different performances both w.r.t.
the detection rate and execution time. These approaches are based respectively on the usage
of a “laplacian of gaussian” (LoG) and a “difference of gaussian” (DoG). The (LoG) blob
detector [54] is a non-separable linear filter capable of finding blob-like structures while having
low responses to edge-like structures. For each X-ray image it is necessary to run three linear
filters and to evaluate the blobness measure:
Blobness LoG(x, y, t0)=  t0(L xx L yy - L xy2 ) (1)
where Lxx, Lyy, Lxy are respectively the convolution of the X-ray image I(x,y) with Gxx, Gyy, Gxy
being the second derivatives of the gaussian filter and t0 = σ2 is used for normalization purposes
equal to the variance of the gaussian filter.
The (DoG) blob detector [55] is an approximation of the “laplacian of gaussian” filter and is
based only on the usage of gaussian filters that are linearly separable. A scale-space represen‐
tation of the image is obtained by filtering the image with a gaussian kernel using increasing
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variances. The difference between two neighboring scale-space images is taken and this latter
result is used as a blobness measure. The mathematical formulation for the 2D gaussian filter
is:





and the blobness measure becomes:
Blobness DoG(x, y, t0)=  I (x, y)*G(x, y, kt0) - I (x, y)*G(x, y, t0) (3)
This detector has a significant response in correspondence to edge-like features in the image
and thus yields more outliers (i.e. higher false positives) when compared to the LoG detector.
False positive candidate electrodes exist. To eliminate these, a Top-Hat filter is implemented
which discards candidates that do not fulfill spatial and geometric constraint characteristics
of an electrode. Since we are looking for “quasi circular” candidates mimicking electrodes, a
structuring element with a circular diameter of 15 pixels is used. This immediately removes
the majority of outliers. Second, since an electrode is metallic (and thus radiopaque), it appears
as a very dark cluster in the X-ray image. Thus, candidate electrodes appearing as a bright
cluster are rejected. From this, the blobness measure can be used to distinguish between
catheter tips and other electrodes (tip-electrodes have a stronger measure as they are larger in
size). For the sake of brevity, we direct readers to [51, 53] for additional details on the various
outlier removal methods. Figure 4 and Figure 5 show intermediate and final results of image-
based catheter detection solutions. The accuracy of the techniques is well above 95% when
compared to ground-truth data.
Figure 4. Examples of blob detections in X-ray images of dog (left) and patient (right). Images taken respectively from
[51] and [53].
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Figure 5. Example images of complete catheter detections in dog (left) and patient (right), after outlier removal. The
different color coding implies detections of different catheter types. Images taken respectively from [51] and [53].
ii. Tracking of catheters
Initial solutions for tracking catheters in X-ray are presented in [52, 53]. In clinical practice, X-
ray fluoroscopy images are acquired at about 15 frames per second depending on the system
settings. Thus, developing image-based solutions that track at the rate of several images per
second would be considered as an acceptable efficiency. The accuracy requirements depend
on the specific application, and millimeter accuracy is roughly comparable with the currently
available mapping navigation systems, while others [56, 57] have found 2-mm accuracy to be
sufficient. Since the clinician needs to position the ablation catheter on heart tissue as it
performs the burning, the most vital information to be tracked accurately is the catheter tip
electrode. A very low false positive rate is also important to reduce any risk of inaccurate or
insufficient treatment [52]. As seen in Figure 4-5, it is common practice that more than one
catheter is used simultaneously; therefore, the ability to track multiple catheters is also an
important requirement satisfied by image-based tracking solutions. For example, tracking the
coronary sinus (CS) catheter can be used for transseptal puncture guidance [52, 58] and
respiratory motion correction [52, 59]. There are several studies on the feasibility and signifi‐
cance of such a method for fluoroscopic-based guidance and mapping. Philips Healthcare has
a product called the EP navigator that requires a user operator to indicate the position of the
ablation catheter on the X-ray image (‘point tagging’). It was evaluated during a catheter
ablation [60], while the authors in [61] found it feasible to use their automatic catheter tracking
method in a clinical environment.
In [52], authors introduce an efficient and robust method for multiple catheter detection and
tracking. The proposed technique exploits the clinical setup knowledge to provide search
constraints and boost both speed and accuracy. The method involves user input only in the
beginning of the case, and runs fully automatically for the rest of the intervention. The method
is based on a computationally efficient geodesic framework to trace the sheath and to find one
or multiple catheter tips. The method was validated on 1107 fluoroscopic images taken from
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settings. Thus, developing image-based solutions that track at the rate of several images per
second would be considered as an acceptable efficiency. The accuracy requirements depend
on the specific application, and millimeter accuracy is roughly comparable with the currently
available mapping navigation systems, while others [56, 57] have found 2-mm accuracy to be
sufficient. Since the clinician needs to position the ablation catheter on heart tissue as it
performs the burning, the most vital information to be tracked accurately is the catheter tip
electrode. A very low false positive rate is also important to reduce any risk of inaccurate or
insufficient treatment [52]. As seen in Figure 4-5, it is common practice that more than one
catheter is used simultaneously; therefore, the ability to track multiple catheters is also an
important requirement satisfied by image-based tracking solutions. For example, tracking the
coronary sinus (CS) catheter can be used for transseptal puncture guidance [52, 58] and
respiratory motion correction [52, 59]. There are several studies on the feasibility and signifi‐
cance of such a method for fluoroscopic-based guidance and mapping. Philips Healthcare has
a product called the EP navigator that requires a user operator to indicate the position of the
ablation catheter on the X-ray image (‘point tagging’). It was evaluated during a catheter
ablation [60], while the authors in [61] found it feasible to use their automatic catheter tracking
method in a clinical environment.
In [52], authors introduce an efficient and robust method for multiple catheter detection and
tracking. The proposed technique exploits the clinical setup knowledge to provide search
constraints and boost both speed and accuracy. The method involves user input only in the
beginning of the case, and runs fully automatically for the rest of the intervention. The method
is based on a computationally efficient geodesic framework to trace the sheath and to find one
or multiple catheter tips. The method was validated on 1107 fluoroscopic images taken from
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four patients from different clinics, demonstrating robust multiple catheters tracking at 10
images/s. The complete details of the algorithm are found in [52]. Figure 6 shows intermediate
and final results of catheter detection.
Figure 6. The original X-ray image with preprocessing (top-row) followed by geodesics properties computation. Final
tip electrodes boxed in yellow (bottom-row).
Lastly, as an alternative tracking solution, authors in [53] develop a template-based approach.
Tracking methods are initialized using the basic detection algorithm of LoG or DoG. This
detection is used to create a customized 2D catheter model comprising a connected graph
which gives information about the initial shape and orientation of the catheter. In subsequent
X-ray image frames, the tracking methods use the same blob detection method and a modified
catheter detection method that uses the customized model of the catheter being used during
intervention [53]. Incorporating the customized model may allow successful tracking in cases
where some catheter electrodes are overlapped with other dense objects or are outside the field
of view. The current implementation requires manual detection of failed tracking, at which
point the operator can restart with the basic detection algorithm [53].
iii. Future trends
There is room to investigate the above methods under various clinical conditions and different
C-arm fluoroscopy devices. The variety in image quality in clinical cases is due to the variability
in patient size, the variability in the image content with the presence of additional or implanted
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devices that were not used in our animal experiment. These must be accounted for when
improving results [62]. Ultimately, achieving automatic detections and tracking can simplify
3D reconstruction of electrodes using single or multi-view approaches [63-64].
3. Conclusions
In summary, this chapter presented the latest findings involving the detection and tracking of
cardiac ablation catheters. Several commercial 3D mapping systems provide non-fluoroscopic
catheters with magnetic tips. These are detected and tracked in real-time using custom
hardware and are used in everyday practice in luminary hospitals. Conventional RF ablation
is still a requirement in many hospitals worldwide that cannot afford the expensive 3D
mapping technologies. The advantages of image-based tracking technologies are many
including being inexpensive and practical. With the advent of real-time computing capabili‐
ties, speed is a non-issue. However, researchers must continue to focus their efforts on
developing mature algorithms for robust tracking – with the right catheter models. The keys
for robustness against large data variation from fluoroscopic sequences involve considering
machine learning approaches and obtaining large data sets for training and quantitative
evaluation.
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1. Introduction
Electrocardiographic  changes  were  mentioned  in  several  noncardiac  diseases,  due  to
multiple mechanisms: changes of the position of the heart, autonomic imbalance, hormo‐
nal  abnormalities,  interposition  of  fluid  or  tissue  between  the  heart  and the  electrodes,
increased blood pressure, cardiomyopathy of systemic diseases, electrolyte imbalances, or
due to therapy [1, 2].
A  prolonged  ECG  QT  interval  and  an  increased  QT  dispersion  (QTd,  the  difference  be‐
tween the longest  and shortest  QT interval  duration in  all  12  standard ECG leads),  are
markers of ventricular arrythmia risk. Sudden cardiac death, a major public health problem,
is caused, mainly, by ventricular fibrillation [3].
Besides a prolonged QT interval, longer than 450 ms in male and 460 ms in female [4], late
ventricular  potentials  (LVPs),  which  are  low  amplitude  and  high  frequency  waveforms,
appearing in the terminal part of the QRS complex, and are markers of an electrophysiolog‐
ical  substrate  for  reentry  ventricular  arrythmias  in  a  diseased  myocardium,  were  also
detected in several extracardiac diseases using signal averaged ECG [5].
Standard 12-lead ECG provides a bedside snapshot of the electrial activity of the heart, but
Holter electrocardiogarphy enables detection of episodes of arrhythmia and evaluate therapeu‐
tic interventions [6].
2. Objective
The aim of the present chapter was to provide a concise overview of available data regarding
epidemiology  and  pathophysiology  of  ventricular  arrhythmias  in  several  noncardiac
© 2014 Mozos; licensee InTech. This is a paper distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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diseases, to mention the main methods used to assess arrhythmia risk, as well as to elucidate
their  relation  to  long-term  outcome.  Dyslipidemia,  obesity,  diabetes  mellitus,  liver,
hematologic, neurologic and psychiatric disorders, are discussed.
3. Dyslipidaemia and ventricular arrhythmia risk
Elevated LDL cholesterol was associated with all manifestations of coronary artery disease
including sudden cardiac death [7]. Hypercholesterolemia is not only atherogenic, but is also
associated  with  autonomic  imbalance,  alteration  of  the  contractile  properties  of  the
myocardium, increased oxidative stress and ventricular electrophysiological remodeling [8,
9]. Myocardial electrical remodeling due to hypercholesterolemia caused prolonged action
potential  durations,  longer  QTc (heart  rate  corrected QT interval  durations),  conduction
slowing and increased repolarization dispersion [9, 10].
Several  clinical  and  autopsy  studies  demonstrated  an  association  between  elevated
cholesterol levels and sudden cardiac death [11, 12].  Gualdiero et al.  reported a positive
correlation  between  cholesterol  level,  QT dispersion  and premature  ventricular  contrac‐
tions in patients with isolated hypercholesterolemia, and normalization of serum cholester‐
ol  and QT dispersion and improvement of  ventricular  ectopic  activity,  with simvastatin
[13]. Szabo et al. found significant correlations of QT interval duration and QT dispersion
with total and LDL cholesterol, triglycerides and apoplipoprotein B, respectively, in patients
with type IIb hyperlipoproteinemia, without myocardial ischemia, suggesting a direct effect of
hyperlipidemia on ventricular repolarization [14]. LDL increases the cholesterol to phospho‐
lipid ratio in the cell membrane, enhancing membrane rigidity and impairing functionali‐
ty of the ion channels and ventricular repolarization [14, 15]. Ventricular repolarization is
reflected by the QT interval on the ECG, which is regulated mainly by potassium chan‐
nels.  On  the  other  hand,  type  II  hyperlipoproteinemia  is  characterized  by  accelerated
atherosclerosis, related to small dense LDL synthesis.
It  was  also  hypothesized  that  hypercholesterolemia  causes  repolarization  abnormalities,
probably, by beta or IK channel phosphorylation mediated mechanisms [9]. Hypercholester‐
olemia  causes  also  endothelial  dysfunction,  with  impaired  microvascular  vasodilatation,
facilitating vasoconstriction, and electrical heterogeneity and extrasystolic activity [13]. The
increase in the QT interval duration in cholesterol fed rabbits was lesser if L-Arginine was
supplemented,  suggesting  a  beneficial  role  of  L-Arginine  (a  nitric  acid  precusror)  in
hypercholesterolemia  induced  repolarization  characteristics  [9].  L-Arginine  increases
endogenous nitric oxide, which may activate ATP dependent K channels, shortening the
action potential [9].
Late ventricular potentials  were detected in patients with high and moderately elevated
serum cholesterol [5, 16].
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Statins  have  antiarrhythmic  properties,  exhibiting  a  protective  effect  against  the  occur‐
rence of ventricular arrhythmias and atrial fibrillation, in addition to their lipid-lowering
and anti-atherogenic  effects  [5,  12,  13,  17,  18].  The main mechanisms explaining,  proba‐
bly,  the  antiarrhythmic  properties  of  statins  are  as  follows:  prevention  of  ischemia-in‐
duced electrophysiological effects that predispose to ventricular arrhythmias and ischemia-
induced oxidative  stress,  decrease in  ischemia-induced myocyte  hypertrophy,  reverse  of
neural  remodeling  induced  by  hypercholesterolemia,  increase  of  heart  rate  variability,
decrease of QT interval duration and variability, reversion of electrophysiological remodel‐
ing  induced  by  hypercholesterolemia,  increase  in  parasympathetic  tone,  changes  in
transmembrane  ion  channel  properties,  decrease  of  the  incidence  of  late  ventricular
potentials [10, 12].
4. Ventricular arrhythmias in obesity and eating disorders
Morbid obesity  was associated with high rates of sudden cardiac death [19, 20]. Lalani et
al. reported a high prevalence of abnormal signal averaged ECGs in obese without known
cardiovascular  disease  [20].  An  increased  QT  dispersion  was  found  in  obese  women,
associated with left ventricular hypertrophy [21] and prolonged QT intervals were measured
in obese patients [22-24]. Several mechanisms explain the high sudden cardiac death risk
in obese,  including: parasympathetic withdrawal,  conduction abnormalities,  cardiomyop‐
athy of obesity with cardiomegaly and myocyte hypertrohy, lipotoxicity of the myocardi‐
um induced by free fatty acids, released from hypertrophied adipocytes in obese persons
with myocardial steatosis, structural heterogeneity due to fatty infiltration of the heart, focal
myocardial  disarray,  fibrosis and mononuclear cell  infiltration [5,  19,  20,  25,  26].  Prema‐
ture ventricular contractions (PVCs) are very prevalent in obese [27] and sudden cardiac
death risk is increased in obese compared to normal weighted survivors of a myocardial
infarction [28].
Weight loss causes a shortening of the QT interval, correlated with diastolic blood pressure
decrease, and changes in time and frequency domain parameters of heart rate variability,
with  recovery  of  the  physiological  autonomic  control  (increase  in  parasympathetic  and
reduction in sympathetic indices [29].
QT prolongation, signal averaged ECG abnormalities and late ventricular potentials were
reported  in  eating  disorders,  including  both  anorexia  and  bulimia  nervosa  [30].  Bulimia
nervosa, an eating disorder characterized by binge eating and purging, was associated with
QT interval  prolongation,  related to  electrolyte  imbalances,  especially  hypokalemia  [31].
Anorexia  nervosa  carries  the  highest  mortality  of  any  psychiatric  disorder,  very  often
attributable  to  sudden  cardiac  death.  Delayed  cardiac  repolarization  and  QT  prolonga‐
tion, not correlated with disease severity, were reported [32]. Any patient with an eating
disorder should undergo standard 12-lead ECG.
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diseases, to mention the main methods used to assess arrhythmia risk, as well as to elucidate
their  relation  to  long-term  outcome.  Dyslipidemia,  obesity,  diabetes  mellitus,  liver,
hematologic, neurologic and psychiatric disorders, are discussed.
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correlation  between  cholesterol  level,  QT dispersion  and premature  ventricular  contrac‐
tions in patients with isolated hypercholesterolemia, and normalization of serum cholester‐
ol  and QT dispersion and improvement of  ventricular  ectopic  activity,  with simvastatin
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supplemented,  suggesting  a  beneficial  role  of  L-Arginine  (a  nitric  acid  precusror)  in
hypercholesterolemia  induced  repolarization  characteristics  [9].  L-Arginine  increases
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Statins  have  antiarrhythmic  properties,  exhibiting  a  protective  effect  against  the  occur‐
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with myocardial steatosis, structural heterogeneity due to fatty infiltration of the heart, focal
myocardial  disarray,  fibrosis and mononuclear cell  infiltration [5,  19,  20,  25,  26].  Prema‐
ture ventricular contractions (PVCs) are very prevalent in obese [27] and sudden cardiac
death risk is increased in obese compared to normal weighted survivors of a myocardial
infarction [28].
Weight loss causes a shortening of the QT interval, correlated with diastolic blood pressure
decrease, and changes in time and frequency domain parameters of heart rate variability,
with  recovery  of  the  physiological  autonomic  control  (increase  in  parasympathetic  and
reduction in sympathetic indices [29].
QT prolongation, signal averaged ECG abnormalities and late ventricular potentials were
reported  in  eating  disorders,  including  both  anorexia  and  bulimia  nervosa  [30].  Bulimia
nervosa, an eating disorder characterized by binge eating and purging, was associated with
QT interval  prolongation,  related to  electrolyte  imbalances,  especially  hypokalemia  [31].
Anorexia  nervosa  carries  the  highest  mortality  of  any  psychiatric  disorder,  very  often
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tion, not correlated with disease severity, were reported [32]. Any patient with an eating
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5. Glucose metabolism disorders and ventricular arrhythmia risk
Several studies associate diabetes mellitus and hyperglycemia with sudden cardiac death,
related to QT interval prolongation, appearance of late ventricular potentials, impaired
depolarization and repolarization, enhanced sympathetic activity, oxidative stress, increased
cytosolic calcium content, defective phosphoinositide 3-kinase signaling with increased
persistent sodium current, premature and accelerated atherosclerosis, transient hypoglycemic
episodes due to drug therapy, duration of diabetes, and renal failure, as target-organ damage,
causing electrolyte imbalances [5, 33-36]. QT interval prolongation and increase of QT
dispersion are predictive for sudden cardiac death in patients with type 1 and 2 diabetes
mellitus [37]. QT interval duration was independently associated with glycated hemoglobin in
patients with type 1 diabetes mellitus [38], and hyperinsulinemia and insulinresistance can
contribute to QTc prolongation [39]. Li et al found a high prevalence of prolonged QTc
intervals, and low height, high waist circumference, increased diastolic blood pressure levels,
high postprandial glucose levels, high fasting insulin and presence of microalbuminuria, as
risk factors for QTc prolongation among Chinese patients with type 2 diabetes mellitus [40].
Stress hyperglycemia on admission was found to be a predictor of mortality and arrhythmias in
patients with acute myocardial infarction and could be used in the stratification of risk in these
patients [5, 41, 42]. An independent association between hyperglycemia and prolonged QTc
and increased QT dispersion was found in healthy, nondiabetic subjects [39].
Severe hypoglycemia is also associated with ventricular repolarization abnormalities, prolon‐
gation of the QT interval, and ventricular arrhythmias [35]. QTc interval prolongation was
observed during the episodes of sever hypoglycemia compared to the recovered stage, in
patients with type 2 diabetes mellitus, associated with increase in serum catecholamines,
altered neural regulation and hypokalemia [43, 44]. The likelihood of ventricular arrhythmias
is increased, particularly when hypoglycemia occurs in a patient with autonomic neuropathy
[35]. Sudden nocturnal death in young people with type 1 diabetes could be due to cardiac
arrhythmias induced by hypoglycemia [45]. Hypokalemia, caused by hyperinsulinemia and
intracellular shift of potassium, could explain the altered cardiac repolarization during the
episodes of hypoglycemia [43].
6. Liver diseases and ventricular arrhythmia risk
Several cardiac problems have been reported in patienst with liver cirrhosis, including chro‐
notrope incompetence, cardiomyopathy and prolonged QT intervals, proportional to the
Child-Pugh class [46]. A prolonged QT interval represents the most common electrocardio‐
graphic (ECG) finding in patients with liver cirrhosis and is the electrophysiological hallmark
of “cirrhotic cardiomyopathy” [47, 48, 49 ]. Cirrhotic cardiomyopathy can appear in all forms
of cirrhosis and includes systolic and diastolic dysfunction and electrophysiological abnor‐
malities, in the absence of any known cardiac disease [48]. Cardiac ion channels remodeling
has been noticed in patients with liver cirrhosis, with impaired K and Ca channels, due to
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cytosolic calcium content, defective phosphoinositide 3-kinase signaling with increased
persistent sodium current, premature and accelerated atherosclerosis, transient hypoglycemic
episodes due to drug therapy, duration of diabetes, and renal failure, as target-organ damage,
causing electrolyte imbalances [5, 33-36]. QT interval prolongation and increase of QT
dispersion are predictive for sudden cardiac death in patients with type 1 and 2 diabetes
mellitus [37]. QT interval duration was independently associated with glycated hemoglobin in
patients with type 1 diabetes mellitus [38], and hyperinsulinemia and insulinresistance can
contribute to QTc prolongation [39]. Li et al found a high prevalence of prolonged QTc
intervals, and low height, high waist circumference, increased diastolic blood pressure levels,
high postprandial glucose levels, high fasting insulin and presence of microalbuminuria, as
risk factors for QTc prolongation among Chinese patients with type 2 diabetes mellitus [40].
Stress hyperglycemia on admission was found to be a predictor of mortality and arrhythmias in
patients with acute myocardial infarction and could be used in the stratification of risk in these
patients [5, 41, 42]. An independent association between hyperglycemia and prolonged QTc
and increased QT dispersion was found in healthy, nondiabetic subjects [39].
Severe hypoglycemia is also associated with ventricular repolarization abnormalities, prolon‐
gation of the QT interval, and ventricular arrhythmias [35]. QTc interval prolongation was
observed during the episodes of sever hypoglycemia compared to the recovered stage, in
patients with type 2 diabetes mellitus, associated with increase in serum catecholamines,
altered neural regulation and hypokalemia [43, 44]. The likelihood of ventricular arrhythmias
is increased, particularly when hypoglycemia occurs in a patient with autonomic neuropathy
[35]. Sudden nocturnal death in young people with type 1 diabetes could be due to cardiac
arrhythmias induced by hypoglycemia [45]. Hypokalemia, caused by hyperinsulinemia and
intracellular shift of potassium, could explain the altered cardiac repolarization during the
episodes of hypoglycemia [43].
6. Liver diseases and ventricular arrhythmia risk
Several cardiac problems have been reported in patienst with liver cirrhosis, including chro‐
notrope incompetence, cardiomyopathy and prolonged QT intervals, proportional to the
Child-Pugh class [46]. A prolonged QT interval represents the most common electrocardio‐
graphic (ECG) finding in patients with liver cirrhosis and is the electrophysiological hallmark
of “cirrhotic cardiomyopathy” [47, 48, 49 ]. Cirrhotic cardiomyopathy can appear in all forms
of cirrhosis and includes systolic and diastolic dysfunction and electrophysiological abnor‐
malities, in the absence of any known cardiac disease [48]. Cardiac ion channels remodeling
has been noticed in patients with liver cirrhosis, with impaired K and Ca channels, due to
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endotoxins and increased biliary acids, which alter beta-adrenoreceptor, G protein and ionic
channels in patients with cholestasis [46].
QT prolongation in liver pathology was first described in alcoholic liver diseases [50]. Alcohol
effects on life-threatening arrhythmias correlate directly with the amount and duration of
alcohol intake; even small quantities are significant in susceptible individuals [35]. Further
studies reported prolonged QT intervals in patients with primary biliary cirrhosis and other
chronic non-alcoholic liver diseases, related to the severity of the autonomic neuropathy, and
could detect patients with increased cardiovascular risk [51]. QT interval prolongation was
related to the pathophysiology of cirrhosis itself and not to a specific cause of cirrhosis [52].
Prolonged QTc intervals were related to the presence of portal hypertension, including mild
portal hypertension, and liver dysfunction [53]. Genovesi et al. reported significant correla‐
tions between QTc and each of the following: plasma calcium level, portal hypertension, and
the hepatic venous pressure gradient [47]. Liver disease severity, alcoholic etiology, and serum
uric acid were associated with prolonged QT interval in patients with liver cirrhosis, according
to another study [48]. Liver transplantation may revert cardiac dysfunction [54] and prolonged
QTc returns to normal values, in most of the patients, after liver transplantation, suggesting
that liver disease may not be the only factor in the pathogenesis of prolonged QTc [52, 55].
Acute gastrointestinal bleeding was found to further prolong QTc in patients with liver
cirrhosis, and QTc prolongation predicted bleeding induced mortality [56].
Concluding, the mechanisms by which liver cirrhosis affects ventricular repolarization are as
follows: electrolyte imbalances, impaired autonomic function, subclinical cardiomyopathy,
reduced β-adrenoreceptor function, postreceptor pathway defects, altered physical properties
of myocyte plasma membrane, elevated levels of cardiotoxins, ion channel remodeling,
portosystemic shunting and systemic circulatory disturbances [46-48, 53, 54, 57].
The clinical significance of QT prolongation in liver cirrhosis is unclear, considering that
sudden cardiac death and torsades de pointes are rare [58].
QTc interval was also measured in patients with chronic hepatitis C, showing non-significant
increases six months after starting combination therapy with pegylated interferon and
ribavirin, in order to achieve sustained virological response [59].
7. Cerebrogenic arrhythmias and ventricular arrhythmia risk in neurologic
diseases
Cardiac diseases are a well-known stroke risk factors and complicate stroke outcome [60].
Cardiac arrhythmias and electrocardiographic abnormalities are frequently observed after
acute cerebrovascular events, even in the absence of structural heart disease [61]. With
improved survival after major cardiovascular events and aging of the population, stroke
followed by myocardial infarction and arrhythmias will be an increasing clinical entity in the
coming decades [60]. The neurologic event is the main cause of death only in the first week
after stroke [62]. After the first year, cardiovascular diseases are the main cause of death in
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stroke patients [63]. Atrial fibrillation, the most common arrhythmia in clinical practice, is a
major risk factor for embolic stroke [60, 64]. Stroke and subarachnoid hemorrhage cause other
cerebrogenic ECG findings as well, prolong the QT interval, increase QT dispersion and
ventricular arrhythmia risk, mainly due to an autonomic nervous system dysregulation [1, 61,
65, 66 ]. Large, inverted T waves following a prolonged QTc interval, common after subar‐
achnoid hemorrhage, are often termed as “cerebral” or “neurogenic” [67]. Brady- and tachyar‐
rhythmia, including polymorphic ventricular tachycardia (PVT), have been also described in
the setting of neurologic injury [68]. The greatest risk of arrhythmias is, probably, within the
first 24 h after stroke, with a marked decline in time [69]. Activation of both sympathetic and
parasympathetic systems has cumulative effect in the development of arrhythmias and
myocardial damage after cerebral incidents, and the damage of the hypothalamic, insular, and
brainstem region is crucial for the genesis of cardiac arrhythmias, due to neural connections
with other cortical sites and the autonomic nervous system [61]. Sander et al, found increased
norepinephrine levels in patients with insular infarction, significantly related to adverse
outcome and QTc [70]. The sympathetic system has a major role in the pathogenesis of
hypokalemia and may indirectly result in QTc prolongation after subarachnoid hemorrhage
[61]. Probably constant catecholamine stimulation of beta-adrenoreceptors linked to mem‐
brane Na+/K+-ATPases causes a potassium influx, resulting in hypokalemia, and thus precip‐
itating ventricular arrhythmias [62]. Both reduced heart-rate variability (HRV) and impaired
baroreceptor reflex sensitivity (BRS) suggest impaired physiological central and cardiac
autonomic reflex function [62]. Ventricular arrhythmogenesis following stroke, related to the
cardiac autonomic imbalance is explained by two hypotheses [62]. The first involves damage
to central nervous structures controlling the autonomic nervous system, resulting in sympa‐
thetic amplification or parasympathetic inhibition, with subsequent ECG changes, without
permanent myocardium damage, and the second hypothesis proposes an augmented sympa‐
thetic discharge, resulting in increased secretion of catecholamine, causing myocytolysis [62].
The insula plays an important role in autonomic nervous function imbalance after stroke [62,
71]. Involvement of the right insula decreases basal sympathetic tone and may result in
parasympathetic hyperactivity, and left insular lesions decrease parasympathetic activity and
augment cardiac sympathetic tone [71]. Sympathetic hyperactivity prolongs repolarization
duration and increases arrhythmogenesis [62].
A concomitant myocardial ischemia or necrosis, elevated blood pressure and heart failure
may  be  also  considered  [1].  Autopsy  of  stroke  patients,  who  developed  repolarization
abnormalities, revealed no obvious coronary artery atherosclerosis in most of them, and the
only findings were petechial subendocardial hemorrhages and focal myofibrillar degenera‐
tion, reproducible with intravenous administration of catecholamines or electrical stimula‐
tion of  the vagus nerve in laboratory animals  [61].  Sudden calcium influx,  mediated by
catecholamines, impairs myocardial relaxation, leads to myocytolysis, myofibrillar degener‐
ation, coronary vasoconstriction, myocardial ischemia and ECG changes, and is proarrhyth‐
mic [61, 62]. Elevated serum uric acid, direct neural interventions, inflammation, reactive
oxygen species, electrolyte imbalances, the structural and electrophysiological changes of a
senescent heart and comorbities can increase sudden cardiac death risk in stroke [61, 66].
Stroke survivors with a prolonged QT in V6,  were identified to have an increased sud‐
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endotoxins and increased biliary acids, which alter beta-adrenoreceptor, G protein and ionic
channels in patients with cholestasis [46].
QT prolongation in liver pathology was first described in alcoholic liver diseases [50]. Alcohol
effects on life-threatening arrhythmias correlate directly with the amount and duration of
alcohol intake; even small quantities are significant in susceptible individuals [35]. Further
studies reported prolonged QT intervals in patients with primary biliary cirrhosis and other
chronic non-alcoholic liver diseases, related to the severity of the autonomic neuropathy, and
could detect patients with increased cardiovascular risk [51]. QT interval prolongation was
related to the pathophysiology of cirrhosis itself and not to a specific cause of cirrhosis [52].
Prolonged QTc intervals were related to the presence of portal hypertension, including mild
portal hypertension, and liver dysfunction [53]. Genovesi et al. reported significant correla‐
tions between QTc and each of the following: plasma calcium level, portal hypertension, and
the hepatic venous pressure gradient [47]. Liver disease severity, alcoholic etiology, and serum
uric acid were associated with prolonged QT interval in patients with liver cirrhosis, according
to another study [48]. Liver transplantation may revert cardiac dysfunction [54] and prolonged
QTc returns to normal values, in most of the patients, after liver transplantation, suggesting
that liver disease may not be the only factor in the pathogenesis of prolonged QTc [52, 55].
Acute gastrointestinal bleeding was found to further prolong QTc in patients with liver
cirrhosis, and QTc prolongation predicted bleeding induced mortality [56].
Concluding, the mechanisms by which liver cirrhosis affects ventricular repolarization are as
follows: electrolyte imbalances, impaired autonomic function, subclinical cardiomyopathy,
reduced β-adrenoreceptor function, postreceptor pathway defects, altered physical properties
of myocyte plasma membrane, elevated levels of cardiotoxins, ion channel remodeling,
portosystemic shunting and systemic circulatory disturbances [46-48, 53, 54, 57].
The clinical significance of QT prolongation in liver cirrhosis is unclear, considering that
sudden cardiac death and torsades de pointes are rare [58].
QTc interval was also measured in patients with chronic hepatitis C, showing non-significant
increases six months after starting combination therapy with pegylated interferon and
ribavirin, in order to achieve sustained virological response [59].
7. Cerebrogenic arrhythmias and ventricular arrhythmia risk in neurologic
diseases
Cardiac diseases are a well-known stroke risk factors and complicate stroke outcome [60].
Cardiac arrhythmias and electrocardiographic abnormalities are frequently observed after
acute cerebrovascular events, even in the absence of structural heart disease [61]. With
improved survival after major cardiovascular events and aging of the population, stroke
followed by myocardial infarction and arrhythmias will be an increasing clinical entity in the
coming decades [60]. The neurologic event is the main cause of death only in the first week
after stroke [62]. After the first year, cardiovascular diseases are the main cause of death in
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stroke patients [63]. Atrial fibrillation, the most common arrhythmia in clinical practice, is a
major risk factor for embolic stroke [60, 64]. Stroke and subarachnoid hemorrhage cause other
cerebrogenic ECG findings as well, prolong the QT interval, increase QT dispersion and
ventricular arrhythmia risk, mainly due to an autonomic nervous system dysregulation [1, 61,
65, 66 ]. Large, inverted T waves following a prolonged QTc interval, common after subar‐
achnoid hemorrhage, are often termed as “cerebral” or “neurogenic” [67]. Brady- and tachyar‐
rhythmia, including polymorphic ventricular tachycardia (PVT), have been also described in
the setting of neurologic injury [68]. The greatest risk of arrhythmias is, probably, within the
first 24 h after stroke, with a marked decline in time [69]. Activation of both sympathetic and
parasympathetic systems has cumulative effect in the development of arrhythmias and
myocardial damage after cerebral incidents, and the damage of the hypothalamic, insular, and
brainstem region is crucial for the genesis of cardiac arrhythmias, due to neural connections
with other cortical sites and the autonomic nervous system [61]. Sander et al, found increased
norepinephrine levels in patients with insular infarction, significantly related to adverse
outcome and QTc [70]. The sympathetic system has a major role in the pathogenesis of
hypokalemia and may indirectly result in QTc prolongation after subarachnoid hemorrhage
[61]. Probably constant catecholamine stimulation of beta-adrenoreceptors linked to mem‐
brane Na+/K+-ATPases causes a potassium influx, resulting in hypokalemia, and thus precip‐
itating ventricular arrhythmias [62]. Both reduced heart-rate variability (HRV) and impaired
baroreceptor reflex sensitivity (BRS) suggest impaired physiological central and cardiac
autonomic reflex function [62]. Ventricular arrhythmogenesis following stroke, related to the
cardiac autonomic imbalance is explained by two hypotheses [62]. The first involves damage
to central nervous structures controlling the autonomic nervous system, resulting in sympa‐
thetic amplification or parasympathetic inhibition, with subsequent ECG changes, without
permanent myocardium damage, and the second hypothesis proposes an augmented sympa‐
thetic discharge, resulting in increased secretion of catecholamine, causing myocytolysis [62].
The insula plays an important role in autonomic nervous function imbalance after stroke [62,
71]. Involvement of the right insula decreases basal sympathetic tone and may result in
parasympathetic hyperactivity, and left insular lesions decrease parasympathetic activity and
augment cardiac sympathetic tone [71]. Sympathetic hyperactivity prolongs repolarization
duration and increases arrhythmogenesis [62].
A concomitant myocardial ischemia or necrosis, elevated blood pressure and heart failure
may  be  also  considered  [1].  Autopsy  of  stroke  patients,  who  developed  repolarization
abnormalities, revealed no obvious coronary artery atherosclerosis in most of them, and the
only findings were petechial subendocardial hemorrhages and focal myofibrillar degenera‐
tion, reproducible with intravenous administration of catecholamines or electrical stimula‐
tion of  the vagus nerve in laboratory animals  [61].  Sudden calcium influx,  mediated by
catecholamines, impairs myocardial relaxation, leads to myocytolysis, myofibrillar degener‐
ation, coronary vasoconstriction, myocardial ischemia and ECG changes, and is proarrhyth‐
mic [61, 62]. Elevated serum uric acid, direct neural interventions, inflammation, reactive
oxygen species, electrolyte imbalances, the structural and electrophysiological changes of a
senescent heart and comorbities can increase sudden cardiac death risk in stroke [61, 66].
Stroke survivors with a prolonged QT in V6,  were identified to have an increased sud‐
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den cardiac death risk [72]. Prolonged QT intervals were associated with decreased survival
rates and worse neurological outcomes at hospital discharge [73]. The prevalence of cardiac
arrhythmias  after  acute  stroke  may  reach  28%,  higher  after  subarachnoid  hemorrhage
(37.5%) and in right sided lesions [61]. The most prevalent ECG findings were, besides atrial
fibrillation,  sinus  tachycardia,  atrio-ventricular  block,  repolarization  changes,  premature
ventricular contractions, R on T phenomenon (R/T), non-sustained, sustained and polymor‐
phic  ventricular  tachycardia  (VT),  ventricular  fibrillation  (VF)  and  flutter  (Vf)  [61,  62].
Independent risk factors for the development of ventricular arrhythmias in patients with
aneurysmal subarachnoid hemorrhage were prolonged QTc and decreased heart rate, and
therapy with angiotensin converting enzyme inhibitors and angiotensin receptor blockers
was protective [74]. Literature data are insufficient to support the hypothesis that subarach‐
noid  hemorrhage  and  stroke  cause  ventricular  arrhythmias,  considering  that  in  most
patients  additional  QT  prolonging  causes  were  mentioned,  including  hypokalemia,
hypomagnesaemia,  and congenital  long QT syndrome,  and patients  with  stroke usually
have risk factors for coronary artery disease, such as hypertension, diabetes mellitus, and
smoking, or advanced age, or left ventricular hypertrophy [61, 62, 75]. Several studies did
not control pre-existing arrhythmias, were of short duration and did not explore the long-
term consequences of ventricular arrhythmogenesis [62].  Another important limitation of
most  of  the  studies  is  the  use  of  single  surface  ECG,  because  it  may  underestimate
arrhythmia incidence in the acute phase of a stroke [62]. Holter monitoring revealed a higher
incidence of ventricular arrhythmias after transient ischemic attacks, cerebral infarction and
intracerebral hemorrhage compared to patients who were not continuously monitored (56%
vs. 8%) [76].
It is also possible that in some cases, prolonged QTc actually existed before the development
of stroke and it could be used as a predictor of future stroke in the general population [75]. The
association of QTc with cardiovascular risk factors does not fully explain the prognostic
significance of QTc as a stroke predictor, but it is possible, that prolonged QTc interval is a
marker of silent undetected atherosclerotic vascular disease [75]. QTc was previously associ‐
ated with markers of subclinical atherosclerosis, including carotid intima media thickness,
arterial stiffness and endothelial dysfunction [77-80]. Probably, QTc prolongation may be a
surrogate indicator of subclinical atherosclerosis and subsequently can be predictive of future
atherosclerotic vascular events such as stroke, but it is not clear if it represents a marker, a
limited adaptive or pathological process [75].
The ECG abnormalities observed in intracranial hemorrhage may also influence clinical outcome.
QTc prolongation correlated with insular cortex involvement, presence of intraventricular
blood, and hydrocephalus on admission CT scans in patients with intracranial hemorrhage
[81]. A case of a 58-year-old woman, with several episodes of self-terminating torsade de
pointes (TdP) following nonspecific ST-T changes, and prolonged QT after brainstem hemor‐
rhage, has been reported in the literature [82]. Maramattom et al. found premature ventricular
contractions and QTc prolongation at 24 hours from admission, not related with the location,
volume and side of the hemorrhage, nor with the presence of hydrocephalus, extraparenchy‐
mal extension or troponin T elevation [83].
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It is uncertain whether ECG abnormalities are caused by the cerebrovascular event itself,
considering that in the majority of studies patients' previous ECG data were unavailable [61].
Current management after stroke focuses mostly on the neurological function [62]. The QT
interval and electrolyte levels should be monitored, and QT prolonging drugs should be
avoided in patients with acute cerebrovascular events, especially for female patients with
insular cortex lesions [61]. Multiple studies recommend continuous ECG monitoring, however,
others believe that only severely QTc interval prolongation predicts cardiac complications [62].
Follow up studies with large sample sizes, considering previous arrhythmias and coronary
heart disease, are needed, to establish the incidence of ventricular arrhythmias after stroke,
and clear guidelines for clinicians approaching stroke patients with increased ventricular
arrhythmia risk [62].
Goldberger et al. reported an unusual case of idiopathic acute encephalopathy, with persistent
fever, refractory seizure, marked ventricular repolarization with bursts of torsade de pointes,
diffuse ST elevations and Brugada-like pattern, treated with propofol [68].
Two mechanisms connecting cardiomyopathies and neurological diseases have been descri‐
bed: cardiomyopathies may either secondarily cause neurological disease or may represent
the cardiac manifestation of a neurological disease, especially neuromuscular disorders [2].
Sudden cardiac death and ventricular arrhythmias occur mainly in neurological diseases
causing hypertrophic cardiomyopathy (in adolescents and young adults), or dilated cardio‐
myopathy (among which syncope is a common clinical manifestation), or arrhythmogenic
right ventricular dysplasia [2]. Takotsubo cardiomyopathy ("the broken heart" syndrome) was
reported after stroke, subarachnoid bleeding, spontaneous intracerebral bleeding, spinal injury
and head trauma, and the patients are prone to arrhythmias, heart failure or thrombus formation
within the left ventricle during the acute phase [2]. Inherited neuromuscular disorders may
predispose to premature ventricular contractions, monomorphic and polymorphic ventricular
tachycardia and sudden cardiac death, due to degenerative changes in the myocardium [35].
Electrical abnormalities, including QTc and JTc dispersion (the difference between the longest
and shortest JT interval duration), may be the earliest manifestation of cardiomyopathy in
patients with Emery-Dreifuss muscular dystrophy, a hereditary muscle disorder characterized
by slowly progressive muscle wasting and weakness, with humero-peroneal distribution [84].
QTc and JTc dispersions (QTcd, JTcd) reflect ventricular repolarization heterogeneities, due to
diffuse fibrosis and fatty acid infiltration in Emery-Dreifuss muscular dystrophy, and if
elevated, increase the risk of development of malignant ventricular arrhythmias via early
afterdepolarization and reentry (polymorphic ventricular tachyarrhythmia), facilitated by
intramural functional conduction blocks [84]. The mechanisms underlying sudden cardiac
death in myotonic dystrophy type 1 are: bradyarrhythmias due to cardiac conduction abnormal‐
ities, and the increased values of the QT variability index, demonstrating an important heart
involvement, extended beyond the conduction system [85]. Duchenne muscular dystrophy,
related to a mutation in the dystrophin gene, the most common neuromuscular disease, causes
progressive proximal muscle weakness of the legs and pelvis and a loss of muscle mass. It
affects also the heart (myocyte degeneration, fibrosis and fatty infiltration), impairing ventric‐
ular repolarization, causing autonomic dysfunction, QTc prolongation and increase of QT
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den cardiac death risk [72]. Prolonged QT intervals were associated with decreased survival
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patients  additional  QT  prolonging  causes  were  mentioned,  including  hypokalemia,
hypomagnesaemia,  and congenital  long QT syndrome,  and patients  with  stroke usually
have risk factors for coronary artery disease, such as hypertension, diabetes mellitus, and
smoking, or advanced age, or left ventricular hypertrophy [61, 62, 75]. Several studies did
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contractions and QTc prolongation at 24 hours from admission, not related with the location,
volume and side of the hemorrhage, nor with the presence of hydrocephalus, extraparenchy‐
mal extension or troponin T elevation [83].
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dispersion, as an independent risk factor for ventricular arrhythmias of Lown grade III or
higher [86-88]. Late ventricular potentials were reported in patients with Duchenne muscular
dystrophy (31%), indicating the presence of a substrate for reentry ventricular arrhythmias,
associated with local myocardial fibrosis, and identifying patients at high risk for sudden
cardiac death [89]. Cardiac involvement was also mentioned in other dystrophinopathies, due
to the replacement of myocardium by connective tissue or fat, but it remains subclinical in
Duchenne and Becker muscular dystrophy [86]. Patients with primary and secondary neuro‐
muscular disorders need to be obligatorily screened for cardiac disease and ventricular
arrhythmia risk, as soon as the neurological diagnosis is established, and cardiac investigations
should be regularly repeated, especially in the case of severe cardiac involvement [2]. Once
cardiac involvement occurs, the clinician should consider invasive electrophysiological studies
and ICD implantation [35].
In Parkinson’s disease factors affecting cardiac conduction may include intrinsic or iatrogenic
autonomic disturbances, cardiovascular comorbidities (cardiac ischemia, ventricular hyper‐
trophy), and electrolyte imbalances due to diuretics [90]. The most common prescribed drugs
with QT prolonging effect were: Dromperidone, with antiemetic effect and also used to treat
symptomatic postural hypotension, Citalopram, an antidepressant, and some antimicrobial
agents (macrolides, azoles and fluoroquinolones) in a study conducted by Malek et al. [90].
Combining such drugs with some antipsychotics, tricyclic antidepressants, antihistamines and
anti-retrovirals has additive influence on QT interval prolongation [90]. Large epidemiological
studies emphasized the difficulties in detecting transient drug-induced ventricular arrhythmia
in outpatient clinics, due to too few events, despite frequent syncope [91]. Oka et al considered
that QTc intervals are closely related to autonomic nervous system dysfunction in patients
with Parkinson’s disease, related to the progression of the disease [92, 93]. Deguchi et al. found
prolonged QTc intervals in patients with Parkinson’s disease, reflecting the degeneration of
cardioselective sympathetic and parasympathetic neurons [94]. Artifacts related to muscle
tremor may affect ECGs in patients with Parkinson’s disease, but methods were found to
reduce noise and variance of QTc [95]. Drugs known to prolong the QT interval are often
prescribed in patients with Parkinson’s disease, and therapy should consider additional risk
factors, especially comorbidities, autonomic dysfunction and degeneration of cardioselective
neurons [90, 94].
Sudden unexpected death in epilepsy is probably caused by periictal cardiorespiratory
alterations, such as central apnea, bradyarrhythmia, and neurogenic pulmonary edema, and
ventricular arrhythmias [96, 97]. Sudden cardiac death in patients with seizure disorders is
facilitated by associated cardiovascular diseases, pathologic cardiac repolarization, sympa‐
thovagal imbalance and therapy used to treat the disease [35, 96, 97]. A pathologic cardiac
repolarization has been described in epileptic patients, with prolonged intercritical and
periictal QT intervals, increased QT dispersion and shortened QTc after generalized tonic-
clonic seizures, but fatal seizure-related ventricular arrhythmias are very rare [96]. On the other
hand, no LVPs and significant standard ECG abnormalities were recorded in patients with
newly diagnosed epilepsy, without clinical evidence of heart disease, three to nine months
after therapy start, demonstrating lack of antiepileptic drugs induced electrocardiographic
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abnormalities [98]. Rejdak et al. reported abnormal SAECGs and late ventricular potentials in
epilepsy patients, associated with disease duration, higher monthly seizure frequency,
refractory epilepsy and tendency for higher number of generalized tonic-clonic seizures,
polytherapy [99]. Data about intercritical QT intervals in epileptic patients are contradictory;
it was found within normal limits, shorter or longer, and antiepileptic drugs and the ketogenic
diet are potential confounders [96]. Transient dysfunction of cortical networks, as interictal
epileptiform electroencephalographic discharges, can impair cardiac repolarization causing
transient QTc prolongation [100]. Potential mechanisms of periictal QTc prolongation include
cerebral dysregulation, ictal hypoxemia and hypercapnia, cardiorespiratory interactions,
sympathetic stimulation, release of stress hormones and cardiac dysfunction [96, 101].
Generalized tonic-clonic seizures are a risk factor for sudden cardiac death, and cause QTc
shortening due probably to seizure-related release of catecholamines, hyperkalemia, and
acidosis [96]. The increased QT dispersion is explained by autonomic dysfunction with
increased sympathetic tone, and subtle perivascular and interstitial fibrosis, which have been
described in epilepsy [102, 103].
In order to reduce the risk of, or prevent, sudden cardiac death, 12-lead ECG should be
performed in every patient with epilepsy, in order to identify those at high risk, and, therapy
may include antiarrhythmic medication and implantation of cardiac combined pacemaker–
defibrillator devices [96]. Cardiogenic syncope is often a difficult differential diagnosis for
seizures, and long QT with recurrent syncope has been mistaken for epilepsy, and, epileptic
seizures, probably due to cerebral hypoperfusion, have been described in patients with
congenital long QT [96, 104]. Mutations of ionic channels could affect both heart and brain
function, thereby leading to a susceptibility to epilepsy and cardiac arrhythmias [96].
8. Hematologic diseases and ventricular arrhythmia risk
Anemia and red blood cells transfusions have been associated with arrhythmias. Several
electrocardiographic changes were previously mentioned in patients with anemia, including
prolonged QT intervals, ST segment depression, inverted T waves, increased R amplitude after
stress test [105]. Anemia was associated with prolonged QT intervals in hypertensive [106] and
end stage renal disease patients [107], as well. Associations between the QT interval and serum
ferritin level [108] and anisocytosis [106], respectively, were mentioned. Scheller et al. [109]
reported a gradual prolongation of the QT and QTc interval in normovolemic anemia. Anemia
may increase cardiac output and heart rate, may lead to eccentric left ventricular hypertrophy,
activation of the sympathetic nervous system, stimulation of the renin angiotensin aldosterone
system, and is closely associated with chronic inflammation and increased oxidative stress
[106, 110]. Tissue hypoxia and changes in blood flow patterns due to low hemoglobin may
play an atherogenic role [110]. The pathophysiological link between anemia and prolonged
QT intervals and ventricular arrhythmia risk is, probably, hypoxia and decreased myocardial
oxygen supply [106].
Jaja et al [111] reported a blunted autonomic cardiovascular response to changes in posture in
patients with sickle cell anemia. Left ventricular systolic and diastolic dysfunction, increased
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dispersion, as an independent risk factor for ventricular arrhythmias of Lown grade III or
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to the replacement of myocardium by connective tissue or fat, but it remains subclinical in
Duchenne and Becker muscular dystrophy [86]. Patients with primary and secondary neuro‐
muscular disorders need to be obligatorily screened for cardiac disease and ventricular
arrhythmia risk, as soon as the neurological diagnosis is established, and cardiac investigations
should be regularly repeated, especially in the case of severe cardiac involvement [2]. Once
cardiac involvement occurs, the clinician should consider invasive electrophysiological studies
and ICD implantation [35].
In Parkinson’s disease factors affecting cardiac conduction may include intrinsic or iatrogenic
autonomic disturbances, cardiovascular comorbidities (cardiac ischemia, ventricular hyper‐
trophy), and electrolyte imbalances due to diuretics [90]. The most common prescribed drugs
with QT prolonging effect were: Dromperidone, with antiemetic effect and also used to treat
symptomatic postural hypotension, Citalopram, an antidepressant, and some antimicrobial
agents (macrolides, azoles and fluoroquinolones) in a study conducted by Malek et al. [90].
Combining such drugs with some antipsychotics, tricyclic antidepressants, antihistamines and
anti-retrovirals has additive influence on QT interval prolongation [90]. Large epidemiological
studies emphasized the difficulties in detecting transient drug-induced ventricular arrhythmia
in outpatient clinics, due to too few events, despite frequent syncope [91]. Oka et al considered
that QTc intervals are closely related to autonomic nervous system dysfunction in patients
with Parkinson’s disease, related to the progression of the disease [92, 93]. Deguchi et al. found
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cardioselective sympathetic and parasympathetic neurons [94]. Artifacts related to muscle
tremor may affect ECGs in patients with Parkinson’s disease, but methods were found to
reduce noise and variance of QTc [95]. Drugs known to prolong the QT interval are often
prescribed in patients with Parkinson’s disease, and therapy should consider additional risk
factors, especially comorbidities, autonomic dysfunction and degeneration of cardioselective
neurons [90, 94].
Sudden unexpected death in epilepsy is probably caused by periictal cardiorespiratory
alterations, such as central apnea, bradyarrhythmia, and neurogenic pulmonary edema, and
ventricular arrhythmias [96, 97]. Sudden cardiac death in patients with seizure disorders is
facilitated by associated cardiovascular diseases, pathologic cardiac repolarization, sympa‐
thovagal imbalance and therapy used to treat the disease [35, 96, 97]. A pathologic cardiac
repolarization has been described in epileptic patients, with prolonged intercritical and
periictal QT intervals, increased QT dispersion and shortened QTc after generalized tonic-
clonic seizures, but fatal seizure-related ventricular arrhythmias are very rare [96]. On the other
hand, no LVPs and significant standard ECG abnormalities were recorded in patients with
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after therapy start, demonstrating lack of antiepileptic drugs induced electrocardiographic
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acidosis [96]. The increased QT dispersion is explained by autonomic dysfunction with
increased sympathetic tone, and subtle perivascular and interstitial fibrosis, which have been
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performed in every patient with epilepsy, in order to identify those at high risk, and, therapy
may include antiarrhythmic medication and implantation of cardiac combined pacemaker–
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seizures, probably due to cerebral hypoperfusion, have been described in patients with
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function, thereby leading to a susceptibility to epilepsy and cardiac arrhythmias [96].
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may increase cardiac output and heart rate, may lead to eccentric left ventricular hypertrophy,
activation of the sympathetic nervous system, stimulation of the renin angiotensin aldosterone
system, and is closely associated with chronic inflammation and increased oxidative stress
[106, 110]. Tissue hypoxia and changes in blood flow patterns due to low hemoglobin may
play an atherogenic role [110]. The pathophysiological link between anemia and prolonged
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oxygen supply [106].
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QTc intervals and QT dispersions and late ventricular potentials were found in patients with
beta-thalassemia, a genetic cause of anemia, due to reduced synthesis of beta-globin chains [112,
113]. Several mechanisms explain increased sudden cardiac death in patients with thalassemia,
including iron overload thalassemic cardiomyopathy, with patchy cardiac iron depostition
(due to intensive blood transfusions), changes in calcium homeostasis, elevated prostaglandin
E2 to prostacyclin ratio, increased interleukin 1 level and lipid peroxidation [106, 113, 114].
Athar et al. reported that packed red blood cells (PRBC) transfusions were independently
associated with an increased risk of new onset cardiac arrhythmias and conduction abnor‐
malities in patients with acute myocardial infarction [64]. Multiple factors contributed to the
development of atrial fibrillation in the setting of acute myocardial infarction, including
pericarditis, atrial ischemia, infarction, changes in autonomic tone, metabolic abnormalities,
increased atrial pressures and inflammation [64]. The inflammatory process, exacerbated by
PRBC transfusion, tissue hypoxia, exacerbations of cardiac ischemia and reinfarctions result‐
ing from deficiencies in the ability of stored packed red blood cells to deliver oxygen to tissue,
may explain the appearance of ventricular arrhythmias [64].
A significant correlation was found between QT dispersion and platelet count in healthy
centenarians, hypothesizing that a reduced number of platelets and the maintenance of normal
QT dispersion may contribute to the extreme longevity and protects centenarians from
cardiovascular events [115].
Anthracyclines, used in therapy of patients with hematological malignancies, may have cardio‐
toxic effects, and the typical cardiac manifestations include cardiomyopathy, QT prolongation,
ventricular ectopy and torsade de pointes [35, 116]. High intermittent doses and excessive
cumulative doses increase the risk of cardiomyopathy and fatal arrhythmias, risk factors
including age, female gender, hypertension, preexisting cardiac diseases, electrolyte imbalan‐
ces, associated therapy with other QT prolonging drugs [35, 117]. Long term cardiac monitor‐
ing of patients is needed, in order to prevent sudden cardiac death and cardiac
decompensation.
9. Conclusions
Sudden cardiac death, due to fatal ventricular arrhythmias, continues to be an important public
health problem in developed countries. A high ventricular arrhythmia risk has been reported
in several noncardiac diseases, including metabolic, liver, blood, neurological and psychiatric
disorders. The most common mechanisms were: autonomic and electrolyte imbalances, ion
channel remodeling, cardiomyopathies, increased oxidative stress and QT prolonging drugs.
Most of the mentioned studies used standard 12-lead ECG and surrogate markers of ventric‐
ular arrhythmia risk (QT interval duration, QT dispersion and signal averaged ECG), but
several papers reported ventricular arrhythmias, as well.
Considering that there are no guidelines for the prevention and therapy of arrhythmias
appearing in most of extracardiac disorders, the present review highlighted important
epidemiological and pathophysiological issues related to this topic.
Cardiac Arrhythmias - Mechanisms, Pathophysiology, and Treatment100
Selected patients could benefit from electrocardiographic monitoring, specific therapy and
avoidance of QT prolonging drugs, decreasing the burden of sudden cardiac death. Large
follow up studies are needed, controlling for previous QT interval durations, arrhythmias,
coronary heart disease and cardiovascular risk factors, in order to assess the prevalence of
ventricular arrhythmias in noncardiac diseases, to identify further mechanisms and risk factors
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1. Introduction
The presence of 3 or more consecutive ventricular premature complexes (VPCs) on an elec‐
trocardiogram is ventricular tachycardia (VT) [1, 2]. VT is sustained if it lasts ≥30 seconds
and nonsustained if its lasts <30 seconds [2]. Complex ventricular arrhythmias (VA) are VT
or paired, multiform, or frequent VPCs. This author diagnoses frequent VPCs if there are an
average of ≥30/hour on a 24-hour ambulatory electrocardiogram (AECG) or ≥6/minute on a
1-minute rhythm strip of an electrocardiogram (ECG) [2, 3]. Simple VA are infrequent VPCs
and no complex forms.
The prevalence of nonsustained VT diagnosed by 24-hour AECGs varied from 2% to 13% in
older persons without cardiovascular disease [1, 4-7], was 9% in 385 older men and 8% in
806 older women with hypertension, valvular disease, or cardiomyopathy [7], and was 16%
in 395 older men and 15% in 771 older women with coronary artery disease (CAD) [7]. The
prevalence of complex VA in older persons in these studies varied from 16% to 50% in older
persons without cardiovascular disease [1, 4-7], was 54% in older men and 55% in older
women with hypertension, valvular disease, or cardiomyopathy [7], and was 69% in older
men and 68% in older women with CAD [7].
In 104 older persons without cardiovascular disease, complex VA were present on 24-hour
AECGs in 33% of persons and on 1-minute rhythm strips in 2% of persons [3]. In 843 older
persons, with cardiovascular disease, complex VA were present on 24-hour AECGs in 55%
of persons and on 1-minute rhythm strips in 4% of persons [3].
In persons with cardiovascular disease, those with an abnormal left ventricular (LV) ejection
fraction [8], with echocardiographic LV hypertrophy [9], or with silent myocardial ischemia
[10] have a higher prevalence of VT and of complex VA than those with normal LV ejection
fraction, normal LV mass, and no myocardial ischemia.
© 2014 Aronow; licensee InTech. This is a paper distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Chapter 5
Treatment of Ventricular Arrhythmias
Wilbert S.  Aronow
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/57545
1. Introduction
The presence of 3 or more consecutive ventricular premature complexes (VPCs) on an elec‐
trocardiogram is ventricular tachycardia (VT) [1, 2]. VT is sustained if it lasts ≥30 seconds
and nonsustained if its lasts <30 seconds [2]. Complex ventricular arrhythmias (VA) are VT
or paired, multiform, or frequent VPCs. This author diagnoses frequent VPCs if there are an
average of ≥30/hour on a 24-hour ambulatory electrocardiogram (AECG) or ≥6/minute on a
1-minute rhythm strip of an electrocardiogram (ECG) [2, 3]. Simple VA are infrequent VPCs
and no complex forms.
The prevalence of nonsustained VT diagnosed by 24-hour AECGs varied from 2% to 13% in
older persons without cardiovascular disease [1, 4-7], was 9% in 385 older men and 8% in
806 older women with hypertension, valvular disease, or cardiomyopathy [7], and was 16%
in 395 older men and 15% in 771 older women with coronary artery disease (CAD) [7]. The
prevalence of complex VA in older persons in these studies varied from 16% to 50% in older
persons without cardiovascular disease [1, 4-7], was 54% in older men and 55% in older
women with hypertension, valvular disease, or cardiomyopathy [7], and was 69% in older
men and 68% in older women with CAD [7].
In 104 older persons without cardiovascular disease, complex VA were present on 24-hour
AECGs in 33% of persons and on 1-minute rhythm strips in 2% of persons [3]. In 843 older
persons, with cardiovascular disease, complex VA were present on 24-hour AECGs in 55%
of persons and on 1-minute rhythm strips in 4% of persons [3].
In persons with cardiovascular disease, those with an abnormal left ventricular (LV) ejection
fraction [8], with echocardiographic LV hypertrophy [9], or with silent myocardial ischemia
[10] have a higher prevalence of VT and of complex VA than those with normal LV ejection
fraction, normal LV mass, and no myocardial ischemia.
© 2014 Aronow; licensee InTech. This is a paper distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Prognosis of ventricular arrhythmias
In the Baltimore Longitudinal Study of Aging, nonsustained VT or complex VA were not as‐
sociated with new
coronary events at 10-year follow-up of 98 persons without heart disease [11]. In this study,
exercise-induced nonsustained VT was not associated with new coronary events at 2-year
follow-up in persons without heart disease [12]. At 5.6-year follow-up in this study, exer‐
cise-induced frequent or repetitive VPCs also were not associated with new coronary events
in persons without heart disease [13].
Nonsustained VT or complex VA diagnosed by 24-hour AECGs were not associated with
new coronary events at 2-year follow-up in 76 persons without heart disease [14] and were
not associated with primary ventricular fibrillation (VF) or sudden cardiac death in 86 per‐
sons without heart disease [15]. Complex VA diagnosed by 24-hour AECGs or by 12-lead
ECGs with 1-minute rhythm strips were also not associated with new coronary events at 39-
month follow-up in 104 persons without heart disease [3]. Nonsustained VT or complex VA
diagnosed by 24-hour AECGs were not associated with new coronary events at 45-month
follow-up of 135 men and at 47-month follow-up of 297 women without cardiovascular dis‐
ease [7].
Because nonsustained VT or complex VA are not associated with new coronary events in
persons without heart disease, asymptomatic nonsustained VT or complex VA in persons
without heart disease should not be treated with antiarrhythmic drugs. Because simple VA
in persons with heart disease are not associated with new coronary events [3, 7, 11, 14, 15],
simple VA in older persons with heart disease should not be treated with antiarrhythmic
drugs.
However, patients with VT (sustained or nonsustained) or with complex VA associated with
heart disease are at increased risk for developing new coronary events, primary VF, and
sudden cardiac death [3, 7, 11, 14-19].
3. Medical therapy
Underlying causes of complex VA should be treated, if possible. Therapy of congestive heart
failure (CHF), digitalis toxicity, hypokalemia, hypomagnesemia, hypertension, LV dysfunc‐
tion, LV hypertrophy, myocardial ischemia by anti-ischemic drugs such as beta blockers or
by coronary revascularization, hypoxia, and other conditions may abolish or decrease com‐
plex VA. Persons should not smoke or drink alcohol and should avoid drugs that may cause
or increase complex VA.
CAD should be treated with aspirin [20-23], with beta blockers [23-28], with angiotensin-
converting enzyme (ACE) inhibitors [23, 28-33], and with 3-hydroxy-3-methylglutaryl coen‐
zyme A reductase inhibitors (statins) [23, 34-40] unless there are contraindications to these
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drugs. The serum low-density lipoprotein (LDL) cholesterol level should be reduced ≥ 50%
by high-dose statins (atorvastatin 40to 80 mg daily or rosuvastatin 20 to 40 mg daily) [40].
Age-related physiologic changes may affect absorption, distribution, metabolism, and excre‐
tion of cardiovascular drugs [41]. Numerous physiologic changes with aging affect pharma‐
codynamics with alterations in end-organ responsiveness to cardiovascular drugs [41]. Drug
interactions between antiarrhythmic drugs and other cardiovascular drugs are common
[41]. There are also important drug-disease interactions [41]. Class I antiarrhythmic drugs
have an unacceptable proarrhythmia rate in patients with heart disease and should be
avoided. Class III antiarrhythmic drugs should also be used with caution in patients with
heart disease since multiple factors may increase proarrhythmia. Except for beta blockers, all
antiarrhythmic drugs may cause torsades de pointes (VT with polymorphous appearance
associated with prolonged QT interval).
Class I antiarrhythmic drugs are sodium channel blockers. Class Ia antiarrhythmic drugs
have intermediate channel kinetics and prolong repolarization. These drugs include quini‐
dine, procainamide, and disopyramide. Class Ib antiarrhythmic drugs have rapid channel
kinetics and slightly shorten repolarization. These drugs include lidocaine, mexilitine, tocai‐
nide, and phenytoin. Class Ic drugs have slow channel kinetics and have little effect on repo‐
larization. These drugs include encainide, flecainide, moricizine, propafenone, and
lorcainide. None of the Class I antiarrhythmic drugs have been found in controlled, clinical
trials to reduce sudden cardiac death, total cardiac death, or total mortality.
The International Mexilitine and Placebo Antiarrhythmic Coronary Trial (IMPACT) was a
prospective, double-blind, randomized study in survivors of myocardial infarction (MI) in
whom 317 persons were randomized to mexilitine and 313 persons to placebo [42]. At 1-year
follow-up, mortality was 7.6% for mexilitine-treated patients versus 4.8% for placebo-treated
patients [42].
The Cardiac Arrhythmia Suppression Trial (CAST) I was a prospective, double-blind,
randomized study in survivors of MI with asymptomatic or mildly symptomatic VA in
which 730 patients were randomized to encainide or flecainide and 725 patients to placebo
[43]. Adequate suppression of VA by encainide or flecainide was needed before randomiza‐
tion. Despite adequate suppression of VA, at 10-month follow-up, encainide and flecainide
significantly increased mortality from arrhythmia or cardiac arrest 3.6 times and significant‐
ly increased total mortality 2.5 times[43). Older age increased the likelihood of adverse
events, including death, in patients treated with encainide and flecainide[44].
CAST II was a prospective, double-blind, randomized study in survivors of MI with asymp‐
tomatic or mildly symptomatic VA in which 581 patients were randomized to moricizine
and 574 patients to placebo. [45]. Adequate suppression of VA by moricizine was required
before randomization. At 18-month follow-up, the mortality from arrhythmia or cardiac ar‐
rest was 8.4% for patients treated with moricizine and 7.3% for patients treated with placebo
[45]. The 2-year survival rate was 81.7% for patients treated with moricizine and 85.6% for
patients treated with placebo [45]. Older age increased the likelihood of adverse events, in‐
cluding death, in patients receiving moricizine [44].
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zyme A reductase inhibitors (statins) [23, 34-40] unless there are contraindications to these
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drugs. The serum low-density lipoprotein (LDL) cholesterol level should be reduced ≥ 50%
by high-dose statins (atorvastatin 40to 80 mg daily or rosuvastatin 20 to 40 mg daily) [40].
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interactions between antiarrhythmic drugs and other cardiovascular drugs are common
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dine, procainamide, and disopyramide. Class Ib antiarrhythmic drugs have rapid channel
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larization. These drugs include encainide, flecainide, moricizine, propafenone, and
lorcainide. None of the Class I antiarrhythmic drugs have been found in controlled, clinical
trials to reduce sudden cardiac death, total cardiac death, or total mortality.
The International Mexilitine and Placebo Antiarrhythmic Coronary Trial (IMPACT) was a
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whom 317 persons were randomized to mexilitine and 313 persons to placebo [42]. At 1-year
follow-up, mortality was 7.6% for mexilitine-treated patients versus 4.8% for placebo-treated
patients [42].
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events, including death, in patients treated with encainide and flecainide[44].
CAST II was a prospective, double-blind, randomized study in survivors of MI with asymp‐
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and 574 patients to placebo. [45]. Adequate suppression of VA by moricizine was required
before randomization. At 18-month follow-up, the mortality from arrhythmia or cardiac ar‐
rest was 8.4% for patients treated with moricizine and 7.3% for patients treated with placebo
[45]. The 2-year survival rate was 81.7% for patients treated with moricizine and 85.6% for
patients treated with placebo [45]. Older age increased the likelihood of adverse events, in‐
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Aronow et al [46] performed a prospective study in 406 persons with heart disease (58%
with prior MI) and asymptomatic complex VA diagnosed by 24-hour AECGs. The preva‐
lence of nonsustained VT was 20%. The prevalence of an abnormal ejection fraction was
32%. The incidence of adverse effects causing cessation of drug was 48% for quinidine and
55% for procainamide. At 24-month follow-up, the incidences of sudden cardiac death, total
cardiac death, and of total death were not significantly different in persons treated with qui‐
nidine or procainamide or with no antiarrhythmic drug [46]. The incidence of total mortality
was 65% for persons treated with quinidine or procainamide and 63% for persons treated
with no antiarrhythmic drug. Quinidine or procainamide did not decrease sudden cardiac
death, total cardiac death, or total death in comparison with no antiarrhythmic drug in older
patients with ischemic or nonischemic heart disease, abnormal or normal LV ejection frac‐
tion, and presence versus absence of VT [46].
Moosvi et al [47] performed a retrospective analysis of the effect of empiric antiarrhythmic
therapy in 209 resuscitated out-of-hospital cardiac arrest patients with CAD. Of the 209 pa‐
tients, 48 received quinidine, 45 received procainamide, and 116 received no antiarrhythmic
drug. The 2-year sudden death survival was 69% for quinidine-treated patients, 69% for pro‐
cainamide-treated patients, and 89% for patients treated with no antiarrhythmic drug [47].
The 2-year total survival was 61% for quinidine-treated patients, 57% for procainamide-
treated patients, and 71% for patients treated with no antiarrhythmic drug [47].
Hallstrom et al [48] performed a retrospective analysis of the effect of antiarrhythmic drug
use in 941 patients resuscitated from prehospital cardiac arrest attributable to VF between
1970 and 1985. Quinidine was given to 19% of patients, procainamide to 18% of patients, be‐
ta blockers to 28% of patients, and no antiarrhythmic drug to 39% of patients. There was a
17% increased incidence of death or recurrent cardiac arrest in patients treated with quini‐
dine or procainamide versus no antiarrhythmic drug. Survival was 57% worse for patients
treated with procainamide than for patients treated with quinidine [48].
A meta-analysis of 6 double-blind studies of 808 patients with chronic atrial fibrillation who
underwent direct-current cardioversion to sinus rhythm showed that the mortality at one
year was higher in patients treated with quinidine (2.9%) than in patients treated with place‐
bo (0.8%) [49]. Of 1, 330 patients in the Stroke Prevention in Atrial Fibrillation Study, 127
were receiving quinidine, 57 procainamide, 15 disopyramide, 34 flecainide, 20 encainide,
and 7 amiodarone [50]. The adjusted relative risk of cardiac mortality was 1.8 times higher
and the adjusted relative risk of arrhythmic death was 2.1 times higher in patients receiving
antiarrhythmic drugs [50]. In patients with a history of CHF, the adjusted relative risk of
cardiac death was 3.3 times higher and the adjusted relative risk of arrhythmic death was 5.8
times higher in patients receiving antiarrhythmic drugs[50].
Morganroth and Goin [51] performed a meta-analysis of 4 randomized, double-blind con‐
trolled trials lasting 2 to 12 weeks in which quinidine (n=502) was compared with flecainide
(n=141), mexiletine (n=246), tocainide (n=67), and propafenone (n=53) in the treatment of
complex VA. There was an increased risk of mortality in patients treated with quinidine
compared with patients treated with the other antiarrhythmic drugs (absolute risk increase =
1.6%) [51].
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Teo et al [52] analyzed 59 randomized controlled trials of 23, 229 patients that investigated
use of Class I antiarrhythmic drugs after MI. The Class I drugs investigated included quini‐
dine, procainamide, disopyramide, imipramine, moricizine, lidocaine, tocainide, phenytoin,
mexiletine, aprindine, encainide, and flecainide. Mortality was 14% higher in patients re‐
ceiving Class I antiarrhythmic drugs than in patients receiving no antiarrhythmic drugs.
None of the 59 studies demonstrated that use of a Class I antiarrhythmic drug decreased
mortality in postinfarction patients [52].On the basis of these data, no Class I antiarrhythmic
drugs should be used for the treatment of VT or complex VA.
Calcium channel blockers are not useful in treatment of complex VA. Although verapamil
can terminate a left septal fascicular VT, hemodynamic collapse can occur if intravenous ve‐
rapamil is given to patients with the more common forms of reentry VT. Teo et al [52] ana‐
lyzed randomized controlled trials of 20, 342 patients that investigated the use of calcium
channel blockers after MI. Mortality was insignificantly 4% higher in patients receiving cal‐
cium channel blockers than in patients receiving no antiarrhythmic drugs [52]. On the basis
of these data, no calcium channel blockers should be used in the treatment of VT or complex
VA.
Teo et al [52] analyzed 55 randomized controlled trials comprising 53, 268 patients that in‐
vestigated use of beta blockers after MI. Mortality was significantly reduced 19% in patients
receiving beta blockers [52]. The decrease in mortality after MI in persons treated with beta
blockers was due to both a reduction in sudden cardiac death and recurrent MI [24-27, 53].
The Beta Blocker Heart Attack Trial was a double-blind, randomized study of 3, 290 patients
after MI [53-55]. At 25-month follow-up, propranolol decreased sudden cardiac death by
28% in patients with complex VA and by 16% in patients without complex VA. Propranolol
significantly reduced total mortality by 34% in patients aged 60 to 69 years (p=0.01) and in‐
significantly reduced total mortality by 19% in patients aged 30 to 59 years [53-55].
Beta blockers decrease complex VA including VT [55-57]. Beta blockers also increase VF
threshold in animal models and have been found to decrease VF in patients with acute MI
[58] A randomized, double-blind, placebo-controlled study of propranolol in high-risk sur‐
vivors of acute MI at 12 Norwegian hospitals showed a 52% significant reduction in sudden
cardiac death in patients treated with propranolol for 1 year [58].
Beta blockers decrease myocardial oxygen demand and myocardial ischemia, which may re‐
duce the likelihood of VF. Stone et al [59] showed by 48-hour AECGs in 50 patients with sta‐
ble angina pectoris that propranolol, but not diltiazem or nifedipine, caused a significant
decrease in mean number of episodes of myocardial ischemia and in mean duration of myo‐
cardial ischemia compared with placebo. Beta blockers also decrease sympathetic tone, in‐
crease vagal tone, and stabilize cardiac membrane potentials which reduces the likelihood of
VF. In addition, beta blockers are antithrombotic [60] and may prevent atherosclerotic pla‐
que rupture [61].
In the retrospective study by Hallstrom et al [48] in 941 patients resuscitated from prehospi‐
tal cardiac arrest attributed to VF, beta blockers were given to 28% of patients and no antiar‐
rhythmic drug to 39% of patients. At 108-month follow-up, patients treated with beta
Treatment of Ventricular Arrhythmias
http://dx.doi.org/10.5772/57545
115
Aronow et al [46] performed a prospective study in 406 persons with heart disease (58%
with prior MI) and asymptomatic complex VA diagnosed by 24-hour AECGs. The preva‐
lence of nonsustained VT was 20%. The prevalence of an abnormal ejection fraction was
32%. The incidence of adverse effects causing cessation of drug was 48% for quinidine and
55% for procainamide. At 24-month follow-up, the incidences of sudden cardiac death, total
cardiac death, and of total death were not significantly different in persons treated with qui‐
nidine or procainamide or with no antiarrhythmic drug [46]. The incidence of total mortality
was 65% for persons treated with quinidine or procainamide and 63% for persons treated
with no antiarrhythmic drug. Quinidine or procainamide did not decrease sudden cardiac
death, total cardiac death, or total death in comparison with no antiarrhythmic drug in older
patients with ischemic or nonischemic heart disease, abnormal or normal LV ejection frac‐
tion, and presence versus absence of VT [46].
Moosvi et al [47] performed a retrospective analysis of the effect of empiric antiarrhythmic
therapy in 209 resuscitated out-of-hospital cardiac arrest patients with CAD. Of the 209 pa‐
tients, 48 received quinidine, 45 received procainamide, and 116 received no antiarrhythmic
drug. The 2-year sudden death survival was 69% for quinidine-treated patients, 69% for pro‐
cainamide-treated patients, and 89% for patients treated with no antiarrhythmic drug [47].
The 2-year total survival was 61% for quinidine-treated patients, 57% for procainamide-
treated patients, and 71% for patients treated with no antiarrhythmic drug [47].
Hallstrom et al [48] performed a retrospective analysis of the effect of antiarrhythmic drug
use in 941 patients resuscitated from prehospital cardiac arrest attributable to VF between
1970 and 1985. Quinidine was given to 19% of patients, procainamide to 18% of patients, be‐
ta blockers to 28% of patients, and no antiarrhythmic drug to 39% of patients. There was a
17% increased incidence of death or recurrent cardiac arrest in patients treated with quini‐
dine or procainamide versus no antiarrhythmic drug. Survival was 57% worse for patients
treated with procainamide than for patients treated with quinidine [48].
A meta-analysis of 6 double-blind studies of 808 patients with chronic atrial fibrillation who
underwent direct-current cardioversion to sinus rhythm showed that the mortality at one
year was higher in patients treated with quinidine (2.9%) than in patients treated with place‐
bo (0.8%) [49]. Of 1, 330 patients in the Stroke Prevention in Atrial Fibrillation Study, 127
were receiving quinidine, 57 procainamide, 15 disopyramide, 34 flecainide, 20 encainide,
and 7 amiodarone [50]. The adjusted relative risk of cardiac mortality was 1.8 times higher
and the adjusted relative risk of arrhythmic death was 2.1 times higher in patients receiving
antiarrhythmic drugs [50]. In patients with a history of CHF, the adjusted relative risk of
cardiac death was 3.3 times higher and the adjusted relative risk of arrhythmic death was 5.8
times higher in patients receiving antiarrhythmic drugs[50].
Morganroth and Goin [51] performed a meta-analysis of 4 randomized, double-blind con‐
trolled trials lasting 2 to 12 weeks in which quinidine (n=502) was compared with flecainide
(n=141), mexiletine (n=246), tocainide (n=67), and propafenone (n=53) in the treatment of
complex VA. There was an increased risk of mortality in patients treated with quinidine
compared with patients treated with the other antiarrhythmic drugs (absolute risk increase =
1.6%) [51].
Cardiac Arrhythmias - Mechanisms, Pathophysiology, and Treatment114
Teo et al [52] analyzed 59 randomized controlled trials of 23, 229 patients that investigated
use of Class I antiarrhythmic drugs after MI. The Class I drugs investigated included quini‐
dine, procainamide, disopyramide, imipramine, moricizine, lidocaine, tocainide, phenytoin,
mexiletine, aprindine, encainide, and flecainide. Mortality was 14% higher in patients re‐
ceiving Class I antiarrhythmic drugs than in patients receiving no antiarrhythmic drugs.
None of the 59 studies demonstrated that use of a Class I antiarrhythmic drug decreased
mortality in postinfarction patients [52].On the basis of these data, no Class I antiarrhythmic
drugs should be used for the treatment of VT or complex VA.
Calcium channel blockers are not useful in treatment of complex VA. Although verapamil
can terminate a left septal fascicular VT, hemodynamic collapse can occur if intravenous ve‐
rapamil is given to patients with the more common forms of reentry VT. Teo et al [52] ana‐
lyzed randomized controlled trials of 20, 342 patients that investigated the use of calcium
channel blockers after MI. Mortality was insignificantly 4% higher in patients receiving cal‐
cium channel blockers than in patients receiving no antiarrhythmic drugs [52]. On the basis
of these data, no calcium channel blockers should be used in the treatment of VT or complex
VA.
Teo et al [52] analyzed 55 randomized controlled trials comprising 53, 268 patients that in‐
vestigated use of beta blockers after MI. Mortality was significantly reduced 19% in patients
receiving beta blockers [52]. The decrease in mortality after MI in persons treated with beta
blockers was due to both a reduction in sudden cardiac death and recurrent MI [24-27, 53].
The Beta Blocker Heart Attack Trial was a double-blind, randomized study of 3, 290 patients
after MI [53-55]. At 25-month follow-up, propranolol decreased sudden cardiac death by
28% in patients with complex VA and by 16% in patients without complex VA. Propranolol
significantly reduced total mortality by 34% in patients aged 60 to 69 years (p=0.01) and in‐
significantly reduced total mortality by 19% in patients aged 30 to 59 years [53-55].
Beta blockers decrease complex VA including VT [55-57]. Beta blockers also increase VF
threshold in animal models and have been found to decrease VF in patients with acute MI
[58] A randomized, double-blind, placebo-controlled study of propranolol in high-risk sur‐
vivors of acute MI at 12 Norwegian hospitals showed a 52% significant reduction in sudden
cardiac death in patients treated with propranolol for 1 year [58].
Beta blockers decrease myocardial oxygen demand and myocardial ischemia, which may re‐
duce the likelihood of VF. Stone et al [59] showed by 48-hour AECGs in 50 patients with sta‐
ble angina pectoris that propranolol, but not diltiazem or nifedipine, caused a significant
decrease in mean number of episodes of myocardial ischemia and in mean duration of myo‐
cardial ischemia compared with placebo. Beta blockers also decrease sympathetic tone, in‐
crease vagal tone, and stabilize cardiac membrane potentials which reduces the likelihood of
VF. In addition, beta blockers are antithrombotic [60] and may prevent atherosclerotic pla‐
que rupture [61].
In the retrospective study by Hallstrom et al [48] in 941 patients resuscitated from prehospi‐
tal cardiac arrest attributed to VF, beta blockers were given to 28% of patients and no antiar‐
rhythmic drug to 39% of patients. At 108-month follow-up, patients treated with beta
Treatment of Ventricular Arrhythmias
http://dx.doi.org/10.5772/57545
115
blockers had a significant 38% decreased incidence of death or recurrent cardiac arrest com‐
pared to patients treated with no antiarrhythmic [48].
Aronow et al [62] performed a prospective study in 245 persons with heart disease (64%
with prior MI and 36% with hypertensive heart disease) and complex VA diagnosed by 24-
hour AECGs and a LV ejection fraction ≥40%. Nonsustained VT occurred in 32% of patients.
Silent myocardial ischemia occurred in 33% of patients. Of 245 patients, 123 were random‐
ized to propranolol and 122 to no antiarrhythmic drug. Follow-up was 29 months. Propra‐
nolol was stopped because of adverse effects in 14 of 123 patients (11%).
Follow-up 24-hour AECGs were obtained at a median of 6 months in 91% of patients treated
with propranolol and in 89% of patients treated with no antiarrhythmic drug [62]. Proprano‐
lol was significantly more effective than no antiarrhythmic drug in reducing VT >90% (71%
versus 25% of patients) and in decreasing the average number of VPCs/hour >70% (71% ver‐
sus 25% of patients) [62]. The prevalence of silent myocardial ischemia on follow-up 24-hour
AECGs was insignificantly higher on no antiarrhythmic drug. However, silent ischemia was
significantly abolished by propranolol, with 37% of patients with silent ischemia on their
baseline 24-hour AECGs having no silent ischemia on their follow-up 24-hour AECGs [62].
Multivariate Cox regression analyses showed that propranolol caused a 47% significant re‐
duction in sudden cardiac death, a 37% significant decrease in total cardiac death, and a 20%
insignificant decrease in total death [62]. Univariate Cox regression analysis showed that
among patients taking propranolol, suppression of complex VA caused a 33% insignificant
reduction in sudden cardiac death, a 27% insignificant decrease in total cardiac death, and a
30% insignificant reduction in total death [63]. Among patients taking propranolol, abolition
of silent myocardial ischemia caused a 70% significant decrease in sudden cardiac death, a
70% significant reduction in total cardiac death, and a 69% significant decrease in total death
[63].
There was also a circadian distribution of sudden cardiac death or fatal MI with the peak
incidence occurring from 6 AM to 12 PM (peak hour was 8 AM and a secondary peak occur‐
red around 7 PM) in patients treated with no antiarrhythmic drug [64] Propranolol abolish‐
ed this circadian distribution of sudden cardiac death or fatal MI [64]. In this study,
propranolol markedly decreased the circadian variation of complex VA [65] and abolished
the circadian variation of myocardial ischemia [66].
In a retrospective analysis of data from the CAST study, Kennedy et al [67] showed that 30%
of patients with a LV ejection fraction ≤40% were receiving beta blockers. Patients on beta
blockers had a significant decrease in all-cause mortality of 43% at 30 days, of 46% at 1 year,
and of 33% at 2 years [67]. Patients treated with beta blockers had a significant reduction in
arrhythmic death or cardiac arrest of 66% at 30 days, of 53% at 1 year, and of 36% at 2 years
[67]. Multivariate analysis showed that beta blockers were an independent factor for de‐
creasing arrhythmic death or cardiac arrest by 40%, for reducing all-cause mortality by 33%,
and for decreasing new or worsened CHF by 32% [67].
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ACE inhibitors have been shown to cause a significant reduction in complex VA in patients
with CHF in some studies [68, 69] but not in other studies [70, 71]. ACE inhibitors have also
been shown to reduce sudden cardiac death in some studies of patients with CHF [32, 72].
ACE inhibitors should be given to reduce total mortality in older and younger patients with
CHF [30, 32, 72, 73], an anterior MI [31], an MI with a LV ejection fraction ≤40% [28, 29, 32],
and in all patients with atherosclerotic cardiovascular disease [23, 33]. ACE inhibitors
should be used to treat patients with CHF with abnormal LV ejection fraction [30, 32, 72, 73]
or with normal LV ejection fraction [74, 75].
On the basis of available data, ACE inhibitors should be used to treat patients with VT or
complex VA associated with CHF, an anterior MI, an MI with LV systolic dysfunction, or
atherosclerotic cardiovascular disease if there are no contraindications to use of ACE inhibi‐
tors. Beta blockers should be used in addition to ACE inhibitors in treating these patients.
Class III antiarrhythmic drugs are potassium channel blockers which prolong repolarization
manifested by an increase in QT interval on the electrocardiogram. These drugs suppress
VA by increasing the refractory period. However, prolonging cardiac repolarization and re‐
fractory period can trigger afterdepolarizations and resultant torsade de pointes.
In the Survival With Oral d-Sotalol (SWORD) Trial, 3, 121 survivors of MI with a LV ejection
fraction ≤40% were randomized to d-sotalol, a pure potassium channel blocker with no beta
blocking activity, or to double-blind placebo [76]. At 148-day follow-up, mortality was 5.0%
in patients treated with d-sotalol versus 3.1% in patients treated with placebo [76]. Pre‐
sumed arrhythmic deaths accounted for the 77% increased mortality (relative risk = 1.77;
95% CI, 1.15 to 2.74) [76].
Studies comparing the effect of d, l-sotalol, a Class III antiarrhythmic drug with beta block‐
ing activity, versus placebo or beta blockers in patients with VT or complex VA have not
been performed. In a study of 1, 486 patients with prior MI, compared with placebo, d, l-
sotalol did not reduce mortality in patients followed for 1 year [77].
In the Electrophysiologic Study versus Electrocardiographic Monitoring (ESVEM) study of
486 patients, Holter monitor-guided therapy significantly predicted antiarrhythmic drug ef‐
ficacy more often than did the electrophysiologic study in patients with sustained VT or sur‐
vivors of cardiac arrest (77% versus 45% of patients) [78]. However, there was no significant
difference in the success of drug therapy selected by the two methods in preventing recur‐
rences of ventricular tachyarrhythmias.
In the ESVEM study, d, l-sotalol was more effective than the other 6 antiarrhythmic drugs
[imipramine, mexiletine, pirmenol, procainamide, propafenone, and quinidine] used in re‐
ducing recurrence of arrhythmia, death from arrhythmia, death from cardiac causes, and
death from any cause [79]. However, 7 of 10 episodes of torsade de pointes during this
study occurred in patients receiving d, l-sotalol [79]. In 481 patients with VT, d, l-sotalol
caused torsade de pointes (12 patients) or an increase in VT episodes (11 patients) in 23 pa‐
tients (4.9%) [80]. Women had a significantly higher risk for drug-induced VF. On the basis
of available data, use of beta blockers is recommended over the use of d, l-sotalol in treating
patients with VT or complex VA associated with heart disease.
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In the Electrophysiologic Study versus Electrocardiographic Monitoring (ESVEM) study of
486 patients, Holter monitor-guided therapy significantly predicted antiarrhythmic drug ef‐
ficacy more often than did the electrophysiologic study in patients with sustained VT or sur‐
vivors of cardiac arrest (77% versus 45% of patients) [78]. However, there was no significant
difference in the success of drug therapy selected by the two methods in preventing recur‐
rences of ventricular tachyarrhythmias.
In the ESVEM study, d, l-sotalol was more effective than the other 6 antiarrhythmic drugs
[imipramine, mexiletine, pirmenol, procainamide, propafenone, and quinidine] used in re‐
ducing recurrence of arrhythmia, death from arrhythmia, death from cardiac causes, and
death from any cause [79]. However, 7 of 10 episodes of torsade de pointes during this
study occurred in patients receiving d, l-sotalol [79]. In 481 patients with VT, d, l-sotalol
caused torsade de pointes (12 patients) or an increase in VT episodes (11 patients) in 23 pa‐
tients (4.9%) [80]. Women had a significantly higher risk for drug-induced VF. On the basis
of available data, use of beta blockers is recommended over the use of d, l-sotalol in treating
patients with VT or complex VA associated with heart disease.
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Amiodarone is very effective in suppressing VT and complex VA associated with heart dis‐
ease [81-83]. However, the incidence of adverse effects from amiodarone approaches 90% af‐
ter 5 years of therapy [84]. In the Cardiac Arrest in Seattle: Conventional Versus
Amiodarone Drug Evaluation study, the incidence of pulmonary toxicity was 10% at 2 years
in patients receiving an amiodarone dose of 158 mg daily [81]. Amiodarone can also cause
cardiac adverse effects, gastrointestinal adverse effects including hepatitis, hyperthyroidism,
hypothyroidism, and neurologic, dermatologic, and ophthalmologic adverse effects.
A double-blind study randomized 674 patients with CHF and complex VA to amiodarone
or placebo [82]. Compared with placebo, amiodarone significantly decreased the number of
episodes of VT and the frequency of complex VA. Twenty-seven percent of patients discon‐
tinued amiodarone in this study. At 2-year follow-up, survival was not different in patients
treated with amiodarone or placebo [82].
The Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT) randomized
1, 202 survivors of MI with nonsustained VT or complex VA to amiodarone or placebo [83]
Early permanent discontinuation of amiodarone for reasons other than adverse events oc‐
curred in 36% of patients taking this drug [83]. At 1.8-year follow-up, amiodarone caused no
significant reduction in mortality [83].
The European Myocardial Infarction Amiodarone Trial (EMIAT) randomized 1, 486 survi‐
vors of MI with a LV ejection fraction ≤40% to amiodarone or placebo [85]. Early permanent
discontinuation of amiodarone occurred in 38.5% of patients taking this drug. At 21-month
follow-up, mortality was similar in patients treated with amiodarone or with placebo [85].
In the Sudden Cardiac Death in Heart Failure Trial (SCD-HEFT), 2, 521 patients with New
York Heart Association (NYHA) class II or III CHF due to ischemic or nonischemic heart
disease, a LV ejection fraction of 35% or less, and a mean QRS duration on the resting ECG
of 120 msec were randomized to placebo, amiodarone, or an automatic implantable cardi‐
overter-defibrillator (AICD) [86]. At 45.5-month median follow-up, compared with placebo,
amiodarone insignificantly increased mortality by 6% [86]. At 45.5-month median follow-up,
compared with placebo, AICD therapy significantly reduced all-cause mortality by 23%,
with an absolute reduction in mortality of 7.2% after 5 years [86].
Since amiodarone has not been found to reduce mortality in patients with VT or complex
VA associated with MI or CHF and has a very high incidence of toxicity, beta blockers
should be used rather than amiodarone in treating these patients. A meta-analysis of 10
randomized trials showed that the use of beta blockers significantly reduced 2-year mortali‐
ty in patients receiving AICD therapy [87]. In a study of 965 patients with AICDs, at 32-
month mean follow-up, use of beta blockers significantly reduced all-cause mortality by
46%, whereas use of amiodarone or sotalolol did not affect mortality [88]. During 33-month
mean follow-up of 1, 038 patients with AICDs, use of beta blockers significantly reduced ap‐
propriate AICD shocks [89]. Use of amiodarone plus a beta blocker was not more effective
than beta blocker therapy alone in reducing AICD shocks for any reason [89]. In this study,
use of sotalol did not reduce appropriate AICD shocks [89].
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4. Invasive intervention
If patients have life-threatening recurrent VT or VF resistant to antiarrhythmic drugs, inva‐
sive intervention should be performed. Patients with critical coronary artery stenosis and se‐
vere myocardial ischemia should undergo coronary artery bypass graft surgery to reduce
mortality [90]. In the Coronary Artery Bypass Graft (CABG) Patch Trial, there was no evi‐
dence of improved survival among patients with CAD, LV ejection fraction <36%, and an
abnormal signal-averaged electrocardiogram undergoing complete coronary revasculariza‐
tion in whom an AICD was implanted prophylactically at the time of elective coronary ar‐
tery bypass graft surgery [91].
Surgical ablation of the arhythmogenic focus in patients with life-threatening ventricular ta‐
chyarrhythmias can be curative. This treatment includes aneurysectomy or infarctectomy
and endocardial resection with or without adjunctive cryoablation based on activation map‐
ping in the operating room [92-94]. However, the perioperative mortality rate is high. En‐
doaneurysmorrhaphy with a pericardial patch combined with mapping-guided
subendocardial resection frequently cures recurrent VT with a low operative mortality and
improvement of LV systolic function [95]. Radiofrequency catheter ablation of VT has been
beneficial in the therapy of selected patients with arrhythmogenic foci of monomorphic VT
[96-98]. Catheter ablation has been effectively used to treat patients with right ventricular
outflow tract VT and LV fascicular VT. Prophylactic VT ablation should be considered be‐
fore implantation of an AICD in patients with stable VT, prior MI, and reduced LV ejection
fraction [99].
4.1. Automatic implantable cardioverter-defibrillator
However, the AICD is the most effective treatment for patients with life-threatening VT or
VF. [93-110]. The Multicenter Automatic Defibrillator Implantation Trial (MADIT) random‐
ized 196 patients, with a prior MI, a LV ejection fraction ≤35%, a documented episode of
asymptomatic nonsustained VT, and inducible nonsuppressible ventricular tachyarrhyth‐
mia on electrophysiologic study to an AICD or conventional medical therapy [100]. At 27-
month follow-up, patients receiving an AICD had a 54% significant reduction in mortality
[100].
In the Antiarrhythmics versus Implantable Defibrillators (AVID) Trial, 1, 016 patients were
randomized to an AICD or class III antiarrhythmic drug therapy [101]. Forty-five percent of
patients had been resuscitated from near-fatal VF. The other 55% of patients had sustained
VT with syncope or sustained VT with a LV ejection fraction ≤40% and symptoms suggest‐
ing severe hemodynamic compromise due to the arrhythmia (near-syncope, CHF, and angi‐
na pectoris). The 1-year survival was 89.3% for patients who had the AICD versus 82.3% for
patients treated with drug therapy (39% reduction by AICD) [101]. The 2-year survival was
81.6% for patients who had the AICD versus 74.7% for patients treated with drug therapy
(27% reduction by AICD) [101]. The 3-year survival was 75.4% for patients who had the
AICD versus 64.1% for patients treated with drug therapy (31% reduction by AICD) [101].
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Amiodarone is very effective in suppressing VT and complex VA associated with heart dis‐
ease [81-83]. However, the incidence of adverse effects from amiodarone approaches 90% af‐
ter 5 years of therapy [84]. In the Cardiac Arrest in Seattle: Conventional Versus
Amiodarone Drug Evaluation study, the incidence of pulmonary toxicity was 10% at 2 years
in patients receiving an amiodarone dose of 158 mg daily [81]. Amiodarone can also cause
cardiac adverse effects, gastrointestinal adverse effects including hepatitis, hyperthyroidism,
hypothyroidism, and neurologic, dermatologic, and ophthalmologic adverse effects.
A double-blind study randomized 674 patients with CHF and complex VA to amiodarone
or placebo [82]. Compared with placebo, amiodarone significantly decreased the number of
episodes of VT and the frequency of complex VA. Twenty-seven percent of patients discon‐
tinued amiodarone in this study. At 2-year follow-up, survival was not different in patients
treated with amiodarone or placebo [82].
The Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT) randomized
1, 202 survivors of MI with nonsustained VT or complex VA to amiodarone or placebo [83]
Early permanent discontinuation of amiodarone for reasons other than adverse events oc‐
curred in 36% of patients taking this drug [83]. At 1.8-year follow-up, amiodarone caused no
significant reduction in mortality [83].
The European Myocardial Infarction Amiodarone Trial (EMIAT) randomized 1, 486 survi‐
vors of MI with a LV ejection fraction ≤40% to amiodarone or placebo [85]. Early permanent
discontinuation of amiodarone occurred in 38.5% of patients taking this drug. At 21-month
follow-up, mortality was similar in patients treated with amiodarone or with placebo [85].
In the Sudden Cardiac Death in Heart Failure Trial (SCD-HEFT), 2, 521 patients with New
York Heart Association (NYHA) class II or III CHF due to ischemic or nonischemic heart
disease, a LV ejection fraction of 35% or less, and a mean QRS duration on the resting ECG
of 120 msec were randomized to placebo, amiodarone, or an automatic implantable cardi‐
overter-defibrillator (AICD) [86]. At 45.5-month median follow-up, compared with placebo,
amiodarone insignificantly increased mortality by 6% [86]. At 45.5-month median follow-up,
compared with placebo, AICD therapy significantly reduced all-cause mortality by 23%,
with an absolute reduction in mortality of 7.2% after 5 years [86].
Since amiodarone has not been found to reduce mortality in patients with VT or complex
VA associated with MI or CHF and has a very high incidence of toxicity, beta blockers
should be used rather than amiodarone in treating these patients. A meta-analysis of 10
randomized trials showed that the use of beta blockers significantly reduced 2-year mortali‐
ty in patients receiving AICD therapy [87]. In a study of 965 patients with AICDs, at 32-
month mean follow-up, use of beta blockers significantly reduced all-cause mortality by
46%, whereas use of amiodarone or sotalolol did not affect mortality [88]. During 33-month
mean follow-up of 1, 038 patients with AICDs, use of beta blockers significantly reduced ap‐
propriate AICD shocks [89]. Use of amiodarone plus a beta blocker was not more effective
than beta blocker therapy alone in reducing AICD shocks for any reason [89]. In this study,
use of sotalol did not reduce appropriate AICD shocks [89].
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4. Invasive intervention
If patients have life-threatening recurrent VT or VF resistant to antiarrhythmic drugs, inva‐
sive intervention should be performed. Patients with critical coronary artery stenosis and se‐
vere myocardial ischemia should undergo coronary artery bypass graft surgery to reduce
mortality [90]. In the Coronary Artery Bypass Graft (CABG) Patch Trial, there was no evi‐
dence of improved survival among patients with CAD, LV ejection fraction <36%, and an
abnormal signal-averaged electrocardiogram undergoing complete coronary revasculariza‐
tion in whom an AICD was implanted prophylactically at the time of elective coronary ar‐
tery bypass graft surgery [91].
Surgical ablation of the arhythmogenic focus in patients with life-threatening ventricular ta‐
chyarrhythmias can be curative. This treatment includes aneurysectomy or infarctectomy
and endocardial resection with or without adjunctive cryoablation based on activation map‐
ping in the operating room [92-94]. However, the perioperative mortality rate is high. En‐
doaneurysmorrhaphy with a pericardial patch combined with mapping-guided
subendocardial resection frequently cures recurrent VT with a low operative mortality and
improvement of LV systolic function [95]. Radiofrequency catheter ablation of VT has been
beneficial in the therapy of selected patients with arrhythmogenic foci of monomorphic VT
[96-98]. Catheter ablation has been effectively used to treat patients with right ventricular
outflow tract VT and LV fascicular VT. Prophylactic VT ablation should be considered be‐
fore implantation of an AICD in patients with stable VT, prior MI, and reduced LV ejection
fraction [99].
4.1. Automatic implantable cardioverter-defibrillator
However, the AICD is the most effective treatment for patients with life-threatening VT or
VF. [93-110]. The Multicenter Automatic Defibrillator Implantation Trial (MADIT) random‐
ized 196 patients, with a prior MI, a LV ejection fraction ≤35%, a documented episode of
asymptomatic nonsustained VT, and inducible nonsuppressible ventricular tachyarrhyth‐
mia on electrophysiologic study to an AICD or conventional medical therapy [100]. At 27-
month follow-up, patients receiving an AICD had a 54% significant reduction in mortality
[100].
In the Antiarrhythmics versus Implantable Defibrillators (AVID) Trial, 1, 016 patients were
randomized to an AICD or class III antiarrhythmic drug therapy [101]. Forty-five percent of
patients had been resuscitated from near-fatal VF. The other 55% of patients had sustained
VT with syncope or sustained VT with a LV ejection fraction ≤40% and symptoms suggest‐
ing severe hemodynamic compromise due to the arrhythmia (near-syncope, CHF, and angi‐
na pectoris). The 1-year survival was 89.3% for patients who had the AICD versus 82.3% for
patients treated with drug therapy (39% reduction by AICD) [101]. The 2-year survival was
81.6% for patients who had the AICD versus 74.7% for patients treated with drug therapy
(27% reduction by AICD) [101]. The 3-year survival was 75.4% for patients who had the
AICD versus 64.1% for patients treated with drug therapy (31% reduction by AICD) [101].
Treatment of Ventricular Arrhythmias
http://dx.doi.org/10.5772/57545
119
The Canadian Implantable Defibrillator Study (CIDS) randomized 659 patients with VF, car‐
diac arrest, or hypotensive VT to an AICD or amiodarone therapy [102]. Cardiac arrhythmic
mortality was 4.5% per year in patients treated with amiodarone versus 3% per year in pa‐
tients treated with an AICD (risk reduction = 33%). Total mortality was 10.2% per year in
patients treated with amiodarone versus 8.3% per year in patients treated with an AICD
(risk reduction = 20%) [102]. In a subset of CIDS, at 5.6-year follow-up, 47% of patients treat‐
ed with amiodarone and 27% of patients treated with an AICD had died [103]. Amiodarone
caused adverse effects in 83% of patients receiving the drug [103].
The Cardiac Arrest Study Hamburg (CASH) randomized 230 patients surviving sudden car‐
diac death due to documented VT and/or VF to propafenone, metoprolol, amiodarone, or an
AICD [104]. Propafenone was stopped after 11 months because mortality from sudden death
and cardiac arrest recurrence was 23% in patients randomized to propafenone versus 0% in
patients randomized to an AICD [104]. The 2-year mortality was 12.6% for 99 patients
randomized to an AICD versus 19.6% for 189 patients randomized to amiodarone or meto‐
prolol (37% reduction) [105].
The Multicenter Unsustained Tachycardia Trial randomized 704 patients with inducible,
sustained ventricular tachyarrhythmias to 3 treatment groups [106]. Compared with electro‐
physiologically guided antiarrhythmic drug therapy, the 5-year total mortality was de‐
creased 20% by an AICD, and the 5-year risk of cardiac arrest or death from an arrhythmia
was reduced 76% by an AICD [106]. Neither total mortality incidence or rate of cardiac ar‐
rest or death from arrhythmia was lower in patients randomized to electrophysiologically
guided therapy and treated with antiarrhythmic drugs than in patients randomized to no
antiarrhythmic treatment [106].
MADIT II randomized 1, 232 patients with prior MI and a LV ejection fraction of ≤30% to an
AICD or to conventional medical therapy [107]. At 20-month follow-up, compared with con‐
ventional medical therapy, the AICD reduced all-cause mortality 31% from 19.8% to 14.2%
[107]. The effect of AICD therapy in improving survival was similar in patients stratified ac‐
cording to age, sex, LV ejection fraction, New York Heart Association class, and QRS inter‐
val [107].
In MADIT-II, the reduction in sudden cardiac death in patients treated with an AICD was
significantly reduced by 68% in 574 patients aged <65 years, by 65% in 455 patients aged
65-74 years, and by 68% in 204 patients aged ≥75 years [108]. The median survival in 348 oc‐
togenarians treated with AICD therapy was >4years [109].
At 8-year follow-up in MADIT II, the cumulative probability of all-cause mortality was 49%
for patients treated with an AICD versus 62% for patients not treated with an AICD [110].
AICD treatment caused a 34% reduction in mortality during treatment years 1-4 and a 26%
reduction in mortality during years 5-8 [110].
After AICD implantation, 35 patients were randomized to treatment with metoprolol and 35
patients to treatment with d, l-sotalol [111]. VT recurrence was 17% at 1 year and 20% at 2
years for patients treated with metoprolol versus 43% at 1 year and 49% at 2 years for pa‐
tients treated with d, l-sotalol. At 26-month follow-up, survival was 91% for patients treated
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with metoprolol plus an AICD versus 83% for patients treated with d, l-sotalol plus an
AICD [111]. In MADIT-II, use of higher doses of beta blockers in patients with ischemic
heart disease and an AICD significantly reduced mortality by 56-58% compared with non‐
use of beta blockers [112]. These data favor using a beta blocker in patients with an AICD.
At 32-month mean follow-up of 965 patients, death occurred in 73 of 515 patients (13%)
treated with beta blockers, in 84 of 494 patients (17%) treated with ACE inhibitors or angio‐
tensin receptor blockers, in 56 of 402 patients (14%) treated with statins, in 40 of 227 patients
(18%) treated with amiodarone, in 5 of 26 patients (19%) treated with sotalol, and in 64 of
265 patients (24%) treated with no beta blocker, ACE inhibitor, angiotensin receptor blocker,
statin, amiodarone, or sotalol [88]. These data favor treating patients with AICDs with beta
blockers, statins, and ACE inhibitors or angiotensin receptor blockers.
The American College of Cardiology Foundation (ACCF)/American Heart Association
(AHA) guidelines(Table 1) recommend that Class I indications for therapy with an AICD are
1) cardiac arrest due to VF or VT not due to a transient or a reversible cause; 2) spontaneous
sustained VT; 3) syncope of undetermined origin with clinically relevant, hemodynamically
significant sustained VT or VF induced at electrophysiologic study when drug therapy is in‐
effective, not tolerated, or not preferred; ; 4) patients with prior MI at least 40 days previous‐
ly with a LV ejection fraction less than 35% who are in NYHA class II or III; 5) patients with
nonischemic dilated cardiomyopathy with a LV ejection fraction less than or equal to 35%
who are in NYHA class II or III; 6) patients with prior MI at least 40 days previously with a
LV ejection fraction less than 30% who are in NYHA class I; and 7) patients with nonsus‐
tained VT due to prior MI with a LV ejection fraction less than 40% and inducible VF or sus‐
tained VT at electrophysiological study [113].
1. Survivors of cardiac arrest due to VF or hemodynamically unstable sustained VT after evaluation to diagnose the
cause and to exclude completely reversible causes
2. Structural heart disease and spontaneous sustained VT, whether hemodynamically stable or unstable
3. Syncope of undetermined etiology with clinically relevant, hemodynamically significant sustained VT or VF induced
at electrophysiological study
4. LV ejection fraction less than 35% due to prior MI at least 40 days previously and NYHA class II or III
5. Nonischemic dilated cardiomyopathy with LV ejection fraction less than or equal to 35% and NYHA class II or III
6. LV ejection fraction less than 30% due to prior myocardial infarction at least 40 days previously and NYHA class I
7. Nonsustained VT due to MI, LV ejection fraction less than 40%, and inducible VF or sustained VT at
electrophysiological study
Table 1. Class I indications for Automatic Implantable Cardioverter-Defibrillator
Adapted from Epstein AE et al [113]
The 2009 updated ACCF/AHA guidelines for treatment of CHF (Table 2) recommend with a
class I indication use of an AICD for 1) secondary prevention to increase survival in patients
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The Canadian Implantable Defibrillator Study (CIDS) randomized 659 patients with VF, car‐
diac arrest, or hypotensive VT to an AICD or amiodarone therapy [102]. Cardiac arrhythmic
mortality was 4.5% per year in patients treated with amiodarone versus 3% per year in pa‐
tients treated with an AICD (risk reduction = 33%). Total mortality was 10.2% per year in
patients treated with amiodarone versus 8.3% per year in patients treated with an AICD
(risk reduction = 20%) [102]. In a subset of CIDS, at 5.6-year follow-up, 47% of patients treat‐
ed with amiodarone and 27% of patients treated with an AICD had died [103]. Amiodarone
caused adverse effects in 83% of patients receiving the drug [103].
The Cardiac Arrest Study Hamburg (CASH) randomized 230 patients surviving sudden car‐
diac death due to documented VT and/or VF to propafenone, metoprolol, amiodarone, or an
AICD [104]. Propafenone was stopped after 11 months because mortality from sudden death
and cardiac arrest recurrence was 23% in patients randomized to propafenone versus 0% in
patients randomized to an AICD [104]. The 2-year mortality was 12.6% for 99 patients
randomized to an AICD versus 19.6% for 189 patients randomized to amiodarone or meto‐
prolol (37% reduction) [105].
The Multicenter Unsustained Tachycardia Trial randomized 704 patients with inducible,
sustained ventricular tachyarrhythmias to 3 treatment groups [106]. Compared with electro‐
physiologically guided antiarrhythmic drug therapy, the 5-year total mortality was de‐
creased 20% by an AICD, and the 5-year risk of cardiac arrest or death from an arrhythmia
was reduced 76% by an AICD [106]. Neither total mortality incidence or rate of cardiac ar‐
rest or death from arrhythmia was lower in patients randomized to electrophysiologically
guided therapy and treated with antiarrhythmic drugs than in patients randomized to no
antiarrhythmic treatment [106].
MADIT II randomized 1, 232 patients with prior MI and a LV ejection fraction of ≤30% to an
AICD or to conventional medical therapy [107]. At 20-month follow-up, compared with con‐
ventional medical therapy, the AICD reduced all-cause mortality 31% from 19.8% to 14.2%
[107]. The effect of AICD therapy in improving survival was similar in patients stratified ac‐
cording to age, sex, LV ejection fraction, New York Heart Association class, and QRS inter‐
val [107].
In MADIT-II, the reduction in sudden cardiac death in patients treated with an AICD was
significantly reduced by 68% in 574 patients aged <65 years, by 65% in 455 patients aged
65-74 years, and by 68% in 204 patients aged ≥75 years [108]. The median survival in 348 oc‐
togenarians treated with AICD therapy was >4years [109].
At 8-year follow-up in MADIT II, the cumulative probability of all-cause mortality was 49%
for patients treated with an AICD versus 62% for patients not treated with an AICD [110].
AICD treatment caused a 34% reduction in mortality during treatment years 1-4 and a 26%
reduction in mortality during years 5-8 [110].
After AICD implantation, 35 patients were randomized to treatment with metoprolol and 35
patients to treatment with d, l-sotalol [111]. VT recurrence was 17% at 1 year and 20% at 2
years for patients treated with metoprolol versus 43% at 1 year and 49% at 2 years for pa‐
tients treated with d, l-sotalol. At 26-month follow-up, survival was 91% for patients treated
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with metoprolol plus an AICD versus 83% for patients treated with d, l-sotalol plus an
AICD [111]. In MADIT-II, use of higher doses of beta blockers in patients with ischemic
heart disease and an AICD significantly reduced mortality by 56-58% compared with non‐
use of beta blockers [112]. These data favor using a beta blocker in patients with an AICD.
At 32-month mean follow-up of 965 patients, death occurred in 73 of 515 patients (13%)
treated with beta blockers, in 84 of 494 patients (17%) treated with ACE inhibitors or angio‐
tensin receptor blockers, in 56 of 402 patients (14%) treated with statins, in 40 of 227 patients
(18%) treated with amiodarone, in 5 of 26 patients (19%) treated with sotalol, and in 64 of
265 patients (24%) treated with no beta blocker, ACE inhibitor, angiotensin receptor blocker,
statin, amiodarone, or sotalol [88]. These data favor treating patients with AICDs with beta
blockers, statins, and ACE inhibitors or angiotensin receptor blockers.
The American College of Cardiology Foundation (ACCF)/American Heart Association
(AHA) guidelines(Table 1) recommend that Class I indications for therapy with an AICD are
1) cardiac arrest due to VF or VT not due to a transient or a reversible cause; 2) spontaneous
sustained VT; 3) syncope of undetermined origin with clinically relevant, hemodynamically
significant sustained VT or VF induced at electrophysiologic study when drug therapy is in‐
effective, not tolerated, or not preferred; ; 4) patients with prior MI at least 40 days previous‐
ly with a LV ejection fraction less than 35% who are in NYHA class II or III; 5) patients with
nonischemic dilated cardiomyopathy with a LV ejection fraction less than or equal to 35%
who are in NYHA class II or III; 6) patients with prior MI at least 40 days previously with a
LV ejection fraction less than 30% who are in NYHA class I; and 7) patients with nonsus‐
tained VT due to prior MI with a LV ejection fraction less than 40% and inducible VF or sus‐
tained VT at electrophysiological study [113].
1. Survivors of cardiac arrest due to VF or hemodynamically unstable sustained VT after evaluation to diagnose the
cause and to exclude completely reversible causes
2. Structural heart disease and spontaneous sustained VT, whether hemodynamically stable or unstable
3. Syncope of undetermined etiology with clinically relevant, hemodynamically significant sustained VT or VF induced
at electrophysiological study
4. LV ejection fraction less than 35% due to prior MI at least 40 days previously and NYHA class II or III
5. Nonischemic dilated cardiomyopathy with LV ejection fraction less than or equal to 35% and NYHA class II or III
6. LV ejection fraction less than 30% due to prior myocardial infarction at least 40 days previously and NYHA class I
7. Nonsustained VT due to MI, LV ejection fraction less than 40%, and inducible VF or sustained VT at
electrophysiological study
Table 1. Class I indications for Automatic Implantable Cardioverter-Defibrillator
Adapted from Epstein AE et al [113]
The 2009 updated ACCF/AHA guidelines for treatment of CHF (Table 2) recommend with a
class I indication use of an AICD for 1) secondary prevention to increase survival in patients
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with current or prior symptoms of heart failure and decreased LV ejection fraction who
have a history of cardiac arrest, VF, or hemodynamically destabilizing VT; 2) primary pre‐
vention of sudden cardiac death to reduce mortality in patients with nonischemic dilated
cardiomyopathy or CAD at least 40 days after MI, a LV ejection fraction less than or equal to
35%, and NYHA class II or III symptoms on optimal medical therapy, with expectation of
survival with good functional status for more than 1 year; and 3) may be used in patients
receiving cardiac resynchronization therapy (CRT) for NYHA class III or ambulatory class
IV symptoms despite recommended optimal medical therapy [114, 115].
1. Secondary prevention to increase survival in patients with current or prior symptoms of heart failure and reduced LV
ejection fraction with a history of cardiac arrest, VF, or hemodynamically destabilizing VT
2. Primary prevention of sudden cardiac death to reduce mortality in patients with nonischemic dilated
cardiomyopathy or ischemic heart disease at least 40 days after MI, a LV ejection fraction less than or equal to 35%,
and NYHA class II or III symptoms on optimal medical therapy, with expectation of survival with good functional status
for more than 1 year
3. May be used in patients receiving cardiac resynchronization therapy for NYHA class III or ambulatory class IV
symptoms despite recommended optimal medical therapy
Table 2. Class I Indications for Implantation of an Automatic Implantable Cardioverter-Defibrillator in Congestive
Heart Failure
Adapted from Jessup M et al [114]
The ACC/AHA guidelines class IIa indications for treatment with an AICD are listed in Ta‐
ble 3 [113].
1. Unexplained syncope, significant LV dysfunction, and nonischemic dilated cardiomyopathy
2. Sustained VT and normal or near normal LV function
3. Hypertrophic cardiomyopathy with 1 or more major risk factor for SCD
4. Prevention of SCD in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy who have 1 or more
risk factor for SCD
5. Reduction of SCD in patients with long-QT syndrome who are having syncope and/or VT while using beta blockers
6. Nonhospitalized patients awaiting cardiac transplantation
7. Brugada syndrome with syncope
8. Brugada syndrome with documented VT that has not resulted in cardiac arrest
9. Catecholaminergic polymorphic VT with syncope and/or documented sustained VT while using beta blockers
10. Cardiac sarcoidosis, giant cell myocarditis, or Chagas disease
Table 3. Class IIa Indications for Implantation of an Automatic Implantable Cardioverter-Defibrillator
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Adapted from Epstein AE et al [113]
If the patient has no indication for pacing and a normal LV ejection fraction, CRT should not
be performed. If the patient has no indication for pacing and a reduced LV ejection fraction,
CRT should not be performed
An AICD may also be effective in preventing sudden death in patients with hypertrophic
cardiomyopathy at high risk for sudden death [116] and in patients at high risk for sudden
death because of a long QT interval or the Brugada syndrome [117]. An AICD may be useful
in preventing sudden death in patients with syncope and ventricular tachyarrhythmias as‐
sociated with poor LV ejection fraction, regardless of the result of the electrophysiologic
study [118]. In addition, an AICD may be useful in survivors of VT or VF as a bridge to car‐
diac transplantation [119].
AICDs were implanted in 378 men and 95 women [120]. At 3.6-year follow-up, survival was
76% in patients who had an AICD because of cardiac arrest due to VF or VT not due to a
transient or reversible cause, 85% in patients who had an AICD because of spontaneous sus‐
tained VT in association with structural heart disease, 92% in patients who had an AICD be‐
cause of syncope of undetermined origin with clinically relevant, hemodynamically
sustained VT or VF induced at electrophysiological study when drug therapy is ineffective,
not tolerated, or not preferred, 84% in patients who had an AICD because of nonsustained
VT with CAD, MI, LV dysfunction, and inducible VF or sustained VT at electrophysiological
study that is not suppressible by a Class I antiarrhythmic drug, and 85% in all 473 patients
[120].
AICDs are not effective in treating patients with LV dysfunction scheduled for elective
CABG [91] or in patients who have had an acute MI within 40 days of the procedure [121,
122]. In patients receiving AICDs early after MI, factors associated with arrhythmias need‐
ing AICD therapy are also associated with a high risk of nonsudden death, negating the
benefit of AICDs [123]. AICDs should also not be used to treat patients with NYHA class IV
CHF despite optimal medical management or in patients with a life expectancy less than 1
year [114]
Of 209 patients with NYHA class III or IV heart failure treated with combined CRT-AICD
therapy, appropriate cardioverter-defibrillator shocks occurred at 34-month follow-up in 22
of 121 patients (18%) on statins and in 30 of 88 patients (34%) not on statins [124]. Death oc‐
curred in 3 of 121 patients (2%) on statins and in 9 of 88 patients (10%) not on statins. Step‐
wise Cox regression analysis showed that significant independent prognostic factors for
appropriate shocks were use of statins (risk ratio = 0.46), smoking (risk ratio = 3.5); and dia‐
betes mellitus (risk ratio = 0.34) [124]. Significant independent prognostic factors for the time
to mortality were use of statins (risk ratio = 0.05), use of digoxin (risk ratio = 4.2), hyperten‐
sion (risk ratio = 14.2), diabetes mellitus (risk ratio = 4.3), and LV ejection fraction (risk ratio
= 1.1) [124].
Of 529 patients with CHF and a reduced LV ejection fraction, 209 (40%) were treated with
CRT plus an AICD and 320 (60%) with an AICD [125]. Mean follow-up was 34 months for
both groups. Stepwise logistic regression analysis showed that significant independent vari‐
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with current or prior symptoms of heart failure and decreased LV ejection fraction who
have a history of cardiac arrest, VF, or hemodynamically destabilizing VT; 2) primary pre‐
vention of sudden cardiac death to reduce mortality in patients with nonischemic dilated
cardiomyopathy or CAD at least 40 days after MI, a LV ejection fraction less than or equal to
35%, and NYHA class II or III symptoms on optimal medical therapy, with expectation of
survival with good functional status for more than 1 year; and 3) may be used in patients
receiving cardiac resynchronization therapy (CRT) for NYHA class III or ambulatory class
IV symptoms despite recommended optimal medical therapy [114, 115].
1. Secondary prevention to increase survival in patients with current or prior symptoms of heart failure and reduced LV
ejection fraction with a history of cardiac arrest, VF, or hemodynamically destabilizing VT
2. Primary prevention of sudden cardiac death to reduce mortality in patients with nonischemic dilated
cardiomyopathy or ischemic heart disease at least 40 days after MI, a LV ejection fraction less than or equal to 35%,
and NYHA class II or III symptoms on optimal medical therapy, with expectation of survival with good functional status
for more than 1 year
3. May be used in patients receiving cardiac resynchronization therapy for NYHA class III or ambulatory class IV
symptoms despite recommended optimal medical therapy
Table 2. Class I Indications for Implantation of an Automatic Implantable Cardioverter-Defibrillator in Congestive
Heart Failure
Adapted from Jessup M et al [114]
The ACC/AHA guidelines class IIa indications for treatment with an AICD are listed in Ta‐
ble 3 [113].
1. Unexplained syncope, significant LV dysfunction, and nonischemic dilated cardiomyopathy
2. Sustained VT and normal or near normal LV function
3. Hypertrophic cardiomyopathy with 1 or more major risk factor for SCD
4. Prevention of SCD in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy who have 1 or more
risk factor for SCD
5. Reduction of SCD in patients with long-QT syndrome who are having syncope and/or VT while using beta blockers
6. Nonhospitalized patients awaiting cardiac transplantation
7. Brugada syndrome with syncope
8. Brugada syndrome with documented VT that has not resulted in cardiac arrest
9. Catecholaminergic polymorphic VT with syncope and/or documented sustained VT while using beta blockers
10. Cardiac sarcoidosis, giant cell myocarditis, or Chagas disease
Table 3. Class IIa Indications for Implantation of an Automatic Implantable Cardioverter-Defibrillator
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Adapted from Epstein AE et al [113]
If the patient has no indication for pacing and a normal LV ejection fraction, CRT should not
be performed. If the patient has no indication for pacing and a reduced LV ejection fraction,
CRT should not be performed
An AICD may also be effective in preventing sudden death in patients with hypertrophic
cardiomyopathy at high risk for sudden death [116] and in patients at high risk for sudden
death because of a long QT interval or the Brugada syndrome [117]. An AICD may be useful
in preventing sudden death in patients with syncope and ventricular tachyarrhythmias as‐
sociated with poor LV ejection fraction, regardless of the result of the electrophysiologic
study [118]. In addition, an AICD may be useful in survivors of VT or VF as a bridge to car‐
diac transplantation [119].
AICDs were implanted in 378 men and 95 women [120]. At 3.6-year follow-up, survival was
76% in patients who had an AICD because of cardiac arrest due to VF or VT not due to a
transient or reversible cause, 85% in patients who had an AICD because of spontaneous sus‐
tained VT in association with structural heart disease, 92% in patients who had an AICD be‐
cause of syncope of undetermined origin with clinically relevant, hemodynamically
sustained VT or VF induced at electrophysiological study when drug therapy is ineffective,
not tolerated, or not preferred, 84% in patients who had an AICD because of nonsustained
VT with CAD, MI, LV dysfunction, and inducible VF or sustained VT at electrophysiological
study that is not suppressible by a Class I antiarrhythmic drug, and 85% in all 473 patients
[120].
AICDs are not effective in treating patients with LV dysfunction scheduled for elective
CABG [91] or in patients who have had an acute MI within 40 days of the procedure [121,
122]. In patients receiving AICDs early after MI, factors associated with arrhythmias need‐
ing AICD therapy are also associated with a high risk of nonsudden death, negating the
benefit of AICDs [123]. AICDs should also not be used to treat patients with NYHA class IV
CHF despite optimal medical management or in patients with a life expectancy less than 1
year [114]
Of 209 patients with NYHA class III or IV heart failure treated with combined CRT-AICD
therapy, appropriate cardioverter-defibrillator shocks occurred at 34-month follow-up in 22
of 121 patients (18%) on statins and in 30 of 88 patients (34%) not on statins [124]. Death oc‐
curred in 3 of 121 patients (2%) on statins and in 9 of 88 patients (10%) not on statins. Step‐
wise Cox regression analysis showed that significant independent prognostic factors for
appropriate shocks were use of statins (risk ratio = 0.46), smoking (risk ratio = 3.5); and dia‐
betes mellitus (risk ratio = 0.34) [124]. Significant independent prognostic factors for the time
to mortality were use of statins (risk ratio = 0.05), use of digoxin (risk ratio = 4.2), hyperten‐
sion (risk ratio = 14.2), diabetes mellitus (risk ratio = 4.3), and LV ejection fraction (risk ratio
= 1.1) [124].
Of 529 patients with CHF and a reduced LV ejection fraction, 209 (40%) were treated with
CRT plus an AICD and 320 (60%) with an AICD [125]. Mean follow-up was 34 months for
both groups. Stepwise logistic regression analysis showed that significant independent vari‐
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ables for appropriate AICD shocks were statins (risk ratio = 0.35), smoking (risk ratio = 2.52),
and digoxin (risk ratio = 1.92). Significant independent variables for time to deaths were use
of CRT (risk ratio = 0.32), statins (risk ratio = 0.18), ACE inhibitors/angiotensin receptor
blockers (ARBs) (risk ratio = 0.10), hypertension (risk ratio = 24.15), diabetes (risk ratio =
2.54), and age (risk ratio = 1.06) [125].
During 1243 days mean follow-up of 549 patients who had an AICD for CHF, 163 (30%) had
appropriate AICD shocks, 71 (13%) had inappropriate AICD shocks, and 63 (12%) died
[126]. Stepwise logistic regression analysis showed that significant independent prognostic
factors for appropriate AICD shocks were smoking (odds ratio = 3.7) and statins (odds ratio
= 0.54), for inappropriate AICD shocks were atrial fibrillation (odds ratio = 6.2) and statins
(odds ratio = 0.52), and for time to mortality were age (hazard ratio = 1.08 per 1-year in‐
crease), ACE inhibitors or angiotensin receptor blockers ARBs (hazard ratio = 0.25), atrial fi‐
brillation (hazard ratio = 4.1), right ventricular pacing (hazard ratio = 3.6), digoxin (hazard
ratio = 2.9), hypertension (hazard ratio = 5.3), and statins (hazard ratio = 0.32) [126].
AICDs were implanted in 485 patients with ischemic cardiomyopathy and in 299 patients
with nonischemic cardiomyopathy [127]. At 33-month follow-up, appropriate ICD shocks
occurred in 179 of 485 patients (37%) with ischemic cardiomyopathy and in 93 of 299 pa‐
tients (31%) with nonischemic cardiomyopathy. All-cause mortality occurred in 162 of 485
patients (33%) with ischemic cardiomyopathy and in 70 of 299 patients (23%) with nonische‐
mic cardiomyopathy [127].
During implantatation and during 38-month follow-up of 1, 060 patients who had AICDs,
complications occurred in 60 patients (5.7%) [128]. These complications consisted of frac‐
tured leads requiring lead revision in 36 patients (3.4%), lead infection requiring antibiotics
in 5 patients (0.5%), device replacement because of malfunction in 5 patients (0.5%), reposi‐
tioning of leads in 3 patients (0.3%), a hematoma at the time of implantation in 3 patients
(0.3%), pneumothorax at the time of implantation in 2 patients (0.2%), repair of a defective
generator in 1 patient (0.1%), replacement of the device because of atrophy of the skin over
the device in 1 patient (0.1%), a transient ischemic attack because of atrial fibrillation devel‐
oping during implantation in 1 patient (0.1%), device replacement because of a recall from
Guidant in 1 patient (0.1%), pocket revision because of pain when lying on the side of the
pacemaker in 1 patient (0.1%), and pacemaker infection in 1 patient (0.1%) [128]. A down‐
loadable algorithm has been developed to reduce inappropriate shocks caused by fractures
of implantable AICD leads [129].
Persistent atrial fibrillation is associated with appropriate shocks and with CHF in patients
with LV dysfunction treated with an AICD [130]. One or more inappropriate AICD shocks
occurred in 83 of 719 MADIT II patients (11.5%) and comprised 31.2% of 590 shocks [131].
Triggers for inappropriate shocks were atrial fibrillation (44%), supraventricular tachycardia
(36%), and abnormal sensing (20%). Patients with inappropriate shocks had a 2.3 times in‐
crease in mortality [ 131].
In 1, 193 patients with combined CRT-AICD therapy, atrial tachycardia/atrial fibrillation
lasting longer than 10 minutes occurred in 361 patients (30%) [132]. Device-detected atrial
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tachycardia/atrial fibrillation was associated with a 2.16 times increased mortality at 13
months median follow-up [132].
Of 958 patients with an AICD, chronic kidney disease was a significant independent predic‐
tor of 1-year mortality [133]. The 1-year mortality was 1.8%, 5.3%, 9.0%, 22%, and 38% for
stages 1, 2, 3, 4, and 5, respectively of renal function. [133].
Successful radiofrequecy ablation was performed in 22 of 84 patients with an AICD who
had inappropriate shocks from atrial tachycardia, atrial flutter, or atrioventricular nodal re‐
entrant tachycardia [134]. Ninety-five percent of 22 patients who underwent successful radi‐
ofrequency ablation for supraventricular tachycardia had no inappropriate AICD shocks at
21-month follow-up compared to 63% of patients with inappropriate shocks for supraven‐
tricular tachycardia who did not have radiofrequency ablation [134].
In patients with AICDs, compared to patients treated with ventricular backup pacing at a
rate of 40/minute, patients treated with dual-chamber rate-responsive pacing at a rate of 70/
minute (DDDR-70) had an increase in mortality [135, 136], worsening of LV ejection fraction
[137], and an increase in new LV wall motion abnormality [137]. One reason why DDDR-70
pacing may increase mortality and worsen LV systolic function is that ventricular electrical
activation proceeds from the right ventricular apex instead of through the existing conduc‐
tion system.
In patients with AICDs and no indication for antibradycardia pacing, 22 of 80 patients (28%)
treated with right ventricular pacing died at 45-month follow-up, and 8 of 81 patients (10%)
treated with biventricular pacing died at 53-month follow-up [138]. At 23-month follow-up,
the LV ejection fraction decreased from 36% to 30% in patients treated with right ventricular
pacing and increased at 38-month follow-up from 35% to 40% in patients treated with biven‐
tricular pacing [138]. New LV wall motion abnormality developed at 23-month follow-up in
23 of 80 patients (29%) treated with right ventricular pacing and at 38-month follow-up in 7
of 81 patients (9%) treated with biventricular pacing [138]. On the basis of available data, pa‐
tients with AICDs should be treated with biventricular pacing, not with DDDR-70 right ven‐
tricular pacing [135-138].
In the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchroniza‐
tion Therapy (MADIT-CRT) trial of 821 patients with nonischemic cardiomyopatyhy, 499
(61%) were treated with statins [139]. At 4-year follow-up, the cumulative probability of fast
VT/VF or death was significantly reduced in patients treated with statins (11%) than in pa‐
tients not treated with statins (19%) [139].
In the 1, 1820 patients in the MADIT-CRT trial, CRT -defibrillator therapy reduced first ven‐
tricular tachyarrhythmic events by 42% in patients with a left bundle branch block but did
not reduce first ventricular tachyarrhythmic events in patients without left bundle branch
block [140]. Recurrent ventricular tachyarrhythmic events were not reduced in patients with
a left bundle branch block and were increased 3.62 times in patients without a left bundle
branch block [140].
At 1.4-year follow-up of 1, 500 patients treated with an AICD for primary prevention, com‐
pared with conventional programming, programming the AICD for tachyarrhythmias of
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ables for appropriate AICD shocks were statins (risk ratio = 0.35), smoking (risk ratio = 2.52),
and digoxin (risk ratio = 1.92). Significant independent variables for time to deaths were use
of CRT (risk ratio = 0.32), statins (risk ratio = 0.18), ACE inhibitors/angiotensin receptor
blockers (ARBs) (risk ratio = 0.10), hypertension (risk ratio = 24.15), diabetes (risk ratio =
2.54), and age (risk ratio = 1.06) [125].
During 1243 days mean follow-up of 549 patients who had an AICD for CHF, 163 (30%) had
appropriate AICD shocks, 71 (13%) had inappropriate AICD shocks, and 63 (12%) died
[126]. Stepwise logistic regression analysis showed that significant independent prognostic
factors for appropriate AICD shocks were smoking (odds ratio = 3.7) and statins (odds ratio
= 0.54), for inappropriate AICD shocks were atrial fibrillation (odds ratio = 6.2) and statins
(odds ratio = 0.52), and for time to mortality were age (hazard ratio = 1.08 per 1-year in‐
crease), ACE inhibitors or angiotensin receptor blockers ARBs (hazard ratio = 0.25), atrial fi‐
brillation (hazard ratio = 4.1), right ventricular pacing (hazard ratio = 3.6), digoxin (hazard
ratio = 2.9), hypertension (hazard ratio = 5.3), and statins (hazard ratio = 0.32) [126].
AICDs were implanted in 485 patients with ischemic cardiomyopathy and in 299 patients
with nonischemic cardiomyopathy [127]. At 33-month follow-up, appropriate ICD shocks
occurred in 179 of 485 patients (37%) with ischemic cardiomyopathy and in 93 of 299 pa‐
tients (31%) with nonischemic cardiomyopathy. All-cause mortality occurred in 162 of 485
patients (33%) with ischemic cardiomyopathy and in 70 of 299 patients (23%) with nonische‐
mic cardiomyopathy [127].
During implantatation and during 38-month follow-up of 1, 060 patients who had AICDs,
complications occurred in 60 patients (5.7%) [128]. These complications consisted of frac‐
tured leads requiring lead revision in 36 patients (3.4%), lead infection requiring antibiotics
in 5 patients (0.5%), device replacement because of malfunction in 5 patients (0.5%), reposi‐
tioning of leads in 3 patients (0.3%), a hematoma at the time of implantation in 3 patients
(0.3%), pneumothorax at the time of implantation in 2 patients (0.2%), repair of a defective
generator in 1 patient (0.1%), replacement of the device because of atrophy of the skin over
the device in 1 patient (0.1%), a transient ischemic attack because of atrial fibrillation devel‐
oping during implantation in 1 patient (0.1%), device replacement because of a recall from
Guidant in 1 patient (0.1%), pocket revision because of pain when lying on the side of the
pacemaker in 1 patient (0.1%), and pacemaker infection in 1 patient (0.1%) [128]. A down‐
loadable algorithm has been developed to reduce inappropriate shocks caused by fractures
of implantable AICD leads [129].
Persistent atrial fibrillation is associated with appropriate shocks and with CHF in patients
with LV dysfunction treated with an AICD [130]. One or more inappropriate AICD shocks
occurred in 83 of 719 MADIT II patients (11.5%) and comprised 31.2% of 590 shocks [131].
Triggers for inappropriate shocks were atrial fibrillation (44%), supraventricular tachycardia
(36%), and abnormal sensing (20%). Patients with inappropriate shocks had a 2.3 times in‐
crease in mortality [ 131].
In 1, 193 patients with combined CRT-AICD therapy, atrial tachycardia/atrial fibrillation
lasting longer than 10 minutes occurred in 361 patients (30%) [132]. Device-detected atrial
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tachycardia/atrial fibrillation was associated with a 2.16 times increased mortality at 13
months median follow-up [132].
Of 958 patients with an AICD, chronic kidney disease was a significant independent predic‐
tor of 1-year mortality [133]. The 1-year mortality was 1.8%, 5.3%, 9.0%, 22%, and 38% for
stages 1, 2, 3, 4, and 5, respectively of renal function. [133].
Successful radiofrequecy ablation was performed in 22 of 84 patients with an AICD who
had inappropriate shocks from atrial tachycardia, atrial flutter, or atrioventricular nodal re‐
entrant tachycardia [134]. Ninety-five percent of 22 patients who underwent successful radi‐
ofrequency ablation for supraventricular tachycardia had no inappropriate AICD shocks at
21-month follow-up compared to 63% of patients with inappropriate shocks for supraven‐
tricular tachycardia who did not have radiofrequency ablation [134].
In patients with AICDs, compared to patients treated with ventricular backup pacing at a
rate of 40/minute, patients treated with dual-chamber rate-responsive pacing at a rate of 70/
minute (DDDR-70) had an increase in mortality [135, 136], worsening of LV ejection fraction
[137], and an increase in new LV wall motion abnormality [137]. One reason why DDDR-70
pacing may increase mortality and worsen LV systolic function is that ventricular electrical
activation proceeds from the right ventricular apex instead of through the existing conduc‐
tion system.
In patients with AICDs and no indication for antibradycardia pacing, 22 of 80 patients (28%)
treated with right ventricular pacing died at 45-month follow-up, and 8 of 81 patients (10%)
treated with biventricular pacing died at 53-month follow-up [138]. At 23-month follow-up,
the LV ejection fraction decreased from 36% to 30% in patients treated with right ventricular
pacing and increased at 38-month follow-up from 35% to 40% in patients treated with biven‐
tricular pacing [138]. New LV wall motion abnormality developed at 23-month follow-up in
23 of 80 patients (29%) treated with right ventricular pacing and at 38-month follow-up in 7
of 81 patients (9%) treated with biventricular pacing [138]. On the basis of available data, pa‐
tients with AICDs should be treated with biventricular pacing, not with DDDR-70 right ven‐
tricular pacing [135-138].
In the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchroniza‐
tion Therapy (MADIT-CRT) trial of 821 patients with nonischemic cardiomyopatyhy, 499
(61%) were treated with statins [139]. At 4-year follow-up, the cumulative probability of fast
VT/VF or death was significantly reduced in patients treated with statins (11%) than in pa‐
tients not treated with statins (19%) [139].
In the 1, 1820 patients in the MADIT-CRT trial, CRT -defibrillator therapy reduced first ven‐
tricular tachyarrhythmic events by 42% in patients with a left bundle branch block but did
not reduce first ventricular tachyarrhythmic events in patients without left bundle branch
block [140]. Recurrent ventricular tachyarrhythmic events were not reduced in patients with
a left bundle branch block and were increased 3.62 times in patients without a left bundle
branch block [140].
At 1.4-year follow-up of 1, 500 patients treated with an AICD for primary prevention, com‐
pared with conventional programming, programming the AICD for tachyarrhythmias of
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200 beats per minute or higher was associated with a significant 79% reduction in inappro‐
priate shocks or inappropriate antitachycardia pacing and a significant 55% reduction in all-
cause mortality [141]. Compared with conventional programming, a prolonged delay in
AICD therapy to 170 beats per minute or higher was associated with a significant 76% re‐
duction in inappropriate shocks or inappropriate antitachycardia pacing and a significant
44% reduction in all-cause mortality [141].
At 1-year follow-up of 1, 902 patients treated with an AICD for primary or secondary pre‐
vention, use of a long-versus standard-detection interval caused a 42% significant reduction
in antitachycardia pacing, a 23% insignificant reduction in appropriate shocks, a 45% signifi‐
cant reduction in inappropriate shocks, and a 13% insignificant reduction in mortality [142].
In a registry of 5, 399 AICD recipients for primary and secondary prevention, rates of appro‐
priate shocks were similar among patients aged 18-49, 50-59, 60-69, 70-79, and ≥ 80 years
[143]. There was no significant difference in mortality between clinical trial patients random‐
ized to an AICD for primary prevention in the MADIT-II and SCD-HEFT trials and a similar
group of clinical registry patient who received an AICD for primary prevention [144].
In patients with an AICD and a CRT-defibrillator, 3, 809 patients who survived a first shock
were matched to 3, 630 patients without a shock [145]. Compared with no shock, mortality
was significantly increased 1.65 times in those who received a shock for monomorphic VT,
2.1 times for those who received a shock for VF/polymorphic VT, and 161 times for those
who received a shock for atrial fibrillation/atrial flutter [145]. Mortality was similar in those
who received a shock for sinus tachycardia, supraventricular tachycardia, and noise/artefact
oversensing compared to no shock [145].
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200 beats per minute or higher was associated with a significant 79% reduction in inappro‐
priate shocks or inappropriate antitachycardia pacing and a significant 55% reduction in all-
cause mortality [141]. Compared with conventional programming, a prolonged delay in
AICD therapy to 170 beats per minute or higher was associated with a significant 76% re‐
duction in inappropriate shocks or inappropriate antitachycardia pacing and a significant
44% reduction in all-cause mortality [141].
At 1-year follow-up of 1, 902 patients treated with an AICD for primary or secondary pre‐
vention, use of a long-versus standard-detection interval caused a 42% significant reduction
in antitachycardia pacing, a 23% insignificant reduction in appropriate shocks, a 45% signifi‐
cant reduction in inappropriate shocks, and a 13% insignificant reduction in mortality [142].
In a registry of 5, 399 AICD recipients for primary and secondary prevention, rates of appro‐
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[143]. There was no significant difference in mortality between clinical trial patients random‐
ized to an AICD for primary prevention in the MADIT-II and SCD-HEFT trials and a similar
group of clinical registry patient who received an AICD for primary prevention [144].
In patients with an AICD and a CRT-defibrillator, 3, 809 patients who survived a first shock
were matched to 3, 630 patients without a shock [145]. Compared with no shock, mortality
was significantly increased 1.65 times in those who received a shock for monomorphic VT,
2.1 times for those who received a shock for VF/polymorphic VT, and 161 times for those
who received a shock for atrial fibrillation/atrial flutter [145]. Mortality was similar in those
who received a shock for sinus tachycardia, supraventricular tachycardia, and noise/artefact
oversensing compared to no shock [145].
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1. Introduction
Atrial Fibrillation (AF) is the commonest cardiac arrhythmia. The Epidemiology of the disease
is presented in Figure 1.
Figure 1. Epidemiology of Atrial Fibrillation
AF is usually associated with underlying cardiovascular disorders, however in around 30% of
the cases, AF occurs alone.
Atrial Fibrillation occurs when high rate depolarizing waves conduct through different lesion
pathways into the atrium leading to asynchronous contraction of atrial wall segments. This
will conduct irregularly through the AV node giving irregular ventricular response rate. This
asynchronous contraction prevents effective atrial contraction resulting in residual stagnant
blood in the chambers leading to thrombus formation which can break off causing CVA.
Furthermore, there is a decrease in cardiac output due to loss of atrial kick, which contribute
up to 30% of forward cardiac output especially during periods of diastolic dysfunction.
There is an increasing incidence with age and sex as per Figure 2.
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Figure 2. Prevalence of diagnosed atrial fibrillation stratified by age and sex.
Classification of Atrial Fibrillation as per Figure 3:
1. Isolated: A Single episode of AF
2. Recurrent: If more than 2 episodes of AF
3. Paroxysmal: Self-limited bouts of AF
4. Persistent: Requires drugs-DC version
5. Permanent: Non-revertable AF
2. Significance of AF
AF contributes significantly to cardiovascular morbidity and mortality [1].
AF consists off an independent risk factor for death (RR 1.5 – 1.9). There is a link between AF
and Thromboembolism [2] :there is a 5 times increased risk of CVA in patients with AF. The
presence of rheumatic valvular disease increases the risk of CVA 17-fold. Ultimately AF is
responsible for 15% of all CVAs.
Moreover, conventional medical therapy for AF is unsatisfactory because the failure rate is
50% at 1 year and 85% at 2 years. There is a haemorrhagic risk with the use of warfarin for AF
and finally antiarrhythmic agents are not specific for atrial activity.
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3. Pathophysiology of AF
1. Historically in 1962, Moe’s developed the “multiple wandering wavelet” hypothesis.
2. Allessie in 1995 eluded on the principles of electrophysiologic changes and electrical
remodelling during AF due to:
a. Intracellular calcium loading.
b. Down-regulated Ca channel activity.
c. ↓ Action potential duration.
d. Shorter refractory period in left atrial tissue.
The functional requirements for re-entrant arrhythmias are: 1) Tissue substrate to support re-
entrant excitation, 2) Area of unidirectional block and 3) Typically areas of slow conduction
as depicted in Figure 4.
1. It was finally noted that AF begets AF [3].
2. The importance of primary local generator single re-entry circuits was somehow proved
with the concept of surgical interruption of macro-re-entrant circuits with the Cox-Maze
procedure.
3. Finally, Haissaguerre in 1998 [4] showed that paroxysmal AF originates from ectopic foci
in the pulmonary veins.
Figure 3. Patterns of atrial fibrillation. (1) episodes that generally last less than or equal to 7 days (most less than 24h;
(2) usually more than 7 days; (3) cardioversion faild or not attempted; and (4) either paroxysmal or persistent AF may
be recurrent.
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The minimum diagnostic work-up of an AF patient is presented in Figure 5.
Figure 5. The minimum diagnostic work-up of an AF patient
Figure 4. The functional requirements for re-entrant arrhythmias
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4. Surgery for AF
The idea of creating a corridor-link between the sinus node and atrio-ventricular node that
could potentially restore regular rhythm became the base of the surgical treatment of AF.
The principles of surgery for AF, takes into account:
• Incisions and creation of lesions in the atria to interrupt macro-re-entrant circuits.
• Creation of blind alleys for atrial electrical activation.
• Appendage excision.
The procedure consists of an open-heart surgical approach, as described by James Cox, namely
making linear lesions in the right and left atria to prevent the occurrence of multiple reentering
circuits.
Based on mapping studies of animal and human AF, Cox and colleagues [5] developed a
surgical procedure (Cox maze procedure) that controls AF in more than 90% of selected
patients. In the original procedure atrial appendages are excised and the pulmonary veins are
isolated. Appropriately placed atrial incisions not only interrupt the conduction routes of the
most common re-entrant circuits, but they also direct the sinus impulse from the surgical
ablation node to the atrio-ventricular node along a specified route.
Although encouraging and successful results were obtained, the original surgical technique,
the Cox maze I procedure, was modified to become the Cox maze II procedure because of late
chrono-tropic problems with the surgical ablation node and intra-atrial conduction delays that
resulted in diminished left atrial contraction. However the Cox maze II procedure proved to
be technically difficult to perform. As a result, it was modified to become the Cox maze III
procedure, which soon became the surgical technique of choice for the treatment of medically
resistant AF.
The results of the Cox Maze III (cut and sew) showed that in 346 patients, the operative
mortality were less than 2%. The AF was cured in >90-95% of the cases. Left and right atrial
function was restored in 93% and 99% of patients correspondingly. 15 % of the patients
required pacemakers. Long-term CVA was very low at 0.1% per year [5, 6].
Temporary postoperative AF was frequent, presenting in 38% of patients. This problem was
related to a shortened atrial refractory period during the procedure and did not preclude long-
term success. Successful ablation treatment of AF was independent of mitral valve disease,
type of AF, and left atrial size.
So, although concomitant organic heart disease did not decrease the effectiveness of the Cox
maze III procedure in the series of Cox and colleagues, Gillinov et al [7] demonstrated
decreased success rate in their study. In most series, concomitant mitral valve surgery with
the Cox maze III procedure cured AF in 75% to 82% of patients.
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5. Beyond the Cox-Maze III
The Cox-Maze III (cut and sew as seen in Figure 6) perceived complexity, is time-consuming
and requires CPB and aortic cross clamp. A systematic review by Khargi et al [8] and a
comparative study by Chiappini et al [9] concluded that there was not any significant differ‐
ence in the postoperative SR conversion rates between the classical 'cut and sew' and the
alternative sources of energy, which were used to treat atrial fibrillation.
Therefore, during the last decade AF surgery was popularized with simpler operations, by
performing only LA maze (Figure 7) and using alternate energy sources for trans-mural lesions
to produce lines of conduction block speedily with minor risk of bleeding.
Of note, during LA ablation one performs pulmonary vein isolation, LA appendage resection,
possibly LA appendage to left PV lesion and lastly a PV connecting to MV annulus (mitral)
lesion.
Table 1 shows the results of LA maze using different energy sources and Table 2 shows the
characteristics and differences between 3 widely used energy sources.
Figure 6. RA and LA Maze (Cox –Maze III)
Author Year Number of Patients Lesion Type
%Sinus Rhythm
mid/long-term follow-up
Sie 2004 200 RF 80
Kondo 2003 31 Cryoablation, RF 79.3
Kress 2002 23 RF 86
Wellens 2002 30 RF 65
Guden 2002 23 RF 81
Benussi 2002 132 Epicardial RF 77
Deneke 2002 21 RF 82
Mohr 2002 234 RF 81.1
Knaut 2002 105 Microwave 61
Pasic 2001 48 RF 92
Table 1. Left atrial Maze: Results of contemporary publications, using various energy sources.
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Radiofrequency Microwave Cryothermy
Current of 350 kHz – 1 MHz. High frequency electromagnetic
radiation causes oscillation of water
molecules.
The mechanism of cryogenic tissue
injury in the early phase is actually
organelle and mitochondrial
dysfunction and subsequent edema
and cell necrosis upon thawing.
Hyperthermic lesions cause a loss of
cellular excitability at 50°C.
The oscillation of the water produces
kinetic energy and subsequent heat, a
process called dielectric heating. The
AFx Microwave device can produce an
endocardial ablation by reaching a
goal temperature of 50° at 5 mm after
25 seconds. The same device produces
an epicardial ablation at 45 seconds
using a slightly higher wattage
The temperature must remain below
100°C to prevent cavitation.
With the early Frigitronics nitrous oxide
based systems, a temperature of –55°C
had to be maintained for two minutes,
and repeated exposures were
sometimes required. Newer, argon-
based systems provide cooler
temperatures that may permit effective
ablations in 45 seconds or less.
Radiofrequency energy ablation is very
similar to standard electro-cautery.
Although there are bipolar and
irrigated unipolar RF options, RF is
generally unipolar and uses very fast
AC current, which avoids depolarizing
the heart. The mechanism is resistive of
ohmic heating, which involves the
concentration of a large amount of
energy on a small surface area. The
energy disperses to the ground pad,
but the area where it is focused is
heated, resulting in ablation. It is
Figure 7. LA maze using alternate energy sources
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possible to control both temperature
and energy. Energy control will permit
precise application of, say, 50 watts,
but temperature is not controlled.
Temperature control allows the device
to maintain a precise goal
temperature.
Lesion depths 3-6 mm Increased depth and volume of heated
tissue
Nirous oxide based cryoprobe
Unipolar or Bipolar Less charring, but less flexible compare
with Radiofrequency.
Difficulty with inflexibility of probes
•bipolar concentrates energy
between electrodes
–easy, quick, narrow lesions




–handle designed for access and
visibility
–malleable electrodes for any heart
size/shape
–jaw head pitch and roll
adaptive transmurality
Unipolar: unfocused energy delivery Risk of damage to surrounding tissues There is no tissue vaporization or
charring
Surface charring may cause
thromboembolic complications
The endocardial surface remains
smooth
Saline cooled systems improve charring
Heat is conducted to surrounding
tissues (risk of damage, e.g.
oesophageal perforation)
“How do I know I am done”?
1) Heating of cells creates a shift in
intracellular fluid to extra-cellular
space
2) Creates a drop in impedance
3) Algorithm monitors changes in
impedance
Table 2. Various energy sources/ Characteristics and properties
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6. Recent important advances in AF surgery
The mid- and long-term success rate is in the 80% range. This has prompted various authorities
to popularized adding Maze procedures to concomitant cardiac surgery; with the view to
potentially treat AF with a simple, short and less invasive procedure. Moreover, minimal
access pulmonary vein isolation has been currently implemented for “lone” AFib or as part of
a mini-Mitral approach.
Wolf et al [10, 11], reported on 27 patients (22Males, mean age 57) who underwent Bilateral
thoracoscopic PVI and LAA excision for AFib (18 paroxysmal, 4 persistent, 5 permanent AFib).
There were no conversions or major complications. There was 91% freedom from AF at 3
months follow-up. The authors concluded that bilateral video-assisted thoracoscopic pulmo‐
nary vein isolation with excision of the left atrial appendage is feasible and safe and offers a
promising, new, minimally invasive, beating-heart approach for curative surgical treatment
of atrial fibrillation.
Jeanmart et al [12] evaluate their practice with the association of the mini-maze procedure,
done with the use of the Cardioblade pen, and concomitant minimally invasive mitral valve
surgery. They studied 103 patients. 41% had intermittent and 59% permanent AFib. At mean
follow up of 17 months, 70% of the patients studied were in Sinus Rhythm and 2% were
pacemaker dependent. The authors concluded that the use of unipolar radiofrequency ablation
to perform a mini-maze during minimally invasive mitral valve surgery is a safe procedure
and is associated with good early results.
7. Postoperative AFib
Post-operative AFib is different to conventional AF (micro- versus macro-re-entrant circuits).
Moreover the local refractory periods may be shorter and re-entrant circuits can be smaller.
Post-operative AFib is common after open-heart surgery (30-50%) and it must be treated with
anti-arrhythmics and anticoagulation, if it persists more than 48 hours. Warfarin should be
continued on all patients for at least 3 months and lastly in patients who remain in AFib for 6
weeks, cardio-version is essential.
If AF with concomitant cardiac surgery “Lone” AF (for younger patients with limiting symptoms,
Contraindication to anticoagulation, Thromboembolic
stroke while on anti-coagulation )
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6. Recent important advances in AF surgery
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Permanent AF: left Maze or Cox-Maze III
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Regardless of the method used, the goals remain the same. The lesions should, ideally, be trans-
mural; when minimally invasive procedures are implemented, the lesions should proceed
from the epicardium of the beating heart, which changes the physics of many of the lesions.
The method must also allow for tissues of variable thickness and characteristics, as a patient
with rheumatic atrial pathology will have a much more difficult atrium to ablate than a
coronary bypass patient.
A natural question arises as to which lesion pattern surgeons should be using. There probably
isn’t a simple answer to this question, because:
a. Data on lesion set efficacy is influenced by patient variables such as left atrial diameter,
duration of preoperative atrial fibrillation, coexisting pathology etc.
b. Comparing the efficacy of one lesion pattern to another in clinical trials will require too
many patients in each treatment arm to achieve statistical power.
c. Not all lesion patterns can be effectively or safely delivered with all energy sources.
Table 3, represents our policy of implementing strategies for the surgical treatment of AF. By
enlarge; the right atrium has a longer effective refractory period than the left atrium and in
general sustains only longer reentry circuits, the most common being the counterclockwise
circuit of typical atrial flutter. Atrial flutter can be ablated, by a trans-mural lesion connecting
the tricuspid annulus to the IVC; additional lesions connecting a lateral right atriotomy to the
IVC or coronary sinus to the IVC is occasionally necessary to ablate an atypical right atrial
flutter.
In summary, in patients with persistent or permanent AF who present for cardiac surgery, the
addition of surgical AF ablation led to a significantly higher rate of sinus rhythm in RCT and
non-RCT studies compared with cardiac surgery alone, and this effect remains robust over the
longer term (1-5 years). Although non-RCT studies suggest the possibility of reduced risk of
stroke and death, this remains to be proven in prospective RCTs with adequate power and
follow-up [13, 14].
9. The future
Further refinements in energy sources, lesion sets, minimally invasive techniques will be
developed. Routine preoperative EP screening and better understanding of selection criteria
will improve success rates. That may be achieved with close collaboration with EP cardiolo‐
gists.
The up till now results are encouraging therefore minimally invasive PVI may be routinely
considered in all cardiac surgical departments. Lastly, Left atrial maze should become standard
treatment of persistent/permanent “lone” AF in selected patients, especially where EP
techniques fail.
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discusses navigation, detection, and tracking during cardiac ablation interventions. 
Chapter 4 discusses epidemiology and pathophysiology of ventricular arrhythmias 
in several noncardiac diseases, methods used to assess arrhythmia risk,  and their 
association with long-term outcomes.  Chapter 5 discusses the treatment of ventricular 
arrhythmias including indications for implantation of an AICD for primary and for 
secondary prevention in patients with and without congestive heart failure. Chapter 6 
discusses surgical management of atrial fibrillation.







s, Pathophysiology, and Treatm
ent
IS  978-953-51-719
